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Abstract 
Lack of adherence to long-tenn therapies has been recognised for many years as a major 
problem, commonly undennining the effectiveness of medical care. The main objectives 
of this thesis were to evaluate the effect of nurse-led adherence support compared with 
usual care on adherence, blood pressure and costs, and to compare a newly developed 
adherence self-report tool with electronic monitoring. 
A total of 245 uncontrolled hypertensive patients with a diagnosis of essential 
hypertension were recruited in 22 general practices in Avon. 
A validation study of an adherence self-report tool compared with electronic monitoring 
showed that self-report can predict timing compliance at higher levels of adherence. 
More research is needed on the usefulness of this tool in day-to-day practice and in a 
more representative study sample. 
The main study of this thesis, the RCT, compared a nurse-led adherence support 
consultation followed by a re-inforcement appointment two months later with usual care 
alone. The main outcomes in this RCT were adherence to blood pressure lowering 
medication ('timing compliance'), systolic and diastolic blood pressure, and costs. 
There was no evidence of an effect of nurse-led adherence support on timing 
compliance (difference between means: -1.0,95% CI: -5.1 to 3.1, p=0.63), systolic 
blood pressure (difference between means: -2.7 mmHg, 95% CI: -7.2 to 1.8, p=0.24) or 
diastolic blood pressure (0.2, 95% CI: -1.9 to 2.3, p=0.85). With respect to the 
evaluation of the adherence self-report tool, there is strong evidence that a reduction of 
one level of self-reported adherence is associated with a decrease in timing compliance 
of around 5% (p=0.0004). 
In conclusion, nurse-led adherence support was no more effective than usual care in 
tenns of increasing adherence or reducing blood pressure. Baseline adherence levels 
were high in both comparison groups, leaving little room for further improvement. In 
the few participants who did have medication problems, the intervention appeared to be 
successful, but further research is needed to consolidate this finding. 
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1 Introduction 
In this first chapter I introduce the problem addressed in this thesis and give a brief 
outline of the current knowledge in the field of medication adherence. I also summarise 
the aims of this research and provide a general overview of the thesis with an outline of 
the remaining chapters. 
1. 1 Background and context for the thesis 
1.1.1 The problem of non-adherence 
The term 'non-adherence' is commonly used in the literature but not entirely helpful, 
because it assumes that people can either be 'adherent' or 'non-adherent'. However, 
adherence to medication should be treated as a continuous variable as described later in 
this thesis, and the term 'non-adherence' relates in fact to sub-optimal or poor 
adherence. Poor adherence to long-term therapies in chronic disease is common and can 
severely undermine the effectiveness of medical care. l The W orId Health Organization 
(WHO) has recognised this as an international problem and recently published a report 
Adherence to Long-term Therapies: Policy for Action to address this topic.2 The aim of 
this WHO report is to identify global issues around medication adherence in important 
medical conditions and to provide guidance on improving the cost-effectiveness of 
health care interventions. This report illustrates that adherence is influenced by various 
factors, which include social and economic circumstances, the health care team and 
system, manifestations of the disease, characteristics of the therapy, and patient-related 
factors. 
Unfortunately, a number of terms are - often interchangeably - being used to discuss 
medication adherence, including compliance, concordance, or persistence, which can be 
rather unhelpful. In this thesis I will mainly use the term adherence for reasons outlined 
in the next chapter, where I will define and contrast these terms in more detail. 
For many decisions made in primary care, both in the field of adherence and in many 
other areas, there appears to be a lack of a sound evidence base.3 Surprisingly, there has 
been little improvement of understanding in the field of adherence.4 This is partly due to 
the fact that medication adherence in chronic disease is an immensely complex topic 
and has led to a proliferation of studies, editorials and research letters in this field, 
which are of varying and often poor quality. 
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Many issues around the research methodology remain unclear and continue to pose 
challenges to researchers and clinicians alike, including the definition and measurement 
of adherence. Although many advances have been made in recent years, particularly in 
the measurement of adherence with the advance of electronic monitoring, a number of 
questions still remain unanswered largely unanswered: How should we defme 
adherence? How should we measure adherence? What is the true level of adherence in 
the community? What interventions work to improve adherence? How does adherence 
relate to clinical outcomes? What do patients think about adherence? 
1.1.2 Non-adherence in hypertension 
This thesis will examine ways to improve adherence in chronic disease, using 
hypertension as a specific example. It is widely acknowledged that hypertension is a 
major risk factor for cardiovascular disease. There is strong evidence from high quality 
randomised controlled trials (RCTs) that treating high blood pressure with medication 
can substantially reduce the risk of heart attack and stroke. The results of major 
systematic reviews suggest that reducing diastolic blood pressure by 5 to 6 mmHg 
reduces the risk of coronary heart disease by 20 to 25% and of stroke by 35 to 40%, 
which is of substantial public health importance.5,6 
However, the control of high blood pressure in the community is far from optimal, with 
lack of medication adherence (estimated to be only around 50 to 70% in uncontrolled 
hypertensive people7,8) likely to be a major factor. 9-1 1 
1.2 The need for research 
So if lack of adherence to medication contributes to such an extent to poor control of 
high blood pressure in the community, how can we improve medication adherence 
effectively? A recent attempt at answering this question is not very encouraging, as the 
latest systematic review ofRCTs of interventions to assist patients to follow 
prescriptions of medications concludes: 
"Current methods of improving medication adherence for chronic health 
problems are mostly complex, labor-intensive, and not predictably effective. 
The full benefits of medications cannot be realised at currently achievable 
levels of adherence; therefore, more studies of innovative approaches to 
assist patients to follow prescriptions for medications are needed. ,,12 
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A Working Party on Concordance in the UK has also recently addressed the problem of 
non-adherence. 13 It recognises the need for a multi-disciplinary approach to research 
into medicine taking and the process of prescribing and also addresses the need for 
effective strategies to improve adherence to medication. The working party also 
introduced the new concept of 'concordance', which emphasises the importance of a 
partnership between prescribers and patients for an effective use of medication. 
It has become evident that new approaches to increase adherence are urgently needed 
that are easy to implement, cost-effective, and acceptable to patients and health 
professionals alike.4 
1.3 Aims of the research 
This thesis aims to investigate new ways to improve adherence to medication in chronic 
disease, taking into account previous research and the above recommendations, and 
using hypertension as the target condition. 
Adherence to medication is closely related to four interacting elements, which include 
(1) condition-related factors such as the severity of the disease, symptoms experienced 
by the patients or the rate of progress, (2) characteristics of therapies like side effect and 
complexity of the treatment regimen, (3) health care team and system-related factors 
such as the organisation and delivery of care, and (4) patient-related factors, which may 
include health beliefs and knowledge about high blood pressure.2,4 The research 
described in this thesis focuses on how addressing health care team and patient related 
factors may help to improve adherence to blood pressure lowering medication. It also 
tries to acknowledge and address the fact that it is the patient's agenda that determines 
whether patients choose to take their medicines or not. 
The objectives of the studies covered by this thesis are to: 
'1. Conduct a systematic review of randomised controlled trials evaluating the 
effectiveness of interventions to increase adherence to blood pressure lowering 
medication 
2. Evaluate a nurse-led intervention to increase adherence to blood pressure 
lowering medication in a RCT 
3. Compare a newly designed adherence self-assessment tool with electronic 
monitoring 
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4. Obtain new data on medication taking in people with high blood pressure by 
using electronic medication monitors to measure adherence 
5. Add to the evidence base on improving the management of chronic conditions in 
primary care, using hypertension as an example 
The overall concern of this thesis is to provide answers to research questions that may 
have a positive impact on patients and health professionals lives in day-to-day primary 
care. 
1.4 Outline of the remaining chapters 
Chapter 2 reviews the literature in the field of adherence in hypertension and provides a 
general and broad overview of important adherence related topics. 
Chapter 3 is a systematic review of interventions to increase adherence to blood 
pressure lowering medication. This systematic review complements the above broad 
literature review, but is different in its methodology and designed to provide a basis for 
the trial as the main study of this thesis by reviewing RCTs of interventions to improve 
adherence to blood pressure lowering medication in more detail. 
Chapter 4 gives a general overview of methodological issues around adherence 
research, discussing the implications of the literature review for the design of the 
studies, the choice of methods and ethical implications. 
Chapter 5 outlines the methods used for the RCT, which is the main study of this thesis, 
including details about the conduct and analysis of the study. 
Chapter 6 presents a study that evaluates an adherence self-report questionnaire to 
identify non-adherence, which uses electronic monitoring as the comparison. 
Chapter 7 presents the RCT results, with an emphasis on describing the effect of the 
intervention on adherence and blood pressure. 
Chapter 8 contains a description of an economic evaluation within the RCT, focusing on 
costs at the general practice level. 
Chapter 9 discusses the findings of this thesis in the light of previous research, taking 
into account methodological limitations that may have affected the results. 
The final Chapter 10 concludes with recommendations for clinical practice and future 
research. 
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2 Overview of the literature 
2.1 Introduction 
The first chapter summarised briefly why improving medication adherence in 
hypertension is important. To put the studies described in this thesis into context the , 
next two chapters aim to provide a broad and comprehensive overview of the theories 
behind research on medication adherence, with an emphasis on the field of 
hypertension. I outline current controversies, summarise recent developments and 
identify future research trends in adherence related research. Both chapters critically 
evaluate work that has been conducted by other researchers in this area to provide a 
theoretical basis for the research described in this thesis and to indicate how this thesis 
might add to the current body of knowledge. 
2.1.1 Issues around the literature search 
Promoting adherence to medical treatments has long been a central aspect of medical 
care and is almost as old as medicine itself. Hippocrates wrote: 
"The physician must not only be prepared to do what is right himself, but 
also to make the patient ... cooperate"(Hippocrates, 5th century B.C.)J4 
Although this paternalistic view of the relationship between patients and health care 
providers has become outdated in modem times, promoting patient adherence to 
treatment is still an important aspect of patient care. More and more powerful and 
effective treatments have become available in recent years for many chronic conditions. 
These therapies can only provide benefit if adherence to treatment is present to a certain 
level. 
Although the evaluation and subsequent improvement of adherence to medical 
treatments have been the focus of research for many years, studying this field is still a 
less than perfect science for a number of reasons. Most importantly, measuring 
adherence is far from straightforward. Using hypertension as an example, a variety of 
different methods to measure adherence have been used, all of which are imperfect at 
best. I5 To make matters even more complicated, all measures of adherence obtained 
through the various methods can be expressed in different ways, making comparison of 
study results particularly difficult (see 2.4.4 Measuring Adherence). The level of 
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adherence to treatment regimens also depends on a variety of different factors, which 
may for instance be related to the therapy itself, the health care setting or any views that 
patients may have about the treatment. 
Reviewing the literature in this field is therefore challenging. It is also based on 
judgements about the relative importance of individually published research. This broad 
and, where appropriate, detailed review therefore uses a perspective that focuses on the 
pragmatic implementation of adherence improving strategies in primary care, which is 
the main topic of this thesis. 
2.2 General review methodology 
2.2.1 Review structure 
The following sections in this review aim to cover the main concepts, theories and 
methodological approaches, including the assumptions and definitions other researchers 
have employed, and the subheadings are as follows: 
A review of hypertension in primary care (Section 2.3) 
This provides a brief review of the diagnosis and management of hypertension in 
primary care with an emphasis on topics relating to medication adherence. This will 
also include an evaluation of the literature on new developments in hypertension 
management in the UK. 
A review of general concept in adherence research (Section 2.4) 
This section critically evaluates the problems of medication adherence in a broader 
sense, as described in the research literature. It includes a summary and discussion of 
the terminology and the methods used in adherence research. It also outlines important 
psychological models and cognitive aspects of adherence in so far as they are important 
for an understanding of adherence related behaviour and the development of the 
intervention tested in the ReT. 
Adherence in hypertension (Section 2.5) 
This section focuses on the particular issues around adherence in the field of 
hypertension. It includes research on the specific differences of adherence in 
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hypertension compared to other conditions. It also covers concepts such as side effects, 
motivation, health beliefs, and knowledge about hypertension, in so far as they are 
important with respect to blood pressure lowering medication. 
2.2.2 Search strategy 
The literature search aimed to identify all the relevant material that was needed to 
inform and further clarify the research question. The following electronic databases 
provided the starting point for the search: The Cochrane Controlled Trials Register, 
MEDLINE, EMBASE, the Cumulative Index of Nursing and Allied Literature 
(CINAHL), and the National Research Register (NRR) were searched to identify 
ongoing studies and unpublished research. 
The initial search used the following search terms alone and in combination, with 
slightly amended search strategies for the individual databases and for the particular 
topics that were being searched: "adher*", "compli*", "concord*", "hypertens*", 
"blood pressure*". This search revealed more than 1 000 titles and abstracts of articles. I 
identified potentially relevant articles by reading the titles and abstracts and retrieved all 
133 publications that appeared relevant. 
I identified further literature through personal communications with colleagues and 
study authors, screening the reference lists of all retrieved articles, reviewing abstracts 
of scientific meetings and by contacting experts in the field. The search was not limited 
to English literature and, where possible, I obtained help with translating articles 
published in other languages. Unpublished studies, theses, dissertations and studies 
published in non-peer reviewed journals were considered for inclusion in the review if 
these seemed relevant and of sufficient scientific rigour. I identified newly published 
papers at any time during the study period by screening the lists of contents of relevant 
journals and included these in the review where appropriate. 
2.2.3 Important topics covered in the review 
There are a number of issues that need to be considered when investigating adherence. 
This includes a definition of terms, which is particularly confusing in the field of 
medication adherence and has led to a continuing debate. Measuring adherence is 
likewise difficult and challenging. This chapter will therefore also look at various ways 
to measure adherence, and how the review of these methods led to the choice of 
measurement instruments used in this study. Hypertension is a chronic condition that 
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often does not cause any symptoms. Its treatment is frequently associated with 
unwanted effects of blood pressure lowering medication, which may be one of the 
factors affecting patient adherence to treatment. Last but not least, the literature review 
covers the involvement of patients in their care, which is of paramount importance when 
trying to increase adherence. 
2.3 A review of hypertension in primary care 
The following section gives an overview of issues around the management of 
hypertension in primary care. There is a focus on areas that either help understand 
problems around medication adherence, or that have provided a basis for the methods 
used in the studies described later. 
2.3.1 Definition of hypertension 
So far there is no generally accepted definition of high blood pressure, and despite good 
evidence from high quality randomised controlled trials, current guidelines are different 
in their emphasis and content. 16 Fahey & Peters found in a cross-sectional study in 18 
general practices in Oxfordshire that the proportion of patients with controlled 
hypertension varied from 17.5% to 84.6% between different international guidelines. 
They concluded that the present guidelines are inconsistent in their recommendations 
with regard to what constitutes controlled blood pressure and that clarification about 
absolute benefits and risks of treatment is warranted.17 
National guidelines from the US define resistant hypertension as blood pressure that 
cannot be reduced to values below 140/90 mmHg in people who take adequate triple 
drug regimens in the correct dosage. 18 Although this definition covers many people with 
high blood pressure, it does not include those for whom the target blood pressure should 
be even lower. In the UK, the treatment thresholds in people with sustained high blood 
pressure used to be equal to or more than 160 mmHg for systolic and equal to or more 
than 100 mmHg diastolic, with different thresholds and targets for people with diabetes 
or evidence of target organ damage, cardiovascular disease, or a 10-year coronary heart 
disease risk of equal to or more than 10% according to the Joint British Societies 
Coronary Heart Disease risk assessment programme and risk chart. 19 However, the 
suggested thresholds have recently been lowered to 140 mmHg and/or 90 mmHg, which 
increases the 'pool' of those individuals who potentially need to be treated.20 
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2.3.2 Epidemiology 
Blood pressure is a normally distributed characteristic in a population.21 The estimated 
prevalence of hypertension depends on the blood pressure level used to define the 
condition, which is arbitrary.22,23 Even when using higher cut-off points for the 
diagnosis of hypertension, though, high blood pressure is common. Overall, 15% of the 
UK population take antihypertensive drugs to lower their blood pressure. The 
prevalence increases sharply in the elderly, to up to 30%. Subsequently, treatment for 
high blood pressure is one of the commonest reasons to visit a family physician. In the 
UK, 160/0 of people aged 65 to 74 and 14% of people aged between 75 and 84 visit their 
general practitioner with high blood pressure.21 
There is some evidence to suggest that detection, treatment and control of high blood 
pressure has improved over the past 25 years in the United States.18 However, Colhoun 
and colleagues have shown in a survey of 12116 adults in England who participated in 
the 1994 Health Survey for England that the control of blood pressure has remained 
inadequate. 9 Even when a liberal criterion of 160/95 mmHg was used, only 300/0 were 
adequately controlled, although 50% of individuals with high blood pressure were 
taking antihypertensive drugs. Thus there appears to be considerable scope for 
improving the management and subsequent control of high blood pressure in England. 
2.3.3 Diagnosis 
High blood pressure is an asymptomatic condition and is usually detected through case 
finding by health professionals. Very rarely, patients may present to their GP with 
symptoms of malignant hypertension. In such patients, the commonest symptoms are 
headache, visual disturbance, dyspnoea due to heart failure, and gastrointestinal 
symptoms such as anorexia, nausea, and vomiting. 23 
Assessment 
When assessing a patient with suspected high blood pressure, the objective is to 
simultaneously evaluate cardiovascular risk, end-organ damage, and likely contributory 
factors. 19 The initial approach should start with a careful history with a focus on other 
symptoms, cardiovascular risk factors, and other medications. Physical examination 
usually includes assessment of height and weight (to calculate the body mass index, 
BMI), and looking for end-organ damage, such as fundal haemorrhages or evidence of 
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heart failure. Basic investigations aim to provide further infonnation on additional risk 
factors (urinalysis for glycosuria, total:HDL cholesterol) or end-organ damage (urea, 
electrolyte and creatinine levels, urinalysis for proteinuria). The accuracy and reliability 
of many of the elements of the history, examination, and investigations undertaken 
when assessing patients with high blood pressure is however unknown.22 
Blood pressure measurement 
Careful attention to blood pressure measurement technique is necessary, so that the 
accuracy and reliability of this diagnostic test is maximised.19,22,24 Accurate 
measurement of blood pressure is important for clinical management and in the conduct 
of research, and taking a patient's blood pressure should follow current consensus 
guidelines (Figure 1).19,21 









The patient is sitting in a quiet environment with the right arm resting on a 
support that places the midpoint of the upper arm at the level of the heart 
Measure sitting blood pressure routinely; standing blood pressure in elderly and 
diabetic patients 
Use cuff of appropriate size (bladder should encircle equal to or more than 80% 
or the arm, and the lower edge should be two cm above the antecubital fossa) 
Inflate cuff rapidly to 70 mmHg and then inflate by 10 mmHg increments 
palpating the radial pulse until the pulse disappears. Note the pressure at which 
the pulse disappears and subsequently reappears during deflation 
Place the low-frequency bell over the brachial artery pulsation 
Inflate the bladder 20 mmHg above the level previously determined by 
palpation. Deflate bladder by 2 mmHg per second. Note the systOlic blood 
pressure level with the appearance of repetitive sounds (Korotkoff phase 1) and 
measure diastolic blood pressure at the disappearance of sounds (Korotkoff 
phase 5). Systolic and diastolic blood pressures should be rounded to the 
nearest 2 mmHg. 
Take two measurements at each visit, at least more than 30 seconds apart 
Use the average for several visits (;;:: three) when estimating sustained blood 
pressure readings. 
Source: Ramsey et al. Guidelines for the management of hypertension: report of the third 
working party of the British Hypertension Society. J Hum Hypert 1999;13:569-92. 
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Health professionals should be aware of patient, health professional and instrument 
factors that may lead to inaccurate blood pressure measurement.22,24 The commonest 
reasons include the use of an inappropriately small cuff, deflating the cuff too quickly, 
failing to palpate the maximal systolic blood pressure before auscultation, and 
'rounding' errors when recording blood pressure readings. 
Mercury sphygmomanometers are likely to be phased out for health and safety reasons. 
There will be increasing use of alternative devices to measure blood pressure including 
aneroid, semi-automated, and automated devices. Substantial evidence has emerged that 
these alternative devices can be inaccurate when subjected to validation. Regular 
calibration is also required, particularly of aneroid sphygmomanometers.19 
2.3.4 Management in primary care 
On a national level, the management of high blood pressure is addressed through the 
National Service Frameworks (NSFs) for Coronary Heart Disease and for Older People, 
which support the implementation of management strategies for hypertension 
particularly in primary care.25,26 These documents mainly advocate improved protocols 
to assess, treat and follow-up people with established coronary heart disease and 
emphasise the importance of appropriate lifestyle changes and the correct use of 
medication to treat high blood pressure. 
The principal objectives when managing high blood pressure are to:22 
1. Decrease cardiovascular risk associated with hypertension 
2. Decrease the risk of any other co-existing cardiovascular risk factors 
3. Select antihypertensive drugs that are likely to do more good than hann for each 
individual's mix of co-existing medical conditions, risk factors, preferences, and 
social circumstances 
4. Minimise the adverse effects and inconvenience of antihypertensive drugs. 
N on-pharmacological treatment 
Risk factor modification is frequently recommended as an initial alternative to drug 
treatment. 27 
The latest systematic review of long-term effects of advice to reduce dietary salt in 
adults by Hooper and colleagues evaluated three trials in normotensive people 
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(n 2326), five trials in those with untreated hypertension (n=387), and three trials in 
people being treated for hypertension (n=801) with follow-up from six months to seven 
years.28 Intensive behavioural interventions, which are likely to be unsuitable to primary 
care or population prevention programmes, reduced systolic blood pressure by 1.1 
mmHg (95% confidence interval (Cn: 1.8 to 0.4 mmHg) and diastolic by 0.6 mmHg 
(95% CI: 1.5 to -0.3 mmHg). This review concluded that advice to reduce sodium 
intake may help people on blood pressure lowering drugs to stop their medication while 
maintaining good blood pressure control. 
In a recent RCT, Blumenthal and colleagues randomly assigned 133 sedentary, over-
weight men and women with unmedicated high normal blood pressure or mild 
hypertension to aerobic exercise alone or in combination with a behavioural weight 
management programme. Weight management was associated with a 7 mmHg systolic 
and a 5 mmHg diastolic net reduction in clinic blood pressure, compared with a 4 
mmHg systolic and diastolic blood pressure reduction associated with aerobic exercise 
(p<0.001, 95 % confidence interval (Cn not reported).29 
Whelton and colleagues performed a meta-analysis of 54 RCTs with a total of2419 
participants investigating the effect of aerobic exercise on blood pressure.30 Aerobic 
exercise was associated with a significant reduction in mean systolic (-3.84 mmHg, 
95% CI: -4.97 to -2.72 mmHg) and diastolic blood pressure (-2.58 mmHg, 95% CI: -
3.35 to -1.81 mmHg). 
In summary, there appears to be an effect of lifestyle interventions on blood pressure, 
but the magnitude of blood pressure reduction for most interventions is fairly 
modest.21 ,31 
Pharmacological treatment 
A wide choice of antihypertensive agents is available for the treatment of high blood 
pressure in general practice, which usually allows practitioners to select an appropriate 
drug or drug combination for individual patients. The six main therapeutic drug classes 
include diuretics, beta blockers, calcium channel blockers, ACE inhibitors, angiotensin 
II antagonists, and alpha-l-adrenoceptor blockers. 19 
Collins & Peto summarised the effects of antihypertensive drug therapy on stroke and 
coronary heart disease and reviewed four large and 13 small unconfounded randomised 
controlled trials, reported between 1965 and 1992.5 Their results indicated strong 
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evidence that reducing diastolic blood pressure by 5 to 6 mmHg leads to a reduction in 
stroke of 38% (95% CI: 31 to 45%) and in coronary heart disease of 16% (95% CI: 8 to 
230/0). There has been a move away from the 'stepped care' approach of drug treatment 
which included starting with a thiazide diuretic or beta blocker and than adding in other 
classes of antihypertensive drugs. A 'tailored care' approach is now favoured, which 
individualises drug therapy to the patient's risk factor and comorbidity profile (see 
Table 1). 
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Table 1 Indications, contra-indications and adverse effects of major antihypertensive drug 
classes 
Common adverse Drug class Indications Contra-indications effects 
Thiazide diuretics Elderly Gout Hypokalaemia 
Diabetes (type 2) Dyslipidaemia Hyponatraemia 
African-Carribean Urinary Sexual dysfunction 
ethnic groups incontinence 
Gout 
Glucose intolerance 
Beta-blockers Myocardial Asthma/COPD Fatigue 
infarction 







ACE inhibitors Diabetes Pregnancy Cough 
Myocardial Renovascular First dose 
infarction disease hypotension 
Angina PVD Taste disturbance 
Heart failure Angio-oedema 
Chronic renal 
disease 
Calcium-channel Elderly Myocardial Constipation 
blockers infarction 











Source: Fahey & Schroeder. High blood pressure. In: Oxford Textbook of Primary Medical Care, 
200321 
ACE = angiotensin converting enzyme; COPO = chronic obstructive pulmonary disease; 
PVO = peripheral vascular disease 
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Thiazide diuretics are still the preferred initial therapy for hypertension. One of the most 
important trials of antihypertensive therapy, the Antihypertensive and Lipid-Lowering 
Treatment to Prevent Heart Attack Trial (ALLHAT), which studied 33357 participants 
with hypertension in 623 North American centres, aimed to determine whether 
treatment with a calcium channel blocker or an angiotensin converting enzyme inhibitor 
lowers the incidence of coronary heart disease or other cardiovascular disease events 
versus treatment with a diuretic.32 The primary outcome was combined fatal or non-fatal 
myocardial infarction, analysed by intention-to-treat. After a mean follow-up of 4.9 
years there was no difference between the effects of chlorthalidone, amlodipine and 
lisinopril (relative risk (RR) 0.98 (95% CI: 0.90 to 1.07) for amlodipine and RR 0.99 
(95% CI: 0.91 to 1.08) for lisinopril. The results of this study are consistent with 
findings from the HANE study, which compared hydrochlorothiazide with atenolol, 
nitrendipine, and enalapril. 33 
Despite these findings, Bloom argued in a recent editorial in the British Medical Journal 
that newer drugs in hypertension should help improve compliance.34 Although this 
notion would be a convenient marketing strategy for the pharmaceutical industry, this is 
certainly untrue in the field of hypertension. There is good evidence that for the 
treatment of high blood pressure, low dose diuretics are as effective as more expensive 
antihypertensive drugs and often have also a better side effect profile than many newer 
drugs.35,36 
Recent guidelines on the combination of drugs in the treatment of hypertension suggest 
to use angiotensin receptor blockers (A) or beta blockers (B) for renin-dependent 
hypertension and to prescribe calcium channel blockers (C) or diuretics (D) in the 
majority of hypertensive patients who have low-renin hypertension, which led to 
development of the AB/CD rule.36 
A recent meta-analysis by Staessen and colleagues indicated that most antihypertensive 
drugs have similar long-term efficacy and safety and that their main effect is mediated 
through blood pressure control rather than individual pharmacological properties. 37 
Combination drug therapy will frequently be necessary to achieve and maintain lower 
blood pressure goals.38 Treatment of older people with hypertension is also effective. 
Mulrow and colleagues conducted a systematic review of 15 randomised trials, which 
involved a total of 21908 elderly persons, and found that treating older persons with 
hypertension is effective, with event rates for cardiovascular morbidity and mortality 
reduced from 177 to 126 events (95% CI: 31 to 76).39 There is increasing evidence that 
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antihypertensive treatment may also protect against dementia in older people with 
systolic hypertension in addition to reducing the risk of heart attack and stroke.4o 
Long-term care 
The main aims for the long-term care of people with high blood pressure are to ensure 
that blood pressure is at target level and to treat relevant co-morbid conditions.21 
Intensive lowering of blood pressure has been shown to reduce cardiovascular disease.37 
Randomised trials that compare aggressive versus less aggressive lowering of blood 
pressure report no adverse J-shaped relationship {too great a lowering of blood pressure 
leading to an increase in cardiovascular events).41 The optimal target blood pressure has 
been proposed as less than 140/90 mmHg for non-diabetic patients and less than 140/80 
mmHg for diabetic patients. 19 
The problem of uncontrolled hypertension 
The care that patients with high blood pressure receive is often variable and incomplete. 
The consequence is that in many countries a large proportion (usually in the range of 40 
to 50%, depending on the blood pressure level used to define target blood pressure) of 
patients taking antihypertensive drugs have not reached target blood pressure goals.41 
These individuals are said to have 'uncontrolled' high blood pressure, although it is 
worth emphasising again that every threshold for determining blood pressure control is 
arbitrary. However, there appears to be a linear and positive relationship between blood 
pressure and the risk of stroke, which suggests that lowering blood pressure leads to 
lower risk of disease.5 There are a number of common reasons and proposed solutions if 
individuals do not reach target blood pressures {see Figure 2).42 
We have recently conducted a systematic review of organisation and delivery of care 
interventions used to improve the control of blood pressure in patients with 
hypertension of 54 studies.43 Although the methodological quality of studies was 
variable, there was good evidence from a single large RCT that regular review together 
with vigorous antihypertensive therapy reduces all-cause mortality.44 Other 
interventions such as self-monitoring of blood pressure led to moderate reduction in 
blood pressure {weighted mean difference (WMD) -2.25 mmHg, 95% confidence 
interval (CI: -3.22 to -1.29), whereas educational interventions aimed at health 
professionals or patients did not appear to be associated with large net reductions in 
43 blood pressure. 
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There is inadequate evidence to recommend an optimal timing for patient review, self-
management strategies (including self-monitoring by patients), and the value of 
dedicated hypertension clinics. There is evidence that increased involvement of the 
primary health care team, particularly practice nurses, improves blood pressure control 
and prevents cardiovascular disease. The same can be said for structured care, which 
may include registration of patients, organised recall and regular review. However, the 
cost-effectiveness of such intensive approaches to long-tenn care is less certain.43 
The British Hypertension Society Guidelines for the Management of Hypertension 
make important recommendations on how hospital and general practitioners should 
approach the management ofhypertension.19 However, the translation and adaptation of 
these recommendations into local guidelines and summaries will be an ongoing 
challenge and should be monitored through clinical audit. This has so far shown 
significant variability among practices and practitioners, which makes comparison 
between audits difficult. 45,46 
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Figure 2 Causes of 'uncontrolled' hypertension and proposed solutions 
Inaccurate blood pressure measurement Follow BHS guidelines for the 
management of hypertension,19 use 
standardised electronic blood pressure 
measurement devices 
White-coat hypertension Ask other health workers to measure 
patient's blood pressure; if still raised, try 
self-monitoring or referral for ABPM. 
Disease progression Can only be attributed to disease 
progression after excluding other possible 
causes. 
Sub-optimal treatment At least half the patients with high blood 
pressure will require two or more classes 
of antihypertensive drugs to ensure 
adequate blood pressure control. 
Non-adherence to antihypertensive drugs There is some evidence that adherence 
can be enhanced by educating and 
discussing adherence related issues with 
patients and by involving other members 
of the primary health care team.41 
Concurrent use of antagonising drugs Several drugs raise blood pressure and 
these should be specifically asked about 
when taking a history. Of particular note, 
NSAIDs are commonly prescribed, 
particularly in the elderly. It is estimated 
that these drugs increase blood pressure 
by about three to five mmHg in 
hypertensive individuals. 
Co-existing conditions Includes excessive alcohol use, obesity, 
anxiety, hyperinsulinism with insulin 
resistance, sleep apnoea, and smoking. 
Secondary hypertension Requires further investigation and 
specialist referral. 
Adapted from: O'Rorke & Richardson. Evidence based management of hypertension: what to 
do if blood pressure is difficult to control. BMJ 2001;322:1229-32. 
ABPM = ambulatory blood pressure monitoring 
NSAID = non-steroidal anti-inflammatory drug 
Non-adherence and non-response 
In clinical practice a major problem is to differentiate between non-adherence to blood 
pressure lowering medication and non-response to treatment, which I will discuss in 
more detail in section 2.4.5. 
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2.3.5 Implications of diagnosing and managing high blood pressure 
There is some evidence of a 'labelling' effect on patients diagnosed as having high 
blood pressure. Knowledge that a person has high blood pressure has been reported to 
increase their absenteeism from work and produce a negative impact on self-reported 
psychological well-being.47 However, the overall impact of high blood pressure on 
quality of life is not thought to be substantia1.22 
Symptomatic adverse effects vary by drug class and by agents within drug classes. 
Overall, 10 to 18% of individuals receiving antihypertensive treatment report side 
effects (see also Table 1).22 It is, therefore, important that general practitioners and other 
health care professionals involved in the care of people with high blood pressure are 
aware of the common adverse effects from the major classes of antihypertensive drugs. 
2.3.6 Hypertension in the context of cardiovascular disease 
It is important not to look at high blood pressure in isolation, but to see this as one of 
the risk factors for cardiovascular disease, which is the most important cause of death 
today.48,49 The UK Department of Health aims to reduce cardiovascular disease in 
people under 75 years of age by two fifths before the year 2010/5 which is expected to 
result from interventions in hypertension and other cardiovascular risk factors such as 
smoking, diabetes, and hypercholesterolaemia for primary prevention. Rather than using 
individual risk factors, risk assessment combining multiple risk factors is preferable but 
associated with practical problems. 50 Cardiovascular risk can be calculated using 
different risk calculation tools in general practice, which can be difficult if data on risk 
factors is not available.51 ,52 In a study in which general practitioners and practice nurses 
compared the New Zealand risk tables with a reference calculation of risk, accuracy was 
only moderate.53 
Dose-response relationships indicate that a given change in blood pressure leads to a 
reduction in cardiovascular risk by a constant proportion, irrespective of the starting 
level of blood pressure.41 ,54 Interventions aiming to change risk factors should therefore 
be determined by an individual's level of risk and not necessarily based on the blood 
pressure level alone. 54 In addition, patient preferences always need to be taken into 
account when making evidence-based decisions in hypertension treatment. Practitioners 
should share decisions with patients, who are the experts in judging their own values 
and whose risk judgements may differ, either qualitatively or quantitatively. 55-58 
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2.3.7 The role of nurses in the management of hypertension 
Effectiveness of nurse-led care in general 
General practitioners, nurses and other health professionals in the primary health care 
team work collaboratively to achieve the aim of improving and maintaining patients' 
health. However, the working relationship between nurses and doctors has not always 
been straightforward. Britain's National Health Service and primary care have 
undergone many organisational changes in recent years, and the role of nurses is 
expanding. 59,60 
A recent systematic review by Horrocks and colleagues of whether nurse practitioners 
working in primary care can provide equivalent care to doctors included 11 trials and 23 
observational studies.61 This review showed that patients were more satisfied with the 
care by a nurse practitioner (standardised mean difference 0.27, 95% CI: 0.07 to 0.47), 
although the effect size was relatively small. Nurse practitioners were found to have 
longer consultations and they requested more investigations. This study found no 
differences in prescriptions, return consultations, or referrals. The results of this review 
suggest that an increase in the availability of nurse practitioners may lead to higher 
levels of patient satisfaction and quality of care. 
The British Medical Journal devoted a special theme issue focusing on this area in April 
2000, looking at new ways of how nurses and doctors can work together. In their 
editorial, Salvage and Smith re-kindled the debate on how best to combine the talents 
and commitment of nurses and doctors to improve patient services.62 They argued that 
dispelling any resentment b~tween doctors and nurses is an important step and that 
disputes about their roles should be replaced with a discussion of how to make the best 
use of the wealth of different skills that the different health professionals bring to 
pnmary care. 
A number of trials of nursing in primary care were also reported in this theme issue. An 
RCT by Shum and colleagues of 1815 patients who requested same day appointments 
showed that patients were more satisfied with nurse consultations compared to doctor 
consultations with mean (standard deviation SD) satisfaction scores of78.6 (16.0) out 
of 100 points versus 76.4 (17.8) for doctors (95% CI for the difference between means: 
-0.38 to 4.07)63. In this study, the nurse consultations were slightly longer (10 minutes 
compared to 8 minutes for doctors), and nurses and doctors wrote prescriptions for a 
similar number of patients. This study illustrates that practice nurses can offer an 
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effective service, although the results are limited to patients who presented with acute 
minor illness. A trial conducted by Kinnersley and colleagues of nurse practitioners 
reported in the same issue of the BMJ supported these results.64 
N nrse-led care in hypertension 
Although nurse-led care appears to be effective in many areas of primary care, there is 
little evidence that nurse-led care is effective in the management of hypertension. 
Oakeshott and colleagues reviewed 10 studies of nurse-led management of high blood 
pressure, which were all of generally high methodological quality in terms of 
randomisation, blinding, and reports of losses to follow-up.65 This review found that 
nurse-led hypertension management and cardiovascular health promotion without a 
change in prescribing had little or no effect on blood pressure. Only one of the included 
trials, in which patients with blood pressure levels above certain cut-off points were 
referred to their GPs for drug treatment, showed an important difference.66 This review 
concluded that the most important advantages of nurse-led care included improved anti-
hypertensive prescribing, better adherence to treatment and better follow-up due to 
rigorous application of national guidelines. The authors identified a need for 
randomised controlled trials based in primary care to further evaluate the effectiveness 
of nurse-led care by specially trained practice nurses in improving blood pressure 
. 
control. 
2.4 General concepts in adherence research 
2.4.1 Introduction 
Therapeutic drugs are powerful tools of modem medicine, but the effect of medicines 
depends on the extent to which they are taken. The quality of a patient's execution of a 
prescribed pharmaceutical regimen has been a focus of research for many years and has 
led to a number of different terms such as compliance, adherence, concordance and 
persistence to describe this topic.67 Different viewpoints, for example from a 
behavioural or therapeutic angle, may be partly responsible for this confusing array of 
terms. In addition, the ambiguity of tenns is also due to the various methods used to 
compile accurate dosing histories of ambulatory patients.67 Because particularly the 
terms compliance and adherence may exaggerate the health professionals' control over 
the process of taking medications, their correct definition and differentiation from the 
. h . f . d b t 68,69 term concordance IS t e tOpIC 0 an ongomg e a e. 
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It is easy for health professionals to see non-adherence as some form of deviant 
behaviour, but this view is unjustified.7o Donovan & Blake took a rather cynical view of 
the term 'compliance' and argued that this concept is largely irrelevant to patients who 
carry out a 'cost-benefit' analysis of each treatment, weighing up the costs and risks of 
each treatment against any benefit that may result from the medication.71 Although this 
view can be justified in cases of intentional non-adherence, it does not help to explain 
and understand the problem with non-intentional non-adherence. 
2.4.2 Definition of terms 
This section provides brief definitions of terms commonly used in ambulatory 
pharmacotherapy. An understanding of these and the different methods and defmitions 
of dosing histories is essential for interpreting research in the field of adherence (see 
Figure 3) 
Figure 3 Definitions in ambulatory pharmacotherapy 
EXECUTION 
Time .n 





Acceptance Time Discontinuation 
Acceptance or adoption 
This is a dichotomous variable, describing whether the patient does or does not accept 
the recommended treatment after discussion of the treatment plan and agreeing to take 
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the proposed medication.72 Whether a patient accepts the proposed treatment plan 
depends on various factors, including the patient's understanding of the diagnosis, the 
risks that are involved in taking or not taking the recommended regimen, and the role of 
the prescribed drug regimen. The phase starting with acceptance ends after the 
pharmacist dispenses the prescription to the patient and the patient takes the first dose.72 
Execution 
Execution is part of the patient's daily life and refers to the daily taking (or not-taking) 
of the prescribed dose at the prescribed time(s) every day72. This tenn describes a 
continuous variable, with a wide spectrum of patterns of deviation from the prescribed 
regimen, which may vary over time. The quality of execution can be described as 
patient compliance (see below). 
Discontinuation 
Although many treatments for chronic conditions are meant to be for life, many patients 
decide for a variety of reasons to discontinue with the prescribed treatment. 
Discontinuation is a term used to describe the time when a patient stops taking the 
prescribed medication regimen. 
Adherence 
Adherence is a useful overall term, which takes into account acceptance, execution and 
discontinuation of medical treatment. Poor adherence to medication can imply problems 
with any of the three terms persistence, compliance and concordance, which I define in 
the following paragraphs. 
Persistence 
The term persistence designates the length of time between acceptance and 
discontinuation of treatment. The crucial element inherent in this term is the time factor 
_ that is, the duration of execution - unlike discontinuation, which is an event. 
Caro and colleagues found a relationship between persistence with blood pressure 
lowering therapy and the initial drug prescribed in a large cohort study in Canada. 8 In a 
sample of 22,000 newly diagnosed and treated hypertensive patients, persistence at 12 
months was generally poor and different for individual drugs, with 80% for diuretics, 
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85% for beta blockers, 86% for calcium channel blockers and 89% for ACE inhibitors 
(p<O.001). This study looked at different explanations for the results but failed to 
acknowledge whether a simple change in medication could have led to the stopping a 
particular drug. The authors also found that persistence with antihypertensive treatment 
decreased in the first six months after starting therapy and continued to decline for the 
following four years.73 Only 78% of the newly diagnosed hypertensive patients 
continued with the therapy for one year, compared to 97% of the patients who had 
established hypertension and had taken blood pressure lowering medication for a 
minimum of 10 months (p<0.001). These results suggest that successfully passing the 
early therapeutic phase after initiation of treatment may be crucial for achieving long-
term persistence. 
Data for UK. general practice indicate that discontinuation rates or changes after new 
prescribing of blood pressure lowering medication may be even higher. A retrospective 
analysis of 37,643 hypertensive patients on an automated database showed that 
discontinuation rates ranged between 40 and 50% for all four classes of antihypertensive 
drugs that were evaluated.74 However, this study could not provide any information 
about the reasons why so many people discontinue treatment with antihypertensive 
medication. 
Compliance 
Compliance describes the quality of execution of the recommended drug regimen, 
mainly from a biomedical perspective. It can be defined as the degree of correspondence 
between the actual dosing history and the prescribed regimen.75 This definition of 
compliance is useful for the analysis of compliance data, as it can take into account 
information about the timing and patterns of medication intake. 'Timing compliance', 
which I will in more detail define later, can, for example, be used in analysing and 
modelling its impact on drug concentrations, drug actions and clinical outcomes and has 
been used as the primary outcome for the RCT described in this thesis. 
Although according to this definition compliance is a neutral term, it has been criticised 
as being problematic, as it may express an ~derlying ideology that assumes that 
patients ought to follow health professionals' instructions with a certain degree of 
deference.76 Earlier definitions of adherence such as 'tending to follow medical 
recommendations', which are widely used in the adherence literature, are not 
meaningful. 
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Compliance also has an important time component, because drug actions depend on the 
dose and the time between doses. Every drug has a specific dose-response curve, which 
describes the rise and fall of the drug action or concentration after each dose. There are 
wide differences between drugs on how long their actions persist after a taken dose, and 
the dose-time response curves can also vary in shape. These curves can also help in 
detennining the extent to which patients need to adhere to a prescribed regimen in order 
to achieve the desired effect. 
Concordance 
The tenn concordance was introduced recently and draws on research providing new 
insights into the relationship between prescriber and patients, taking a more patient-
centred approach. l3 Every clinical encounter between health professional and patient 
has to take into account the health beliefs of both patient and prescriber.77 It should be 
the task of the patient to infonn the health professional of his or her health beliefs, and 
the health professional's task is to enable the patient to do this. This aims to fonn a 
'therapeutic alliance' to help the patient with making a more infonned choice about the 
medical diagnosis and its management. 77 This model has been named concordance, 
which, in contrast to the tenn compliance, aims to describe an agreement between 
patient and health care professional about the whole process of medication taking. 13,78,79 
However, it is important to acknowledge that the tenn concordance does not aim to 
replace the other tenns mentioned above. It focuses more on what actually happens 
during the consultation between patient and prescriber rather than describing the extent 
of medication taking. 
2.4.3 Issues around adherence related terms 
Adherence, compliance and concordance are often used interchangeably when studying 
health behaviour change, but their meanings are in fact different, particularly in the 
context of controlled clinical trials examining interventions aimed at improving 
adherence. According to Brawley & Culos-Reed, the tenn adherence takes into account 
that people choose to take their medicines, have control over their use, and develop an 
agreement with health care professionals about their management. 80 In their opinion, 
compliance implies obeying behaviour and that people follow instructions and 
prescriptions assigned by a health care provider. The main difference between the tenns 
adherence and compliance is on a motivational level. The fonner implies a more active 
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role of patients in their management, whereas the latter is characterised by more passive 
behaviour. Unfortunately, as a result of trying to apply 'political correctness' the tenn 
concordance has occasionally, and not always appropriately, replaced the terms 
1· 69 . comp lance or adherence. The current and so far stlll open debate over these terms is 
perhaps a gentle reminder that the relationship between patient and health professional 
is also often based on poor communication and misunderstandings. 
A further unhelpful distinction is the classification of patients into adherers and non-
adherers, which implies an all-or-nothing behaviour.4 Instead, adherence should be 
based on the specific level of adherence that is required to achieve a desired therapeutic 
response.81 
For this thesis, I have chosen to use the term adherence, because of the motivational 
perspective associated with this term. Adherence is also the expression that is currently 
being used by the World Health Organisation.2 Although adherence is often defined as 
above, that more traditional definition does require some modification, which should 
take into account cut-off points for specific diseases and therapeutic drug groups. 
Adherence is thus a useful overall term. Timing compliance, a specific term to describe 
the execution aspect of adherence, was the primary outcome for the trial described later 
in this thesis. 
2.4.4 Measuring adherence 
No single method of measuring adherence is suitable for all settings or outcomes.82,83 
Regarding assessment strategies for any outcome, assessment of adherence must 
demonstrate validity and reliability. According to Pullar & Feely, the ideal measurement 
of adherence should: a) be usable over a prolonged period, b) be unobtrusive, c) be non-
invasive, d) be practicable and cheap, e) yield immediate results, and f) not be open to 
manipulation.84 Based on these stringent criteria, the objective measurement of 
adherence is difficult and poses a major problem for researchers and clinicians alike. 
What follows is a brief description of the most commonly used methods of measuring 
adherence, starting from more traditional methods and then moving on to more recent 
advances. These can be separated into direct methods, which prove ingestion of the drug 
(such as the measurement of drug metabolites in plasma), or indirect methods, which do 
not prove ingestion of the drug (such as self-report or electronic monitoring). 
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Prescribing data 
Data on medication prescriptions can be used as a simple method to assess primary non-
adherence, that is, the rate of patient who do not redeem their prescriptions. Although 
this method detects non-adherence in those people who have not redeemed their 
prescription, it does not provide much useful information about those people who have 
had their medication dispensed to them. 
Beardon and colleagues performed an observational study on 4854 patients and found 
that 14.5% of the study participants did not redeem their prescriptions during the study 
. d ( 85 peno 11.5% men and 16.3 % women). Their results also showed that non-
redemption was associated with age, sex, general practitioner, exemption status, and on 
which day of the week the prescription was written. The rates of non-redemption were 
particularly high for cardiovascular drugs (52% for men and 57% for women). 
Self-report or patient interview 
Morisky and colleagues conducted a study on concurrent and predictive validity of a 
self-reported structured four-point adherence measure in 400 patients in two outpatient 
clinics ofa large teaching hospita1.86 They found that 75% of the patients who scored 
high on the four-item scale at year two had controlled blood pressure at year five, 
compared with 47 per cent of those participants scoring low (p<0.01). However, these 
results have to be interpreted with caution, as adherence was not validated using another 
method of measuring adherence such as electronic monitoring, which was not widely 
available at the time of the study. 
Despite being relatively eaSy to conduct, patient self-report unfortunately cannot 
provide detailed information about the execution of the drug regimen and is therefore of 
limited value ifhigh quality data about adherence are required. However, when trying to 
assess adherence in the medical interview, a non-accusatory, open-ended and matter-of-
fact approach is most likely to be ofvalue.87 There is also evidence to suggest that it is 
easier to change the self-report of adherence rather than adherence itself.88 
Although it has its limitations, adherence self-report is the easiest method to employ in 
clinical practice, because it is inexpensive, quick and non-invasive. For this reason 
adherence self-assessment tools continue to be developed and evaluated. More recent 
studies validated these tools using electronic medication monitors (MEMS~ with 
promising results.89,90 I will discuss the latest research in this area in more detail in the 
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background section of Chapter 6, which describes a validation study of an adherence 
self-assessment tool. 
Pill counts 
Using this method, the pill bottle contains more tablets than needed for the course of 
treatment. At the end of the course the pill bottle is recovered, and the remaining 
number of pills is used to calculate pill consumption. Pill counts give numerical values 
of doubtful objectivity and precision. It is easy for patients to discard or hoard untaken 
doses to create the impression of good adherence with the prescribed drug regimen - an 
occurrence that has been widely documented.83,91-94 In an ambulatory hypertensive drug 
trial, pill counts misclassified adherent subjects in 220/0 of visits compared to electronic 
monitoring.95 In this study, adherence was almost perfect with 92% and 99% for both 
treatment groups; electronic monitoring confirmed that fewer than half of the openings 
occurred at the prescribed interval of 12 ± 2 hours. Cramer and colleagues found in a 
relatively small study of 24 study participants with epilepsy that pill counts 
overestimated adherence increasingly as adherence with the prescribed regimen 
declined.93 The study team used electronic monitoring in the comparison group and 
discovered that neither drug serum concentrations nor pill counts would have identified 
the number of skipped d0ses that were revealed through electronic monitoring. Guerrero 
and colleagues assessed medication taking in 19 ambulatory hypertensive patients, 
using both pill counts and electronic monitoring, and confirmed these findings. In their 
study, 51 % of the monitored periods between two visits displayed 80% or more of vial 
openings within the desirable range of 24 + 6 hours. In contrast, pill counts detected 
only 2% of these SUboptimal dosing intervals. Despite this being a small study, it adds 
to the evidence that pill counts tend to overestimate adherence substantially. 
Clinical outcome 
If no other method of measuring adherence is available or appropriate, clinical measures 
(such as heart rate in the use of beta blockers or direct therapeutic response) in addition 
to non-threatening approaches for asking open questions about medication adherence 
may have some value in helping the clinician to decide whether a patient is taking 
medication as prescribed.96 Positive information about non-adherence is helpful, but 
. .• 93 false negatIve reportIng IS common. 
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Haynes and colleagues compared clinical assessments with pill counts in 134 newly 
treated hypertensive steel workers during the first six months of their treatment with 
blood pressure lowering medication.97 In this study, participants overestimated 
adherence by an average of 170/0, but 900/0 of those who admitted to not taking their 
medicines as prescribed were indeed found to be non-adherent. 
Clinical measures of adherence largely depend on the condition being studied and 
assume a cause and effect relationship, which is rarely applicable. They also have to 
take into account the stage of the development of the disease and knowledge about the 
efficacy of the drug that is being administered, as well as the clinical skills of the 
practitioner performing the outcome measurement. If a medication is 'forgiving', that is, 
has a long duration of action, then incomplete adherence may not influence the 
effectiveness of the medication. 
Pharmacological indicators 
By adding a low dose of another compound to the medication being studied, this can be 
used as a pharmacological indicator if it has an appropriate plasma half life and 
elimination curve. It is also important that this substance is easy to measure in blood or, 
preferably, urine. Although this technique is relatively accurate and reproducible,4 there 
is a problem relating to the sampling. This method only allows an estimate of adherence 
for a certain time before the assessment, often not more than one or two days prior to 
sampling, which is only a small fraction of typical treatment times. Blood sampling will 
mostly occur at the time of scheduled visits, but in patients who do not fully adhere to 
the treatment regimen the several days prior to the scheduled visit are often a period of 
particularly good adherence, which is also called 'white-coat compliance' .98,99 The use 
of this method of measuring adherence is further limited because it is invasive, often 
requires explicit patient consent, needs special laboratory equipment and personnel and 
is prone to intra- and inter-patient variations. This method is, therefore, often not 
appropriate for assessing adherence in research or clinical practice. 
Monitoring the primary therapeutic agent 
The plasma concentration of the primary therapeutic drug in question can also be 
measured in many instances, but this method always depends on the pharmacokinetics, 
that is, the uptake, distribution and elimination of the prescribed drug and accurate data 
on the timing of the last dose. However, pharm . etics depend on numerous other 
, 11\],.', .' , " Yf'" - j.. ~ 
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factors, which include gastric acidity, total body fat, or renal function. It is also 
impossible to estimate blood levels between measurements using this method, which 
makes it therefore unsuitable for use in the primary care setting. This method also has a 
limited value in that it only provides data for the days preceding the blood test. 
Electronic monitoring 
Micro-electronic methods have greatly advanced over the past decades and allow 
recordings of the timing and frequency of drug ingestion, which make them the only 
method to provide data on drug taking patterns. Devices are now available for tablets, 
capsules in blister packs, eye drops, or inhaled aerosol medication, which record the 
opening or activation of the medication container.4 
One of these devices used for tablets is the Medication Event Monitoring System 
(MEMS~. The MEMS® uses standard tablet containers, but the lids have a spring-
loaded mechanism which is connected to a microprocessor, recording the time and date 
of opening. Current processors can record about 2000 openings and have a shelf life of 
up to three years. Data can be downloaded onto a personal computer with a so-called 
downloading port, and data can be displayed graphically using the PowerView® 
software. 
A great advantage of this method is that it can provide detailed data on the execution, 
which includes information on dosing patterns such as day-to-day variability in 
medication taking, a rise in adherence in the days preceding the consultation (,white 
coat compliance'), an absence of dosing during weekends, or lapses in medication 
taking ('drug holidays'), which can occur at any time.98,lOO It allows the calculation of 
unique adherence variables such as taking compliance, correct dosing, timing 
compliance and therapeutic coverage (these terms will be defined in more detail later) 
and is the only method of detecting 'drug holidays'. 
There are, however, limitations to electronic monitoring. First, there is no guarantee an 
opening of the medication container is followed by ingestion of the correct dose. 
Second, the recorded opening of the monitor does not indicate how many drug doses 
were removed. However, it is more difficult to falsify than any of the other methods, 
because a patient has to open the medication monitor every day at the correct time to be 
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classified as adherent. Third, patients may prefer their drugs being dispensed in a multi-
dose organiser. Fourth, the health professional handing over the monitor must 
accurately record the time when the monitor was handed over to the patient and when it 
was retrieved, as only between those times are all the recorded openings and closures of 
the monitor attributable to the patient. 101 Errors of a day or two in long-term drug use 
will hardly have any consequences, but in the investigation of acute and short-term 
illness, small errors can pose major problems for data interpretation. Patient feedback is 
therefore required to assess whether the devices were used appropriately at all times. 
Although bias may occur by patients being aware of being monitored and therefore 
changing their behaviour, any so-called reactivity bias is usually short-lived, with 
patients returning to their regular self-medication behaviour patterns after about four 
weeks.98 Although electronic monitoring is currently regarded as the method which is 
closest to a 'gold standard' in measuring adherence,lOl it has so far been used mainly as 
a research tool due to its relatively high cost. 
2.4.5 Distinction between non-adherence and non-response 
A reliable dosing history is necessary to provide the basis of an objective assessment of 
patient adherence to help distinguish between non-adherence and non-response relating 
to pharmacological therapy.l02,103 Pharmacological non-response is likely if good 
adherence can be demonstrated, and non-response in the presence of gross non-
adherence is convincing that non-adherence is a sufficient, if not necessary, cause for 
the lack of clinical response. There is, however, an intermediate zone where it is useful 
to know how much adherence is required to achieve the desired clinical effect, which is 
a particularly important question in patients who are prescribed long-acting drugS. 101 
The relationship between adherence and treatment response is not simple and can 
influence the extent to which health professionals and patients perceive the importance 
of complete adherence.88 A recent 'prospective case control study' with 110 consecutive 
medical outpatients with hypertension who have taken at least two antihypertensive 
drugs for at least four weeks claimed that non adherence to blood pressure lowering 
medication was not more common in treatment resistant high blood pressure than in 
patients who responded to treatment. 104 However, the authors did not take side effects or 
pharmacological aspects of the medication into consideration. The study was too short 
and too small to reach any firm conclusions about the relationship between adherence 
1105 and blood pressure contro . 
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2.4.6 Presentation of adherence data 
Electronic medication monitoring can provide detailed data on adherence and can take 
into account not only the number of doses taken, but also the number of days during 
which the correct number of doses was taken. Different definitions have emerged, 
which can be expressed in percentages:67,106 
1. Based on dosing: the number of doses recorded as taken, divided by the number 
of days of treatment mUltiplied by the number of doses prescribed during a 
monitored period 
2. Based on number of days with correct dosing: the number of days during which 
the correct number of doses were taken, divided by the number of days of 
intended treatment 
3. Based on the interval between doses: the number of correct intervals between 
doses divided by the total number of intervals between prescribed regimens 
based on a defined threshold, also known as 'therapeutic coverage' 
4. Based on the interval between doses: treatment time during which the intervals 
between doses correspond, within predefined limits, to the prescribed interval 
(timing compliance) 
5. Based on a pharmacodynamic (PD) and pharmacokinetic (PK) model: time that 
simulated concentrations, via a robust PK-PD model, of drug in plasma and drug 
actions fell within a defined therapeutic range 
It is worth noting that time has a central role in all but the first of these expressions of 
compliance data. 
2.4.7 Reasons for non-adherence 
There are a number of reasons why patients may not take their medication as prescribed, 
either intentionally or involuntarily (see Figure 4). 107 All these factors may be 
responsible for non-adherence either alone or in combination, which adds to the 
complexity in this field. Non-adherence is universal and not connected with any specific 
demographic or socio-economic factor. 108 It is encountered both in symptomatic 
109110 . di . I din diseases such as epilepsy or asthma ' as well as asymptomatIc seases mc u g 
hypertension and hyperlipidaemia,81,11 1,112 and even serious illness such as infection 
. d fi . . (HIV) 113 with the human lmmuno e clency VIruS . 
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Figure 4 Common reasons for non-adherence 
Condition-related 
• Disease severity 
• Symptoms 




Appropriateness of the prescription 
Side effects 
• Number of daily doses 
• Drug presentation/formulation 
• 
• 
Number of drugs prescribed concurrently 









• External factors 
• Environment (e.g. home, work) 
Adapted from: Sackett & Haynes. Compliance with therapeutic regimens. Baltimore & London: 
The Johns Hopkins University Press, 1976. 
Unintentional lack of adherence may, for example, simply be the result of forgetfulness 
due to a busy lifestyle, lack of memory associated with dementia, failing to understand 
the prescriber's directions, failure to understand the importance of long-term 
maintenance therapy, polypharmacy, or a complex dosage regimen of more than one 
dose per day. With regard to the number of daily doses, a recent review article by 
Claxton and colleagues found that the prescribed number of daily doses is inversely 
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related to medication adherence in a number of different therapeutic drug classes. I 14 
Only studies using electronic monitoring were included, and the pooled results showed 
that mean dose taking for a once daily regimen was 71 % ± 17% (range 34 to 97%) and 
declined with an increasing number of daily doses with 51 % ± 20% for a four times 
daily regimen (p<0.001). 
Intentional poor adherence may be based on a rational decision not to take a medicine as 
prescribed. People have their own beliefs about health, illness and the use of medicines 
in general, which may sometimes be in contrast to those of health professionals. I 15,1 16 
These beliefs can be influenced by people's socio-cultural background, the knowledge 
about the disease and its management, the individual's perception of the risk of not 
taking the medicines, information from friends and relatives or the media, the 
relationship with the health professional or prescriber, dislike of side effects, fear of 
developing immunity, dislike of artificial chemicals, desire for autonomy, and many 
other behavioural or psychological determinants.4 
A qualitative study nested within a pragmatic randomised controlled trial on non-
adherence with physiotherapy in 20 patients with osteoarthritis of the lmee highlighted 
the importance of understanding the reasons for non-adherence ifhealth professionals 
want to provide supportive care. I 17 The results of this study showed that adherence-
related behaviour was complex and depended on issues around loyalty to the health care 
professionals, willingness to accommodate the treatment into daily life, the perceived 
severity of symptoms, attitudes to the illness, previous experiences of patients' diseases 
and the belief that the physical treatment was effective in improving pain and other 
unwanted symptoms. 
Social factors such as a weak social support network, lack of transportation, social 
isolation, visual problems, or concerns about leaving the house also need to be taken 
into consideration. I 18 
2.4.8 Lay views of medicines 
Whether people take prescribed medicines is not only informed by beliefs about 
medicines but also by beliefs about the medical condition, which the medication intends 
to prevent or treat. 1 15,1 19 A number of qualitative studies have been conducted in this 
field which have shown that people have specific beliefs about medication in , 
general I 16,120 and about hypertension in particular. 121 
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Despite the large number of studies on adherence in hypertension, there is still little 
understanding about how patients themselves perceive blood pressure lowering 
treatment and about possible variations between different ethnic groups. 122 Morgan 
described in a qualitative study based in 15 London general practices how 30 White and 
30 Afro-Carribean hypertensive patients were aware of and often commented on the 
ambivalent status of being ''under the doctor" for blood pressure but not "sick" as 
SUCh.122 Respondents in this study were generally well aware of the fact that high blood 
pressure could lead to an increased risk of death, heart attack, and stroke. Major 
concerns in both groups were worries about possible "side effects", that is, drug adverse 
effects of an unwanted or serious nature, in the future. Another important reason for 
people's dislike of medicines was a perceived risk of becoming "addicted" to the drugs. 
Whether people stop taking their tablets for these reasons or become less adherent will 
depend on the strength of these beliefs, patients' assessments of the seriousness of their 
condition, and the perceived benefits of their medication. 
Horne and colleagues have recently developed a questionnaire-based method for 
assessing beliefs about specific and general medication, the 'Beliefs about Medicines 
Questionnaire' .123 The core themes relating to the prescribed medication for the patients 
were beliefs about medicines helping to maintain health and concerns about the 
medication. 
2.4.9 Psychological concepts of health-related behaviour 
To increase adherence to medication effectively, interventions have to help patients 
change their behaviour. A number of different models and theories have been used to 
predict, explain and understand adherence. 80 Theories of health behaviour commonly 
used in adherence research are the self-regulatory model of illness behaviour, the self-
efficacy/social cognitive theory,124 the relapse prevention model,125 and the 
transtheoretical model. 80,126 Most of the models used in adherence research attempt to 
explain the processes that are inherent in behaviour change, and all these theories 
assume that people are able to make goal-directed rational decisions. However, it is 
imp<?rtant to recognise that many of these models, such as the health belief model or the 
self-efficacy theory, are relatively simplistic and have often failed to provide an 
adequate explanation of adherence related behaviour. 
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This section looks at some of the differences between these models and theories and 
discusses the rationale behind why I chose the self-regulatory model as a theoretical 
basis for this thesis. 
Social cognitive theory 
This theory, formed by Bandura in 1986, used a social-cognitive viewpoint to analyse 
and understand human cognitions, actions, motivations and related emotions in within a 
broad theoretical framework. 124 This model not only discusses learning, but it also 
includes other issues such as psychosocial factors that cannot be explained by social 
learning theory. A central element of this theory is an assumed interaction between the 
person, the behaviour and the environment, with each of these factors helping to 
determine the others. This does not mean that all these factors influence each other 
equally or simultaneously, but they are all important to understand behaviour.8o,124 In 
relation to adherence, this theory recognises that people are not passive individuals open 
to any kind of intervention. 
Relapse prevention model 
The relapse prevention model, as well as the transtheoretical model covered next, is a 
fairly recent and relatively complex model.125 The main idea of this model is that the 
success of an individual in maintaining a new behaviour, such as adhering to a 
medication regimen depends on the ability to cope with a relapse to a behaviour that is 
less desirable, which might include not taking medication or taking it irregularly. This 
model aims to help people develop skills in self-awareness to differentiate a lapse, 
which might be accompanied by warning signs of changing back to an undesirable 
behaviour, from a complete relapse, which is characterised by a complete reversion to 
the undesirable behaviour. By using this model, individuals are also taught to use skills 
in self-regulation to cope with any lapses effectively in order to avoid complete 
relapses. 
Transtheoretical model 
This model has become popular among health care practitioners despite relatively little 
objective research support.80,126 It is based on the assumption that when attempting to 
change health behaviour people pass through five stages on the way from contemplating 
a health behaviour change to maintaining the desired behaviour. These stages include a 
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precontemplation phase followed by contemplation of the envisaged behaviour, 
preparation for change, eventual action and then maintenance of the desired behaviour. 
This model appears to be appealing due to its intuitive approach to changing health 
behaviour, because in each stage individuals show a certain readiness for change. 
Although people usually proceed through these stages in sequential order, they can 
advance and regress in a spiral-like fashion before maintaining a newly acquired health 
behaviour. 126 
Health belief model 
According to J anz & Becker, health behaviour is influenced by four main beliefs, which 
include: a) the perceived risk of developing a particular disease or condition, b) the 
perceived seriousness of the health threat, c) the perceived benefit associated with 
taking preventive action, and d) the perceived barriers associated with taking preventive 
action (for example, disadvantages, costs, discomfort).127 In relation to adherence, 
higher adherence would occur in individuals who see their condition as being serious, 
who feel that they are at risk and believe that the benefits of adhering to the treatment 
regimen outweigh the costs. 
This model is very intuitive and has become popular in the adherence literature to help 
explain non-adherent behaviour. According to this theory, non-adherent people do not 
perceive themselves as ill, are less inclined to take into account the benefits that may 
result from the prescribed treatment regimen. However, based on work by Haynes and 
collagues, the assessment of patients' health beliefs is not always helpful, as there are 
many other reasons for non-adherence than those based on patients' perceptions (see 
Figure 4). 
Self-regulatory model of illness behaviour 
. f bl I' 128-This model was developed by Leventhal and IS based on models 0 pro em-so vrng. 
130 It suggests that individuals deal with illness or medical symptoms in the same way as 
they deal with other problems. Assuming a health-related problem such as a new illness 
or having to take medicines for the first time, an individual will be motivated to solve 
the problem and to re-establish the preceding state of normality. 
The self-regulatory model consists of three stages. Stage one includes interpretation of 
the problem and assigning a meaning to it by taking into account the individual's illness 
cognitions. This stage is followed by developing and identifying suitable coping 
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strategies in stage two. The two broad coping strategies usually employed are approach 
coping, which might include the taking of prescribed pills, or avoidance coping 
characterised by denial or wishful thinking. The third stage of the self-regulatory model 
consists of an appraisal and evaluation of the strategy, during which an individual 
decides about continuing with the strategy or whether to try a different one. 
Rationale for using the self-regulatory model for this thesis 
Despite useful models being available for studying adherence-related behaviour, there is 
so far no convincing evidence to endorse a single model. 80 I have chosen the self-
regulatory model as the main theoretical basis for this thesis, because people have 
beliefs about illness in a similar way as they have about health. Evidence from mainly 
qualitative research shows that people have a variety of beliefs about their illness as 
well as its treatment with medication. 13,1 16 The particular strength of the self-regulatory 
model is that it takes into account individual symptom perception, emotional responses 
to a health threat such as fear or depression, coping strategies including approach and 
avoidance, and finally an appraisal as to whether the coping strategy was effective. 
Because traditionally many consultations in primary care use a problem-solving 
approach, this appeared to be the right model to describe how patients make sense of 
their illness and their medication management. The novel and distinguishing features of 
this model are that patients' assessment of their treatment plays a central role in it and 
that it recognises that emotional as well as cognitive processes are involved in making 
decisions as to whether or not to take prescribed medication.131 Based on this model we 
designed a nurse-led adherence support intervention, which aimed to identify and 
address individual medication problems together with each patient. The way this model 
assisted in the design of the intervention is described in section 5.9.2. 
2.4.10 Problems and consequences of non-adherence 
It is difficult to make general statements about the medical and economic consequences 
of variation in dose-timing, as these are specific to the particular medicine being used, 
the disease in question, the severity or extent of the medical condition as well as the 
. . b'd'ty 132 type and influence of any slgruficant co-mor 1 1 . 
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Clinical consequences 
The formulation and medication regimen also play an important role in determining the 
peaks, troughs, and the rates of a rise and fall in drug blood concentration.133 These 
factors, which can be influenced by the uptake, distribution and elimination of the drug 
in question, can affect the margin of error in dose-timing and reduce the risk of rate-
dependent adverse or rebound effects (an example of which would be a higher than 
expected transient rise in blood pressure after suddenly stopping an antihypertensive 
drug).134 The term 'forgiving' is used to describe medicines that have a substantial 
margin of error in dose-timing.132 For example, the original oral contraceptives had high 
oestrogen doses and were relatively forgiving in terms of missed doses.135 Modem 
combined oral contraceptives, and the progesteron-only pill in particular, are much less 
forgiving. They carry a warning in the UK that if there is a delay in taking the pill by 
more than 12 hours, barrier contraception should be used for the next 7 days.136 Oral 
contraceptives are more or less the only type of medicine for which explicit instructions 
are being issued on what to do if a dose is missed by a certain amount of time. 132 
Economics of non-adherence 
Non-adherence may cause additional health care costs in a number of ways. In terms of 
clinical outcomes, non-adherence has been shown to be associated with increased 
morbidity and mortality in chronic disease.137 There is some evidence that non-
adherence is likely to be associated with costly hospitalisations and visits to emergency 
departments. An economic evaluation carried out in the United States estimates that 
about 5% of all hospital admissions are linked to poor adherence, leading to 1.9 million 
admissions annually at a cost of several billion dollars.
l3S 
To evaluate the evidence on the economic effects of non-adherence, Cleemput and 
col~eagues conducted a review of 18 studies that attempted to calculate costs relating to 
non-adherence. 139 Perhaps not surprisingly, they found similar problems as the general 
adherence literature: many studies used diverse designs, defined and measured 
adherence inaccurately, and used invalid methods for calculating economic costs. The 
investigators did not find any studies from before 1982, which indicates how relatively 
new this research topic is. The review shows that the standard principles of good 
economic evaluation have rarely been applied in the adherence literature to date. The 
authors therefore concluded that more research of higher quality is needed to assess the 
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impact of non-compliance and the cost-effectiveness of interventions to improve 
adherence. 
Hughes and colleagues provided recommendations for taking non-adherence into 
account in pharmaco-economic evaluations, which include consideration of the 
influence of premature drug discontinuation, the frequency of drug holidays, modelling 
consequences for chronic conditions, therapeutic coverage, stating any assumptions 
made and performing sensitivity analyses for adherence level and the outcomes 
associated with each level.140 
2.4.11 Involving patients in their management 
Medical models have in the past been formulated that see the patient as a passive 
recipient of medical care. These have been replaced by models that include the patients' 
values and preferences in the treatment decision-making process. This is particularly 
important in the field of adherence where patients should be encouraged to participate in 
decisions in order to gain maximum benefits for themselves. 141 
The concept of patient centred care 
Patient centred care has received more importance in recent years. Although the term 
'patient centeredness' is widely used, it remains a little understood concept in medical 
practice.142 The relationship between health professionals and patients is complex, and a 
partnership between the two can take different forms. 143 A common misconception, 
however, appears to be that patient centeredness means sharing every piece of 
information and all decisions. l44 The correct meaning of the term encompasses the 
patient's desire to share information and decisions and for the health professional to 
respond appropriately.142 Involving patients in the management of their medical 
conditions is important for good quality health care, particularly relating to the problem 
of intentional non-adherence. 145 Most people like more information about their diseases 
and the different treatment options available.71 ,146 Patients in primary care also appear to 
want a patient centred approach with an emphasis on communication, partnership, and 
health promotion, as a questionnaire study by Little and colleagues with 865 patients in 
three general practices showed.147 This study identified five components of patients' 
perceptions, which included communication and partnership, personal relationship, 
health promotion, positive approach to diagnosis and prognosis, and interest in the 
effect on life, each of which was found to predict different consultation outcomes.148 
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Patients make decisions about their treatment all the time but often based on , 
incomplete or false knowledge about their drugs, adverse effects and the most effective 
way to take them. The provision of simple information therefore could help them to 
make more informed decisions and assist with choices that fit into their current 
lifestyle. 149,15o Elwyn and colleagues argued in a recent discussion paper that the part of 
the consultation where decisions are made and future management is agreed has been 
neglected at a time when the development of communication skills has focused on 
establishing patient agendas at the beginning of the consultation.1S1 They conclude that 
primary care practitioners are placed in an ideal position to share decisions with 
patients, but that this process will require, among other things, more time in the 
consultation. However, involving patients in health care decision also needs a 
willingness of patients to accept greater responsibility for choosing between alternative 
management strategies and for the resulting outcomes of the treatment. 145 
Other models have been used to describe treatment decision-making which include the 
paternalistic model, the informed model and the shared model. 144 The paternalistic 
model is characterised by the patient passively accepting the authority of the health 
professional. In the informed model, a partnership between patient and practitioner is 
formed, but information transfer is the only main responsibility of the professional. 
Only in the shared model do health professional and patient interact at any stage of the 
decision-making process at any time. In day-to-day medical practice, a combination of 
these models is likely to be employed, with varying emphasis on the different models, 
which may be adjusted to the needs of individual patients. l44 
Characteristics of shared decision-making 
Different models of shared decision-making have been developed. One of these has four 
characteristics, which include: a) both the patient and the health professional are 
involved, b) both parties share information, c) both parties take steps to build a 
consensus about the preferred treatment and d) and agreement is reached on the 
treatment which is to be implemented.152 
Using this model, a qualitative study by Stephenson and colleagues of 62 patients and 
20 doctors showed little evidence that doctors and patients participate during the 
consultation in this way. Even the first two of the above characteristics were not 
generally present in the consultations that were studied, so there was no basis on which 
to base consensus decisions on the preferred treatment. 153 
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Another study by Britten and colleagues investigated misunderstandings between 
patients and doctors that have potential or actual adverse consequences for taking 
medication.154 This study, conducted with 20 general practitioners and 35 consulting 
patients in the West Midlands and South East England, identified 14 categories of 
misunderstandings, which related to patient information unknown to the doctor, doctor 
information unknown to the patient, conflicting information, disagreement about the 
attribution of adverse effects, failure of communication about the doctor's decision and , 
relationship factors. All of these factors were related to potential or actual outcomes 
such as non-adherence. This study highlighted the importance of patient participation in 
the consultation and subsequent decision-making. 
Providing risk information for patients 
Discussion of risk is an important element of the clinical consultation, but it can be 
difficult for patients to understand risk and recall information relating to risk. 155 
Clinicians often use quantitative information such as relative risks or percentages, 
whereas many lay people may code information qualitatively.156 How an individual 
perceives language or statistics used by a health professional depends on various 
factors, which among other things include the importance placed on an adverse event.155 
It is important to remember that patients' understanding of risk can be different from 
that of health professionals. Guidance from the European Union recommends the 
qualitative description for five risk bands ranging from very rare (risk <0.01 %) to very 
common (>10%).157 
A study by Misselbrook & Armstrong pointed out the powerful effect that occurs when 
information is presented in different ways. 158 They found in a postal questionnaire study 
with 102 hypertensive patients and 207 matched non-hypertensive patients in a UK 
general practice that different ways of presenting risk to patients produced substantially 
different decisions among patients as to whether or not to agree to medical treatment. Of 
89% who responded, 92% would accept medication based on information about relative 
risks (75% using absolute risk model, 68% using a number needed to treat model, and 
44% with a personal probability of benefit model). However, this study is likely to be of 
limited generalisability, because it only recruited patients from one general practice. 
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Shared decision-making in hypertension 
Decision aids are health care interventions to help people with making specific and 
deliberate choices among different options, which may include maintaining the status 
quo. This also includes providing all the relevant information desired by patients on the 
different options and the health outcomes that a relevant to people's health. Various 
decision aids have been developed that have the potential to achieve more infonned 
decision-making in the general practice consultation. 
A systematic review by O'Connor and colleagues found that decision aids are superior 
to usual care interventions in improving knowledge and realistic expectations of the 
benefits and harms of options and lowering decisional conflict, but they have little 
effect on anxiety or satisfaction with the decision-making process.159 The authors also 
concluded that the effects of decision aids on medication adherence and health 
outcomes require further studies. 
In their review article, Montgomery and Fahey highlighted the difficulties and 
challenges of shared decision-making if patients and clinicians do not agree in their 
preferences for different treatment options.160 They found that differences in treatment 
preferences exist between patients and health professionals in cardiovascular disease 
and other specialties. Fo~ example, McAlister and colleagues investigated the treatment 
thresholds of family physicians and hypertensive patients for mild, uncomplicated 
hypertension in Canada. They found that patients were less likely to want 
antihypertensive medication than physicians, particularly in case of low baseline 
cardiovascular risk (e.g. 68% versus 92% for a five year cardiovascular risk of 5%, 
p<O.OO 1 ).161 
Montgomery and colleagues also conducted an observational study that aimed to 
investigate the impact of patient preferences on treatment recommendations for 
hypertension using individual decision analysis in 52 hypertensive patients.162 The study 
results showed that individual patient preferences had a substantial impact on the 
proportion of patients for whom treatment with medication would be recommended. 
There was marked disagreement between the results from the decision analysis and the 
recommendations, resulting in kappa values of 0.18 or less. They found no difference 
between the outcome of the decision analysis and adherence to blood pressure lowering 
medication (p=0.5). However, this finding has to be interpreted with caution due to the 
limited value of repeat prescribing in measuring adherence. 
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Measuring patient involvement in decision-making 
To date, no generally accepted measurement instrument exists that helps with the 
measurement of patient involvement in decision-making, although several instruments 
have been developed, as described in a systematic review by Elwyn and colleagues. 163 
However, none of these instruments have been specifically developed for the purpose of 
measuring patient involvement in clinical consultations. 
Promoting patient centred care in clinical consultations 
A Cochrane systematic review of interventions for providers to promote a patient-
centred approach in clinical consultations included 17 studies, which displayed 
considerable heterogeneity between the interventions, the health problems on which 
these interventions focused, and the outcomes assessed. l64 However, there was some 
evidence that the interventions assessed in this review may increase the patient 
centredness of care, but there was mixed evidence on the effect on patients' health care 
behaviours or health outcomes. Because there is currently no 'gold standard' of 
assessing and defining patient centredness and in view of the heterogeneity between the 
included trials, these findings have to be interpreted with caution. However, this review 
highlighted that assessing the effects of increased patient-centredness on patient 
behaviour and health outcomes should be an important element of future studies. 
Eastabrooks and colleagues conducted a systematic review of mainly randomised 
controlled trials on the effectiveness of decision aid in medical practice. 165 They 
reviewed 20 studies that met their inclusion criteria and found little evidence to suggest 
that structured decision support interventions help to influence treatment preferences or 
actual treatment decision and called for further research in this area. 
In a qualitative study of 29 participants, Dowell & Hudson found that most patients 
'test' a medicine before accepting it fully and that a frank discussion of this testing 
phase could help patients with adhering to their drug treatment. 166 However, the authors 
acknowledged that, for example in blood pressure lowering treatment, drugs can often 
be stopped without any immediate symptomatic consequences. A testing phase could, 
therefore, help with establishing the tolerability of a drug for individual patients. 
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Competencies required for informed shared decision-making 
Towle and Godolphin identified and proposed competencies for informed shared 
decision-making that aim to provide a framework to be used in teaching, learning, 
clinical practice and research (Figure 5).167 
Figure 5 Competencies for physicians for informed decision-making 
1. Develop a partnership with the patient 
2. Establish or review patients' preferences for information (such as amount 
or format) 
3. Establish patients' preferences for their role in decision-making (such as 
risk taking and the degree of involvement of self and others) and the 
existence and nature of any uncertainty about the course of action to 
take 
4. Ascertain and respond to patients' ideas, concerns, and expectations 
(e.g. about management options) 
5. Identify choices (including ideas and information that patients may have) 
and evaluate the research evidence in relation to individual patients 
6. Present (or direct patients to) evidence, taking into account the above 
competencies and help patients to reflect on and assess the impact of 
alternative decisions with regard to their values and lifestyle 
7. Make or negotiate a decision in partnership with patients and resolve 
conflict 
8. Agree an action plan and complete arrangements for follow-up 
9. I nformed decision-making may also involve a team of health 
professionals, others such as patients' families, and can differ across 
cultural, social and age groups 
Adapted from Towle & Godolphin, BMJ 1999;319:766-771.
167 
2.4.12 Interventions for increasing adherence 
It seems appropriate that when trying to increase adherence, health professionals' 
prejudices as well as patients' perceptions have to be taken into account, and strategies 
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for improvement have to include educating the practitioner as well as counselling 
individual patients. 70 
A number of systematic reviews have investigated the effect of interventions to increase 
adherence to medication in general (interventions to increase adherence to blood 
pressure lowering medication will be discussed separately - see Chapter 3).2,12,168,169 
Despite a wealth of studies in this field that examine the effects of educational , 
behavioural, or cognitive interventions in various chronic diseases, there have been 
mixed results. The main conclusion common to these reviews is that so far no single 
strategy can be recommended to improve adherence. 
The most recent systematic review by McDonald and colleagues found 6568 citations 
and included 33 trials testing 39 different interventions. 12 Interventions were tested that 
included: a) patient education (oral and written material and programmed learning), b) 
improved communication including counselling (for example, compliance therapy, 
automated computer assisted monitoring by telephone, manual telephone follow-up or 
family interventions), c) improving the convenience of care through self-monitoring of 
blood pressure, d) reminders (for example, tailoring the regimen to daily habits, special 
reminder pill packaging, dose-dispensing units of medication and medication charts, 
appointment and prescription refill reminders) and e) reinforcement or rewards for both 
treatment success and improved adherence. The chronic conditions in question included 
hypertension, schizophrenia or acute psychosis, asthma and chronic obstructive 
pUlmonary disease, depression, HN infection, diabetes, rheumatoid arthritis, epilepsy, 
hyperlipidaemia, and cardiovascular disease. Forty-nine per cent of interventions tested 
(19 out of39 interventions in 33 studies) showed statistically significant increases in 
medication adherence and 17 showed improvements in treatment outcomes. These 
results have to be interpreted with a certain degree of caution, because studies, 
populations, interventions and outcome measures were heterogeneous, making 
comparison of trials difficult. This review highlighted the need for further development 
of effective interventions, which should be rigorously assessed. 
The World Health Organization (WHO) has also recognised poor adherence as an 
international problem and recently published a report with the title Adherence to long-
term therapies: evidence for action? Written by leading experts in adherence-related 
issues and targeted mainly at policy-makers and health managers, it aims to provide a 
critical review of what is known about adherence to long-term therapies. This WHO 
report delivers an overview of general adherence issues and reviews ways to improve 
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adherence in a variety of conditions, including asthma, cancer, depression, diabetes, 
epilepsy, HIV / AIDS, hypertension, tobacco smoking cessation and tuberculosis. The 
overall conclusions are that patients need to be supported and not blamed, and that 
patient-tailored interventions are required that use a multi-disciplinary approach. This 
report also emphasises the need for further research in this field due to the lack of high 
quality studies. 
2.5 Adherence in hypertension 
General issues around antihypertensive treatment 
Treating hypertension in ambulatory patients is based on long-term oral medications 
that lower blood pressure and thereby delay or prevent cardiovascular morbidity and 
mortality. The management of hypertension, therefore, involves largely healthy 
individuals who are at increased risk of developing cardiovascular disease. The 
psychological concepts and models described above can be used to help explain risk 
behaviour as well as preventive or protective behaviour, but a number of additional 
issues need to be mentioned. 
Epidemiology of non-adherence 
Relatively little is known about the extent to which poor adherence is present in people 
taking antihypertensive medication. It is estimated that in the US poor adherence to 
therapy contributes to lack of blood pressure control in more than two thirds of people 
with treated hypertension.27 For many years it was thought that poor adherence to blood 
pressure lowering medication is a result of inconvenient regimens and the side effects of 
non-specific drugs. Although more convenient regimens and specific drugs have been 
developed in recent years, studies conducted in Switzerland showed that lack of 
adherence to antihypertensive medication is still widespread. In,I73 To our knowledge, 
no reliable data exist on adherence levels in hypertension in the UK. 
Barriers to adherence 
There are several barriers to adherence with blood pressure lowering medication, some 
of which are similar for other chronic conditions, but others are specific to 
antihypertensive treatment. These barriers can interfere with full adherence at any time 
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of the therapeutic process.107 Patients may resist being labelled as 'hypertensive' in the 
period after diagnosis and may therefore not keep regular appointments. They may not 
purchase or use prescribed medications, and side effects, which may be related to 
ingestion of each dose, could lead to stopping the therapy prematurely. Delayed adverse 
effects such as impotence or cough caused by particular drugs can lead to patient 
complaints or concealed non-adherence. Despite efforts to simplify the drug therapy in 
hypertension, this remains largely a process of choosing and adding drugs in an 
informed trial and error, based on each patient's individual circumstances and 
comorbidity (see Section 2.3.4). Stanton found in a study of 116 hypertensive patients at 
a health maintenance organisation in the US that greater expectancy for internal control 
over health and hypertension, greater knowledge about the medication regimen, and 
stronger social support were important determinants of adherence. 170 The study used 
self-report of adherence and kept appointments as outcome measures, and despite 
leading to helpful hypotheses, the results of this study have to be interpreted cautiously. 
Benson & Britten conducted a study on why patients choose to take drug treatment for 
hypertension and exposed the ambivalence that some people feel about taking 
medication for chronic disease.171 Reasons for not taking the medicines were often 
unrelated to the pharmacology of the drug itself, and any reservations about drugs 
developed in a way that made sense for individual patients (see Figure 6 and Figure 7). 
This study is another example showing the dilemma that many patients face when they 
try to resolve conflicting thoughts and ideas with regard to medical advice. Their work 
suggests that directly asking patients about their reservations, their reasons for taking 
the prescribed medication, and the balance between them, may help to improve the 
understanding between patients and health professionals. 
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Figure 6 Patients' reservations about medicines 
Reservations about drugs in general 
• Drugs are best avoided 
• Drugs are unnatural or unsafe 
• Drugs are perceived adversely because of previous experience 
• Drugs are signifiers of ill health 
• Patient brought up to avoid drugs 
• Doctors prescribe drugs too readily 
Reservations about antihypertensive drugs specifically 
• Desire to discontinue using antihypertensives 
• Preference for an alternative to drugs 
• Patient questioned continued necessity 
• Possible long term or hidden risks 
Source: Benson & Britten, BMJ 2002;325:873-6.171 
Figure 7 Patients' reasons to take antihypertensive drugs 
Positive experiences with doctors 
• Advice from doctors 
• Trust in doctors 
• Improved blood pressure readings 
Perceived benefits of medication 
• Achieving a good outcome 
• Feeling better 
• Gaining. peace of mind 
Pragmatic considerations 
• Absence of a practical alternative to drugs 
• Absence of symptoms to guide medicine use 
• Drug use overshadowed by some other consideration 
Source: Benson & Britten, BMJ 2002;325:873-6.171 
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Common medication errors 
Based on data from electronic monitors, the most common errors with regard to 
adherence to antihypertensive medication include, in decreasing order of frequency: a) a 
delay in dosing, b) missing a single dose (for example, an interval of more than 48 
hours in a once-daily dosing regimen), c) missing two successive doses (for example, an 
interval of more than 72 hours in a once daily regimen), and d) longer lapses in drug 
doses called 'drug holidays,.72 
Recent developments 
A study by Burnier and colleagues used electronic monitors to assist in the management 
of high blood pressure in subjects not responding to antihypertensive medication 
(refractory hypertension). 172 Forty-one participants with resistance to a three-drug 
regimen and a mean (± SD) blood pressure of 156/106 ± 23/11 mmHg were recruited to 
take part in a prospective non-randomised study and used electronic monitors for two 
months without any change in treatment. Using the medication monitors alone was 
associated with an improvement of blood pressure at two months (145/97 ± 20/15 (SD) 
mmHg, p<O.O 1). Because this study was small and did not have a control group, the 
results have to be interpr~ted with caution. However, this study introduced the new 
concept of using electronic monitoring as an intervention as well as an outcome 
measure. 
In an earlier study among uncontrolled hypertensive patients in a Swiss primary care 
centre and a tertiary hypertension clinic, Bertholet and colleagues divided patients who 
after one to two months of electronic monitoring were at target blood pressure (group 
one), those who had markedly improved (group two) and those who remained 
unchanged (group three).174 They found that electronic monitoring identified: a) 
potentially overtreated patients in group one, b) poor adherence to the prescribed 
regimen in all groups, and c) participants who clearly needed a change in treatment in 
group three. Despite this being another small and uncontrolled study, it highlighted the 
potential of electronic monitoring in differentiating between non-adherence and non-
response, which still poses immense difficulties for health professionals in many 
specialties. 
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2.6 Summary and implications for this project 
This chapter has provided an overview of current issues in adherence research in 
connection with the management of high blood pressure in the community. This review 
of the general hypertension and adherence literature highlights the complexity and 
challenges that any research in adherence faces, stressing the importance of using 
appropriate methods for measuring adherence that are as objective as possible. This led 
to including electronic monitoring for outcome measurement and 'timing compliance' 
as a more stringent definition of adherence in the ReT described later in this thesis. At 
the appropriate places in the following chapters I further justify why I have decided to 
use these methods to measure adherence. 
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3 How can we improve adherence to blood pressure lowering 
medication? A systematic review of ReTs 
3.1 Introduction 
While the previous chapter described and discussed the broader literature in the field of 
medication adherence in hypertension, this chapter focuses on interventions aiming to 
increase adherence. The main objective of this systematic review ofRCTs was to 
determine the effectiveness of interventions to increase adherence to blood pressure 
lowering medication with the aim to inform our research question and the development 
. of the intervention for the RCT described in chapters 5 and 6. It is based on a previous 
systematic review of detection, adherence and control of hypertension by Shah Ebrahim 
and was conducted collaboratively with Shah Ebrahim and Tom Fahey.41 
My own contribution to this review included drafting the original protocol, performing 
the literature searches together with Margaret Burke, Trial Search Coordinator from the 
Cochrane Heart Group, screening titles and abstracts to select studies for the review, 
designing the original data extraction sheets, extracting the data, entering and 
summarising the data, and drafting the manuscripts. Although I was primarily 
responsible for all aspects of conducting this systematic review, I felt that I should use 
the plural 'we' rather than'!, in this chapter to emphasise that this work was carried out 
collaboratively. 
This systematic review is registered with the Cochrane Hypertension Group and was 
conducted according to guidelines laid out by the Cochrane Handbook and by Egger 
and colleagues.175,176 
3.2 Overview and choice of methods used for this review 
We chose to conduct a systematic review ofRCTs, because studies using this design are 
likely to provide more reliable information about the effectiveness of health care 
interventions than other sources of evidence. Whereas the literature review presented in 
the previous chapter followed more traditional lines, the systematic review described 
here used a more comprehensive and unbiased search, aiming to identify all 
publications relevant to the research question. We aimed to achieve this by searching 
multiple databases and by investigating a variety of other sources to identify pertinent 
studies. We prepared a study protocol in advance, which was peer reviewed by editors 
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from the Cochrane Colloborative Review Group before the review was conducted. The 
protocol contained details about the review question, the a priori definition of our 
inclusion and exclusion criteria for RCTs to be included, our search strategy and plan 
for data collection and analysis. 
3.3 Background 
A variety of interventions aiming to improve adherence to antihypertensive medication 
have been evaluated in randomised controlled trials (RCTs), and four systematic 
reviews have tried to summarise the evidence in this field. 12,41,177,178 The searches in 
three of these reviews were limited to studies indexed only in MEDLINE,41,177,I78 
thereby lacking in sensitivity and specificity,179 and only included English language 
publications. None of these reviews could recommend any single approaches that" 
increase adherence to blood pressure lowering medication. The most recent and more 
general review used a more comprehensive literature search and included six studies in 
hypertension. 12 
Since more trials in this area have emerged recently, 180-182 this prompted us to carry out 
a new systematic review of the literature to establish which types of interventions to 
increase adherence are most effective, using a more comprehensive search strategy and 
including foreign language publications. We also aimed to investigate and report the 
effect of individual interventions used in factorial trials. This review was initially 
registered with the Cochrane Heart Group, but during its conduct it was transferred to 
the Cochrane Hypertension Group for eventual inclusion in the Cochrane Library. 
3.4 Methods 
This section describes first our thoughts that led to the development of the research 
question. What follows is an account of the methods that we employed to conduct this 
systematic review. Section 3.4.1 contains the elements that formed the basis of the study 
protocol, whereas from section 3.4.2 onwards I report how the review was eventually 
conducted, including changes to the protocol and their justification. 
3.4.1 Formulating the research question 
A major objective in formulating the research question was to inform the literature 
search and the data collection process by: a) determining the criteria that we would use 
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to select appropriate studies for review and b) deciding what data should be abstracted 
from studies that met these selection criteria. We formulated the research question by 
specifying the key components, namely the types of studies, types of participants, types 
of interventions, and types of outcomes. 
During this process we had to make decisions about how precisely to define these 
components, which directly affected the level of focus in the review. The aim was for 
the review to be sufficiently broad to include all potentially promising interventions that 
could be used in primary care without being overly complex and unwieldy. It was 
appreciated, however, that a broad review could have implications for the literature 
search in being time consuming and that the synthesis, interpretation and presentation of 
data gained from heterogeneous studies can be challenging. In the following paragraphs 
I describe our objectives and discuss the choices we made with regard to formulating 
our research questions. 
Objectives of this review 
The a priori objectives for this systematic review were: 
1. To locate and describe studies evaluating interventions aimed at improving 
adherence to antihypertensive medication 
2. Undertake a critical review of the quality of the methods of these interventions 
looking in particular at study design and validity 
3. Summarise the effectiveness of the above interventions 
4. Indicate areas for future research 
Types of studies 
We decided to consider only randomised controlled and quasi-experimental studies for 
inclusion in the review. These designs are superior when answering questions about the 
effectiveness of health care interventions and are more reliable than observational study 
designs such as case-control or cohort studies, which are more suitable to address 
questions on, for example, disease aetiology, exposure to risk factors, or incidence of 
disease. 
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Types of participants 
Our population of interest included adult people diagnosed as having raised blood 
pressure in a primary care, outpatient or other community setting. We anticipated that 
this population would be heterogenous and, for example, might include patients who 
had either newly diagnosed or established hypertension, were controlled or uncontrolled 
in respect to a pre-defined blood pressure threshold, or non-adherent after an initial 
adherence enhancing strategy. Given that all these types of patients present in day-to-
day general practice, we felt that a narrower focus with regard to the study population 
would have been inappropriate. However, we appreciated that there may have been 
important differences in effects among the various subgroups of, for example, people 
with newly diagnosed or established hypertension, and planned to take this into account 
in the analysis and interpretation of the results. With regard to the inclusion criteria, we 
made no restrictions in terms of age, sex, race, educational status, or presence or 
absence of any comorbid conditions such as angina or diabetes, in order to reflect 
people usually seen in a typical primary care setting. We excluded participants with 
secondary hypertension, for example, related to pregnancy or endocrine causes. 
Since there is no internationally agreed threshold above which blood pressure can be 
called 'raised' or 'controlled' (as discussed in section 2.3.1), we decided to include all 
studies that used the definition of 'high blood pressure' in their inclusion criteria and 
provide details about individual cut-offpoints for studies included in the review. 
We only considered studies for inclusion that were conducted in a community setting. 
The only exception was hospital outpatient clinics, if participants were not hospitalised 
and subsequently followed up in the community. 
Types of interventions 
We evaluated various kinds of intervention including, but not exclusive to: 
1. Education to carers and patients (e.g. counselling, health education) 
2. Dosage regimens 
3. Involvement of allied health professionals (e.g. nurses, pharmacists) 
4. Monitoring (e.g. vial caps, blood pressure self-measurement) 
5. Motivation (e.g. financial incentives, reminder packages, reminder aids including 
diaries or follow-up appointments) 
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This grouping of interventions laid out in the protocol was arbitrary and partly based on 
the classifications used in previous systematic reviews. However, we realised that some 
interventions would potentially not be easy to assign to a particular group due to mixing 
of different strategies or complex factorial designs (for example, a nurse-led 
intervention using educational and motivational strategies). We did not impose any 
restrictions on the timings, frequency or duration of the interventions, which we realised 
would be variable. 
We specified that acceptable control groups should either receive no intervention or 
'usual care'. We appreciated that usual care is often not exactly defined and may vary 
from study to study, but it was thought that this information, if missing, could be sought 
from the study authors. 
Types of outcomes 
Our primary outcomes of interest were adherence to blood pressure lowering 
medication and blood pressure. We did not demand explicit criteria for establishing the 
presence of those outcomes because adherence and blood pressure have been measured 
and defined in a variety of different ways. We chose these outcomes to be our primary 
outcomes because they were likely to be meaningful to people making decisions about 
how to address the problem of non-adherence in the community. We also planned to 
collect information on costs if provided by the study authors. 
3.4.2 Literature search 
Defining the research question in advance was essential for determining the key 
components to focus on in our initial search strategy. Due to the nature of the various 
and often complex interventions and outcomes that we expected to find in studies of 
interventions to improve adherence, we designed our search strategy in close 
collaboration with Margaret Burke, search co-ordinator from the Cochrane Heart Group. 
To help construct our search strategy, we went through articles already available to us 
and listed all search terms that we felt would be relevant for our literature search. 
We initially identified original RCTs by an all-language search of articles (any year) in 
the Cochrane Controlled Trials Register (CCTR), MEDLINE, EMBASE and CINAHL 
in February 2002, using an approach advocated by the Cochrane Heart Group (see 
http://www.epi.bris.ac.uklcochrane/strategy.html for further information). In addition, 
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we also searched the National Research Register, Current Controlled Trials and 
PsychInfo. 
Figure 8 provides details about the search tenns that we used for searching the Cochrane 
Controlled Trials Register. In addition, we screened the references of all retrieved 
articles as well as manuscripts that were present in our individual files to identify 
additional publications. We also contacted study authors of all included studies and 
experts in the field about other relevant trials or unpublished material. 
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Figure 8 S.ear9h strategy used to identify RCTs of adherence improving interventions in 
hypertensIon In the Cochrane Controlled Trials Register a 
1 HYPERTENS* 
2 BLOOD-PRESSURE*:ME 
3 (BLOOD:TI near PRESSURE:TI) 
4 BLOOD-PRESSURE-DETERMINATION*:ME 
5 BLOOD:TI next PRESSURE:TI near MONITOR*:TI 
6 #1 or #2 or#3 or #4 or #5 
7 PATIENT near COMPLIANCE 
8 COMPLIANCE and :TI or ADHERENCE:TI 
9 PATIENT next EDUCATION 








18 ATTITUDE-TO .. HEALTH*:ME 
19 EDUCATION* next METHODS 
20 EDUCATION* next MATERIAL* 
21 PUBLICATIONS*:ME 
22 PAMPHLET* or BROCHURE* or LEAFLET* or POSTER* 
23 #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14 or #15 or #16 or #17 
or #18 or #19 or #20 or #21 or #22 
24 #6 and #23 
a slightly amended search strategies were used for searching MEDLINE, E:MBASE and 
CINAHL 
3.4.3 Study selection 
Two of the authors (KS and TF) assessed lists of citations and abstracts produced by the 
initial database search independently and in duplicate. We were not masked with regard 
to authors or journal. We selected studies for review if they fulfilled our inclusion 
criteria as outlined above, using an inlout sheet (Appendix I). We did not include 
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studies that tested interventions not designed to increase adherence or where 
participants suffered from secondary hypertension (for example, due to endocrine 
causes or pregnancy related). Each reviewer indicated whether a citation was potentially 
relevant (that is, appearing to meet the inclusion criteria), was clearly not relevant, or 
gave insufficient information to make a judgment. To be included a study had to meet 
all of the inclusion criteria. We resolved differences by discussion and obtained reprints 
of all potentially relevant citations. 
3.4.4 Data extraction 
We (KS and TF) independently extracted data in duplicate concerning study design, 
methods, clinicians and patients, interventions, outcomes and potential sources of bias, 
using a structured data collection form (Appendix 2) designed with Microsoft 
Word2000® software. The purpose of this data extraction form was to serve as: a) a 
visual representation of the review question, b) a record of the decisions that occurred 
during the review process and c) a database from which to conduct the analysis. We 
designed this data collection form based on details with respect to our final research 
question and piloted it on five studies, which led to a number of minor amendments. We 
kept both electronic as well as paper copies of completed data extraction sheets, as 
identifying and addressing errors was easier on paper forms. After we had extracted data 
from all included studies, we compared data extraction forms completed by two 
reviewers to identify and address errors. A third rater (SE) verified the data extraction 
and made corrections where necessary. Any disagreement was resolved by consensus. 
We wrote to 28 corresponding authors of studies to request missing data and clarify 
study details if required. 
3.4.5 Data management 
We prepared the Cochrane version of this systematic review using ReviewManager® 
version 4.1 (Update Software, Oxford, 2003). This software is essential for every 
Cochrane Review and assists with data management, quantitative analyses and 
generation of the review and is supplied free of charge to every Cochrane Reviewer. 
3.4.6 Quality assessment 
Two reviewers assessed the quality of the studies independently and in duplicate. We 
handled disagreements by consensus and requested additional information about study 
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design from the authors if necessary. We extracted data on potential sources of bias 
including the method of patient randomisation, blinding of the outcome assessor, and 
differential losses to follow-up rather than providing a summary score. The approach we 
adopted is that advocated by the Cochrane Heart Group. 
3.4.7 Quantitative data analysis 
Due to heterogeneity between studies in terms of interventions and the various methods 
that were used to measure adherence, we felt that pooling of the results was 
inappropriate. We grouped and reported the individual arms of factorial trials separately 
in the respective groups. 
3.5 Results 
3.5.1 Study characteristics 
We screened 1929 citations and included 38 studies that met all the predefined criteria, 
involving a total of 15519 patients and testing 57 different interventions (Figure 9).10,180-
216 Appendix 3 summarises the characteristics of included RCTs, which were conducted 
between 1975 and 2000. The majority of trials were performed in the USA (n=20) and 
Canada (n=8) with the remainder located in Europe (n=8), Australia (n= 1) and South 
Africa (n=I). Study participants fell into a number of different categories that included 
newly diagnosed patients, patients with established hypertension on medication, patients 
with controlled or uncontrolled hypertension, patients adherent or non-adherent to 
medication or infrequent attendees at clinic. Given the lack of a generally accepted 
categorisation, we grouped studies into the following four pragmatic categories: (i) 
simplification of dosing regimens, (ii) patient education, (iii) patient motivation, support 
and reminders and (iv) complex health and organisational interventions including 
interventions in combination. Adherence was measured in different ways, including 
self-report, direct questioning, pill counts, and the medication event monitoring system 
(MEMS®), and various criteria for adherence were used in the different studies. We 
treated the different arms of studies using a factorial design as separate studies and 
present the results of these accordingly. All studies examined both men and women in 
varying proportions, and the duration of follow-up ranged from two to 60 months. 
60 
Figure 9 Trial flow for systematic review 
Potentially relevant RCTs identified and screened for retrieval: n=1929 
RCTs excluded: n=1850 
. Single main reasons: 
Int~ryentlons and outcomes were not investigating adherence· n=1359 
Participants had non-essential high blood pressure or other CO~dition not 
. . relevant for this review: n=220 
Participants were hosp.italised as opposed to ambulatory: n=181 
Study population was not adult and human: 90 
RCTs retrieved for more detailed evaluation: n=79 
RCTs excluded: n=37 
Reasons: 
No adherence outcome: n=26 
Design not RCT: n=7 
Results already reported in another publication: n=3 
Setting not primary care: n=1 
Potentially appropriate RCTs to be included in the review: n=42 
RCTs included in the review: n=38 
RCTs excluded from the review: n=4 
Reasons: 
Full results not reported or unable to interpret results: n=3 
Follow-up publication not available: n=l 
3.5 .. 2 Quality of the primary studies 
The methodological quality of included studies was generally low (Appendix 4). The 
randomisation process was reported and provided adequate concealment of allocation in 
only 10 out of the 38 studies (26%).182,185,1~7,188,193,204,205,207,214,216 The outcome assessors 
were blind to treatment allocation in 12 studies (32%).10,185,188,190,193,198,202,205-207,212,214 
Losses to follow-up were well documented in 33 studies (87%). Only eight trials (21 %) 
reported a power calculation,t87,191,198,200,205,207,210,212 and most of the remaining trials 
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appeared too small to detect clinically important differences. None of the included 
studies fulfilled all the quality criteria. 
3.5.3 Effect on adherence and blood pressure 
Individual RCTs reported results on adherence in many different ways, making a pooled 
analysis inappropriate (Appendix 3). Nineteen studies reported an improvement in 
adherence alone, seven found improvement in adherence combined with a reduction in 
blood pressure, and in seven studies a reduction in blood pressure occurred without an 
increase in adherence. Fifteen of the included studies (40%) did not report a blood 
pressure outcome, and none of the studies examined major clinical endpoints. Please 
note that in the following section the total number ofRCTs (that is, interventions) is 58 
rather than 38, because some factorial RCTs tested interventions in different categories, 
which therefore counted more than once. 
Simplification of dosing regimens 
In this group, nine RCTs tested nine different interventions. Simplifying dosing 
. . d dh' f h . d' 182184186-190 ·th regunens Improve a erence In seven out 0 t ose rune stu les, " WI 
relative improvement in adherence in terms of numbers of participants who took 80% or 
more of their medication between 8% to 19.6%. All the studies that used objective 
outcome measurement (MEMS~ showed an improvement in adherence through the use 
'1' d f . d'l d . 182186188-190 lth gh c. fth of once-dal y Instea 0 twIce- at y osage regunens, " a ou .lour 0 ese 
compared two different drugS. 182,186,188,189 Only one study showed an increase in 
adherence (90% vs. 82%, p<O.OI) together with a reduction in systolic blood pressure of 
6mmHg systolic (p<0.01).188 
Patient education 
Six RCTs tested six different interventions in this group. Patient education seemed 
largely unsuccessful. Only a single small trial improved adherence (93% vs. 69%, 
195 ed . p<0.002) with no reported effect on blood pressure. This study used group ucatIon 
in groups of 15 people over 90 minutes and additional postal information leaflets at one, 
three and five months. 
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Patient motivation, support and reminders 
Sixteen RCTs tested 24 different interventions in this group. Motivational strategies 
were partly successful in 10 out of 24 study interventions with mostly small increases in 
adherence up to a maximum of23% 192,197,199,202,208,209,214 All fth tudi d I 
. 0 ese s es use ess 
reliable methods of measuring adherence such as pill counts, self-report, direct 
questioning, and prescription refill records. Successful interventions included daily drug 
reminder charts (mean adherence score 82.4% vs. 70.4%, p=O.002),197 training on self-
determination (4.6 out of7 weeks adherent vs. 3.3 weeks in the control group, 
p<O. 001 ), 199 reminders and packaging (alone and in combination, increase in adherence 
between 8% for reminders alone and 23 % for reminders and packaging in combination, 
p<0.05),214 social support (98% achieved maximum adherence score vs. 930/0, 
p<0.05),192 nurse phone calls (96% achieved maximum adherence score vs. 91 %, 
p<0.05),192 family member support (53% high adherers vs. 40%, p<0.05)/09 electronic 
medication aid cap (mean adherence 95% vs. 78%, p=0.0002),208 and telephone-linked 
computer counseling (18% adherent vs. 12%, p=0.03).202 
Complex health and organisational interventions including interventions in 
combination 
Seventeen RCTs investigated 18 different interventions in this group. Eight complex 
interventions successfully increased adherence, ranging from 5% to a maximum of 
41 %.180,201,206,213,215 Worksite care through specially trained nurses providing patient-
tailored care improved adherence (67% vs. 49%, p<0.005) and led to a net reduction in 
blood pressure of 4 nunHg between intervention and control groups (p<0.001).206 A 
combination of home visits, education and special dosing devices improved adherence 
in a small trial of 16 patients (92% vs. 71 %, p<0.001).201 A strategy involving an 
educational leaflet, a telephone reminder, a mailed reminder and an educational 
newsletter was successful in both previously treated hypertensive patients ('medication 
possession ratio' 82% vs. 48%, p<0.05) and those who were newly diagnosed (93% vs. 
52%, p<0.05).213 Two fairly recent trials reported weak evidence of an effect ofa 
patient-centred pharmaceutical care model (compliance score 0.23 vs. 0.61, p<0.05)21S 
and a combination of structured brief questioning protocol with advice, information and 
referral to the family practitioner (62% adherent vs. 50%, p<0.05).180 In this study blood 
pressure was also better controlled in the intervention group (35.7% became controlled 
vs. 17.1 %, p<0.05). 
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3.6 Discussion 
3.6.1 Key findings 
From this systematic review, simplification of dosing regimens increased adherence in 
seven out of nine studies, with improvement in adherence ranging from 8% to 19.6%. 
Adherence in these studies was mainly measured with electronic monitors, and these 
results confirm findings from past research. In a small number of studies, nurse led 
interventions, which were often complex, were also effective in increasing adherence. 
There was mixed evidence for the effect of motivational and more complex 
interventions. Education alone appeared largely unsuccessful. A combined effect on 
adherence and blood pressure was only observed in 7 out of 58 study interventions 
(12%). 
3.6.2 Interpretation of the results in the light of previous research 
This review differs from previously published reviews in that we used a more 
comprehensive search strategy and different methodology. Compared to the latest 
reviews on adherence enhancing strategies,12,178 we found and included considerably 
more studies (nine and 32 more studies respectively). The review by Morrison extracted 
categorical data in preference to continuous data, and ignored evidence from trials 
where data could not be converted. This may have been particularly relevant for the 
results in the group with changes in medication dosing, where we come to the opposite 
conclusion. This review is also different in that we have reported the results from 
individual arms of factorial trials separately. 
We agree with the review by McDonald and colleagues that for complex interventions it 
is often difficult to estimate the independent effects of individual interventions. 12 It also 
remains difficult to disentangle specific adherence effects as opposed to non-specific 
effects of increased attention. Our findings confirm that even the most effective 
interventions do not appear to lead to large improvements in adherence and treatment 
outcomes. 
An earlier review of research on adherence reported benefits of educational 
interventions in improving adherence. l77 However, we were unable to confirm this 
finding, perhaps because we only included RCTs in our review. 
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3.6.3 Limitations of this review 
Comparing the RCTs included in this review was difficult. Many RCTs showed marked 
heterogeneity in terms of participants, interventions and outcomes. Study authors also 
measured and reported adherence inconsistently. Individual RCTs demonstrated 
variable and often poor methodological quality, particularly with regard to 
randomization, blinding of outcome assessment and losses to follow-up, whilst the 
sample sizes of many trials were too small to detect clinically relevant differences. 
Rather surprisingly, 15 out of the included 38 studies (40%) did not report a blood 
pressure outcome, and none reported major clinical endpoints. 
There are also some difficulties in interpreting the results of this systematic review. 
Adherence was measured (for example, self-report, pill counts, direct questioning, 
electronic monitoring, drug blood levels) and calculated in different ways (for example, 
using arbitrary cut-offpoints to define adherence, such as 800/0), and in addition was 
usually assessed unblinded to allocation status, which made the comparison ofRCTs 
difficult. Levels of adherence in the control groups of the trials studied ranged from 
12% to 94%, which is indicative of the heterogeneity in both the criteria for defining 
adherence and the participants studied. 
With no agreed definitiot,ls on how adherence should be measured and defined, it is not 
surprising that for most interventions the impact on adherence and blood pressure 
appears to be variable. Given the different definitions for adherence that have been 
adopted in individual RCTs, it has not been possible to examine the relationship 
between adherence to medication and subsequent blood pressure control. Our 
categorisation and grouping of trials was developed specifically for the review, and the 
group allocation of some trials might be debatable. 
3.6.4 Implications for practice 
Our findings suggest that introducing simpler dosing regimens could be effective in 
improving adherence, but the effect on subsequent blood pressure reduction has not 
been established and may not be clinically important. The results of various 
motivational and more complex interventions are promising, although there is 
insufficient evidence to suggest a single approach. In many countries, the role of allied 
health professionals such as nurses or physician assistants is expanding, which may lead 
t opportum·ties for tackling adherence-related problems in patients to new managemen 
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with high blood pressure Ho " -
, wever, we suggest that mnovanve approaches should be 
introduced in the context of further RCTs It l'S un' portant th t h " f 
. a p YS1C1ans are aware 0 
the various reasons for poor adherence and aim to simplify dosing regimes as far as 
possible. 
3.6.5 Implications for future research 
The results of this review highlight a number of problem areas in adherence related 
research. Many studies used unreliable methods of measuring adherence such as self-
report and pill counts. It appears that electronic monitoring provides more objective and 
reliable results and, in addition, produces data on medication taking patterns. Although 
a large number of studies have been conducted in this area, larger trials of higher quality 
are needed that use reliable methods of measuring adherence and that also investigate 
the relationship between adherence and blood pressure reduction. This is particularly 
important in the context of an increasing elderly popUlation of people who often take 
multiple medications. Hypertensive patients may fail to take their medication due to the 
long duration of therapy, the symptomless nature of the condition, side effects of 
medication, complicated drug regimens, lack of understanding about hypertension 
management, lack of motivation and the challenge to individual patients' health 
beliefs.41 ,131 It would seem logical that future studies should try and adopt a 'tailored' 
approach aimed at individual patients and addressing the above-mentioned barriers to 
adherence. Using combinations of strategies that include simpler dosage regimens, 
patient motivation and that involve other health professionals in a patient-centered 
approach should be further investigated. In addition, patients' views should be taken 
into account when piloting interventions, and the interventions themselves should be 
based on shared decision-making and a true partnership between patient and 
practitioner. 145,217-219 Finally, it is of paramount importance that every study which 
evaluates an intervention to increase adherence to blood pressure lowering medication 
should also measure blood pressure as a secondary outcome, which will help establish 
the often unclear relationship between adherence and blood pressure control. 
3.6.6 Implications for this thesis 
This systematic review highlighted a number of issues that were relevant for the design 
of the randomised trial, which I describe later in this thesis (Chapter 5). In particular, the 
design of the intervention and the measurement of adherence emerged as topics 
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-requiring careful consideration. The main impact of this review on the trial design was 
that a) electronic monitoring replaced our initial choice of outcome assessment, namely 
self-report of adherence and analysis of repeat prescriptions, and b) that the intervention 
had to take into account patients' individual needs rather than providing a 'blanket 
approach' like, for example, the provision of group-based information or education. 
3.6.7 Conclusions 
Simplification of dosing regimens appears to be the most promising intervention to 
increase adherence to blood pressure lowering medication. In terms of other strategies, 
we cannot recommend a single approach, and a combination of interventions appears 
most promising. We believe these should include the simplification of dosage regimens 
and involve other health professionals such as nurses who provide tailored care to 
individual patients. The evidence for the effect of motivational and more complex 
interventions is mixed and inconclusive. The results of this review should be interpreted 
with caution due to the poor methodological quality and heterogeneity of many trials 
included in this review. The findings emphasize the need for further RCTs with 
sufficient power and of rigorous methodology. 
The increasing rol~ that nurses play in the management of hypertension in the UK and 
some existing evidence from this review that nurse led interventions may be effective 
prompted us to develop and evaluate a pragmatic nurse led intervention, which we 
evaluated by means of an RCT (see Chapter 5). 
3.7 Summary 
This chapter described a systematic review ofRCTs evaluating interventions to improve 
adherence to blood pressure lowering medication and concludes the literature review for 
this thesis. In the following chapter I will outline how the findings from this systematic 
review and Chapter 2 have informed the discussion of the choice of methods that I have 
used for the studies described in Chapters 5 to 8. 
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4 Overview of methodological issues 
4.1 Introduction 
This chapter explains how the literature reviews infonned further clarification of, and 
changes in, the research question of the studies described in this thesis, particularly with 
regard to the design and methods of the RCT reported in chapters 5 and 6. The findings 
from both the traditional literature review (Chapter 2) and the systematic review of 
RCTs of interventions to increase adherence to blood pressure lowering medication 
(Chapter 3) led to significant changes in the research question. In the following sections 
I summarise the most important findings from both literature reviews that are relevant to 
this thesis and discuss the issues arising from those findings. 
4.2 Summary of important research themes 
The literature reviews revealed a number of themes, of which many have to a greater or 
lesser extent influenced the framing of the research questions. With regard to 
developing an intervention to increase adherence in primary care, two themes emerged 
which appeared to be of particular importance: first, involving patients in their 
management and second, a multi-professional approach to managing chronic disease. 
Other important areas that became apparent are the definition and measurement of 
adherence and the various reasons for non-adherence to medication. 
4.2.1 Patient-centred ness and shared decision-making 
Traditionally the relationship between health care professionals and patients was often 
based on a paternalistic model, which did not take into account patients' values and 
preferences with regard to making decisions about whether or not to accept treatment 
decisions. In the past few years a growing body of evidence has emerged which 
highlights the importance of involving patients, particularly in the management of their 
chronic diseases. 141,142,148 What do we really mean by 'involving patients' or 'patient 
centredness', though, and how can we address these issues in health care interventions? 
This question, unfortunately, is difficult to answer, as there appears to be considerable 
uncertainty about what these expressions mean. 142,144 A helpful construct appears to be 
the idea of improving communication, about information that patients need and want to 
know (for example, with respect to diagnosis, management, risks and prognosis of their 
condition), about sharing decisions as well as responsibility, and about becoming true 
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partners when making decisions about health care 71,149,151-153 S -.&'. ~ th . l' 1 
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evidence that this is happening during the consultation.153 Tools which might help to 
improve communication and patient involvement include more time during the 
It ' 151· . 
consu atlOn, Improvmg the language used when talking about risks,156,157 or the use 
of decision aids. 159 
4.2.2 Multi-disciplinary approach 
A multi-disciplinary approach is widely advocated to provide care for people with 
chronic illnesses.
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,60 Although there is evidence that practice nurses can offer an 
effective service, there is little evidence from a recent review by Oakeshott and 
colleagues that nurse-led management of hypertension is effective in terms of 
improving blood pressure control in primary care.65 The authors concluded that the most 
important differences between GP and nurse-led care would be improved 
antihypertensive prescribing and adherence to treatment due to rigorous application of 
national guidelines. For example, the use of risk charts in coronary heart disease by 
trained practice nurses and GPs in UK primary care led to a reduction in systolic blood 
pressure, mainly due to increased prescribing.220 Further RCTs in this area are needed to 
evaluate whether nurse-led care can lead to improved blood pressure control. 65 
A small number of RCTs evaluated the effect of nurse-led care on adherence to blood 
pressure lowering medication. 192,206,207,221 These trials were heterogeneous with regard 
to study popUlations, interventions and outcomes, but showed some promising results in 
terms of improving medication adherence (see Chapter 3 and Appendix 3). The World 
Health Organization now encourages a multi-disciplinary approach to improve 
medication adherence not only in hypertension, but also in a number of other clinical 
conditions.2 
4.2.3 Outcome measurement and definition of adherence 
The literature reviews described earlier in this thesis (Chapters 2 and 3) have shown that 
adherence is defined and measured in many different ways, making a comparison of 
individual studies difficult. Although no 'gold standard' of measuring adherence exists, 
electronic devices appear to be the most accurate instruments in assessing patient 
adherence. Their advantage lies in the precision of data in terms of logging the exact 
time and date of each opening, but their main drawback so far has been the relatively 
high cost. Electronic medication monitors have therefore mainly been used in research 
rather than in day-to-day clinical practice. 
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4.2.4 Reasons for non-adherence 
There are a number of reasons why patients can find it difficult to take their medicines 
as prescribed. As outlined in Section 2.4.7, these may be related to: (a) the drugs in 
terms of side effects, number of tablets, or duration of treatment, (b) the health 
professional with regard to poor communication, lack of information or suboptimal 
follow-up, or (c) the patient with respect to forgetfulness, mistakes, beliefs about 
medication, or external factors. However, reasons for non-adherence are usually 
complex and multifactorial and not due to a single cause.2 
4.2.5 Inadequacies within the existing literature 
The review of the literature has identified a number of inadequacies in adherence 
research. There is a continuing debate with regard to defining and measuring adherence. 
Since these issues are not clear-cut, it is hardly surprising that the latest scientific review 
of interventions to enhance patient adherence to medication prescriptions concludes that 
the literature in this field "remains surprisingly weak" and that "there are only a few 
rigorous trials of adherence interventions". 12 
A number of major issues still remain largely unanswered. How should we define 
adherence? How should we measure adherence? What is the true level of adherence in 
the community? What interventions work to improve adherence? How does adherence 
relate to clinical outcomes? What do patients think about adherence? 
Studies that have evaluated interventions to improve adherence to blood pressure 
lowering medication defined adherence in many different ways, making a comparison 
of studies difficult. In addition, adherence has been measured using a variety of 
methods, with only a minority of studies using comparatively reliable outcome 
measures such as electronic medication monitoring. The often quoted estimate that only 
about 40-50% of people are adherent to medication also seems to be based on little 
reliable data. Evidence from recent randomised trials suggests that although simpler 
dosing regimens increase adherence, this does not necessarily lead to better blood 
pressure control. 
4.3 Implications of the literature review for the design of the study 
The main themes identified in the literature review highlighted a number of general 
implications for the design of the studies described in this thesis. 
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First, it is important that studies use the most reliable outcome ~easures available. This 
should, where possible, include electronic mOnitoring, which can provide data on dose 
timings and patterns of medication taking. Such data are unobtainable by any other 
method. Although electronic monitors are still relatively expensive, the modest increase 
in research budgets is often more than outweighed by the quality and richness of the 
data obtained. 
Second, to be able to improve adherence, a more standardised approach to defining 
desired levels of adherence and how to measure it is needed. The commonly used cut-
offpoint of '80% adherence' above which adherence is thought to be sufficient is in 
many cases meaningless and not based on pharmaco-epidemiological evidence linking 
frequency of medication taking with clinical outcomes. Indeed, it may be preferable to 
avoid artificial cut-off points altogether and utilise a continuous measure of adherence 
in the analysis of adherence data. 
Third, investigations aiming to improve adherence should be multi-disciplinary and 
involve patients in the management of their condition. An important aspect for the 
design of adherence improving interventions is to allow a tailored approach to 
identifying and solving medication problems in individual patients. 
Fourth, there has thus far been little research on the relationship between adherence and 
subsequent 'control' of the disease. We do not really know what level of adherence is 
necessary for individual drug classes used in a number of medical conditions, as some 
drugs are much more 'forgiving' than others in terms of missed doses and the timing of 
ingestion. Although so far even the most effective interventions have had only modest 
effects, these could be effe~tive on a population level in reducing the overall burden of 
disease. 
4.3.1 Impact of the literature review on the research question and design 
The original aim of this thesis was to investigate new ways to improve adherence to 
medication in chronic disease, using hypertension as the target condition. The research 
described in this thesis aimed to address health care and patient related factors while 
ackilowledging the fact that it is the patient's agenda that determines whether patients 
choose to take their medicines or not. 
The main objective was to evaluate an intervention to increase adherence to blood 
pressure lowering medication by means of a ReT. The findings of the literature review 
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-led to the development of an intervention that aimed to encomp~s -most of the areas that 
were identified as important: (a) a nurse-led approach (b) an h' . 
, emp aslS on patlent 
involvement, (c) flexible strategies adapted for individual patients, and (d) objective 
outcome measurement of adherence. 
It seemed logical that any intervention to increase adherence to medication would need 
to be easy to introduce into routine care. We therefore combined components of the 
interventions that showed promising results in previous RCTs into an intervention that 
could be delivered by practice nurses without the need for extensive training. 
4.4 Choice of methods 
4.4.1 Overview of desirable research methods 
A number of publications have acknowledged the lack of a sound evidence base to 
inform many of the clinical decisions that are made in day-to-day general 
practice.3,222,223 One of the reasons for the lack of evidence for many interventions used 
in primary care is that randomised trials have traditionally played a less dominant role 
in primary care research compared to observational studies.224 It is generally accepted 
that randomised controlled trials are the method of choice when evaluating the 
effectiveness of health care interventions. The main study described in this thesis is 
therefore a randomised trial, and the following sections describe in more detail the 
justification for using this design for the main study. In addition, I will outline the 
reasons for using observational study designs for the other studies described in this 
thesis. 
4.4.2 Choice of a randomised controlled trial as the design for the main 
study 
Since one of the main aims of the research described in this thesis was to evaluate the 
effectiveness of an intervention to increase adherence to blood pressure lowering 
medication, the randomised trial was the obvious choice for the conduct of the main 
study. This trial was informed by a systematic review ofRCT as described in Chapter 3. 
There is general consensus that the randomised controlled trial represents the current 
'gold standard' in study design when evaluating the effectiveness of health care 
interventions, mainly because the process of patient randomisation allows controlling 
for known and unknown confounding factors. Various trial designs can be used in 
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primary care, which may include patient preference trials, RCT~ in single patients (so-
called n-of-l trials), factorial trials, crossover trials, or cluster randomised trials.3 The 
trial described in Chapters 5 and 7 is a parallel group pragmatic trial with randomisation 
by individual. 
4.4.3 Choice of outcome measures 
Ideal outcomes for this trial would have been direct clinical endpoints such as mortality 
or morbidity in terms of heart attacks and strokes. Estimation of these endpoints would 
have required a larger sample size and a much longer study duration, both of which 
were outside the scope of this study. Instead, adherence and blood pressure were chosen 
as surrogate endpoints, which aim to predict the direct measures of harm, that is, heart 
attacks and strokes. Although blood pressure is not in itself a direct measure of either 
harm or clinical benefit, it is widely accepted as a risk factor for heart attacks and 
strokes.5,6,37,225 Although the relationship between adherence and blood pressure control 
has not been universally proven, adequate adherence is regarded as an important 
prerequisite for improving the outcomes in chronic disease.2 Both therefore fulfil the 
criteria for surrogate endpoints and are also relatively easy to measure. 
The initial methods of choice for measuring adherence were patient self-report and 
prescription refill records. However, based on findings from the literature review and 
discussions with experts in the field at a workshop on methods in adherence research in 
Pittsburgh, it was decided to use electronic medication monitors for outcome 
measurement of adherence instead. These, as outlined before, provide much more 
reliable data on medication taking than the initial methods of choice. Chapter 5 provides 
more detail about the way adherence was measured and defined in this study. 
4.4.4 Rejected research methods 
The initial design of the RCT was a 2x2 factorial trial, which would have allowed 
simultaneous evaluation of a second intervention, that is, an information leaflet on 
problems with medication adherence. During the planning phase of the study new 
evidence emerged from a trial conducted in Bristol, which raised the possibility of an 
interaction between nurse-led adherence support and providing an information leaflet.
226 
When conducting factorial trials it is usually assumed that there is no interaction 
between the interventions tested in the trial arm. If an interaction is expected, then the 
trial size has to be inflated considerably to provide enough power to detect or rule out 
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this interaction. In the light of the evidence226 that there was a r~alistic chance of such 
an interaction for the proposed trial, we abandoned our original idea and changed the 
trial to a parallel group design. We felt that the information leaflet was the least 
important component of the intervention and, to make the intervention less complex, did 
not include the leaflet in our parallel group design. 
4.5 Ethical implications 
Having reviewed the literature in the field of adherence and designed the study protocol, 
I reassessed the study design by taking into account principles of biomedical ethics.227 
One of the most popular ways of thinking in the field of biomedical ethics is the idea of 
'principlism', which was first described by the American philosophers Beauchamp and 
Childress in the 1960s.228 The concept of principlism argues that by taking into account 
the four principles of autonomy, non-maleficence, beneficence, and justice, any medico-
ethical dilemma can be analysed, which also applies to research projects. 
Based on these principles, there are three types of ethical problems that arise in 
healthcare research, which include (a) goal-based questions, that is the outcome and 
moral worth of the study, (b) duty-based questions relating to the risks and handling of 
research participants, and (c) rights-based questions in connection with informed 
consent and confidentiality. 
Ethical justification for conducting the trial 
The trial was designed to evaluate the effect of a nurse-led intervention on adherence to 
blood pressure lowering medication. As outlined above, the design of this study took 
into account findings from past research, which have been searched for and evaluated in 
a systematic way. Both the protocols for the systematic review and the randomised trial 
underwent peer review by the Cochrane Collaboration and the Medical Research 
Council, which funded the main trial. There is ample evidence in the literature that 
further research in this area is needed and relevant to the provision ofhealthcare.
2 
Duty to research participants 
As already discussed, involving patients in their management was an important aspect 
of this study, thereby increasing their autonomy in terms of getting more involved in the 
management of their condition. There did not appear to be any major risks for patients 
as a result of this intervention that would not also occur as part of routine medical care. 
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Any additional risks (for example, an increase of drug adverse effects due to previously 
non-adherent patients starting to take their medicines more regularly as a result of the 
intervention) appeared acceptable under the circumstances. 
Consent and confidentiality 
To protect the rights and respect of individuals, we designed an extensive patient 
information sheet to allow study participants to give informed consent to take part in the 
study. Informed consent was sought in a non-coercive way, and patients were reminded 
on several occasions that taking part in the study would be voluntary, and that not 
taking part in the study would not in any way affect their routine care. At all times 
patient confidentiality was respected according to the Data Protection Act 1998. 
Ethics committee approval 
This study was designed and conducted in accordance with the MRC Guidelines for 
Good Clinical Practice in Clinical Trial, and approval from the South and West Multi-
centre Ethics Committee was granted.229 
4.6 Summary 
This Chapter summarised how the findings from the literature review influenced the 
aims and objectives of the main study in this thesis and the methods used in the trial. It 
drew attention to some of the theoretical foundations for the study, which led to a 
reflection on the overall research design. In the next chapter I describe the methods used 
in the RCT in more detail to provide information that allows assessing the internal and 
external validity of the study. 
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5 Methods of the ReT of nurse-led adherence support in 
hypertension 
5.1 Introduction 
This chapter describes the methods used in the RCT of nurse-led adherence support in 
hypertension described in Chapter 6. The project was part of a MRC Training 
Fellowship in Health Services Research and funded by the Medical Research Council 
and the Division of Primary Health Care. This chapter is reported according to the 
revised recommendations for improving the quality or reports of parallel group 
randomised trials (CONSORT statement) and includes further additional information 
that is relevant to this thesis.23o 
Tom Fahey and Tim Peters originally conceived the study, which was designed by the 
three of us. Tim Peters conducted the randomisation, and I was the principal 
investigator on this trial, which included responsibility for the day-to-day running of the 
study and management of the trial budget. 
5.2 Objectives 
The main objective of this study was to evaluate the effectiveness of a nurse-led 
adherence support intervention aiming to increase adherence to medication and reduce 
blood pressure in uncontrolled hypertensive people. The primary outcome was 
adherence, defined as 'timing compliance'. Secondary outcomes were systolic and 
diastolic blood pressure, 'taking compliance' and 'correct dosing'. 
5.3 Study design 
As outlined in Chapter 4, this trial was designed as a pragmatic, primary care based 
parallel group trial with randomisation by individual, comparing nurse-led adherence 
support in addition to usual care with usual care alone. 
5.3.1 Justification of choice of study design 
This trial aimed to improve health care to uncontrolled hypertensive patients and 
provide a basis for decisions about the delivery of care for this patient group. Results of 
efficacy trials of antihypertensive drugs have shown that treating high blood pressure 
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can lead to a reduction of heart attacks and strokes.5;37 Since various components that 
were combined in the intervention have shown promising results in RCTs (see Chapter 
3), a pragmatic randomised trial was conducted to help decision makers and clinicians 
in primary care assess the potential value of the intervention in the routine clinical 
setting in a representative group of patients. 
5.3.2 Adjustments made to the study methods 
In addition to modifications to the study design described in the previous chapter, the 
main change to the study protocol affected the outcome measurement of adherence. The 
initial strategy for measuring adherence was to use a mixture of patient self-report and 
repeat prescribing data. Since electronic monitoring has emerged to be a superior 
method in terms of accuracy and validity, I adapted the study protocol to incorporate the 
use of electronic monitors instead of using repeat prescribing data. 
5.4 Overview of the study schedule 
Figure 10 gives an overview of the study schedule. Consenting participants attended an 
initial appointment in which they were given an electronic medication monitor and 
informed about the trial schedule. In the intervention group, the main adherence-support 
consultation took place after a baseline-monitoring phase of 30 days, followed by a 
reinforcement appointment two months later. All study participants were followed up 
for six months. 
77 
Figure 10 Overview of study appointment schedule 
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5.5 Setting and practice recruitment 
I wrote to 82 general practices in Avon, UK. Of the 45 practices that replied, 24 gave 
time constraints and staff shortages as the main reasons for declining to take part. 
Twenty-one general practices in rural and urban settings took part in the study. Fourteen 
practices were teaching practices, and 11 belonged to a Culyer-funded research 
consortium. All practices ran nurse-led clinics, which contributed to the care of their 
hypertensive patients. 
5.6 Participant recruitment and eligibility criteria 
The overall aim of the recruitment strategy was to ensure to be as inclusive as possible 
in order to give all patients registered with the practice who fulfilled the inclusion 
criteria the same chance of being in the trial. Participating practices performed a 
computerised search of their practice registers for patients who were coded as having 
hypertension, were prescribed antihypertensive medication and had a latest blood 
pressure recording of~150 mmHg systolic and/or 90 nunHg diastolic (British 
Hypertension Society (BHS) audit standard for general practice). 19 We recruited eligible 
participants from June 2001 to December 2001 and followed them up until December 
2002. 
Due to the pragmatic nature of the trial we aimed to keep the exclusion criteria to a 
minimum. GPs and practice nurses screened this list and excluded patients in whom the 
following reasons for exclusion were present: (l) individuals did not control their 
medication intake (e.g. some nursing home patients), (2) secondary hypertension (e.g. 
endocrine, renal or pregnancy related), (3) severe dementia, (4) using a dose organiser, 
or (5) other reasons given by the practice nurses or GPs for not approaching their 
patients (for example, terminal illness or recent bereavement). Using computer-
generated random numbers supplied by the research team, the practices identified a 
random sample of patients on this list, stratified by age «60 and ~60 years) and sex. 
The aim of the stratification was to increase the generalisibility of the study by selecting 
study participants with a similar age/sex distribution as shown for hypertensive adults in 
the community.9 The practice nurses or GPs sent information about the study to the 
sampled patients, asking them to take part in this study. 
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5.7 Consent 
Patients who were potentially interested to take part were asked to return a reply slip to 
us and subsequently received more detailed information about the study together with a 
consent form. Study participants were informed that at any stage of the trial they were 
free to leave the study without giving any reasons and without any consequences to 
their usual medical care. 
5.8 Initial appointment 
At the initial appointment, study participants received an electronic medication monitor 
to be used to assess adherence to one of their blood pressure lowering drugs. The drug 
to be used with the monitor was chosen by the practice nurse according to a flow chart 
(Appendix 6). This favoured diuretics to beta blockers and other drugs, since diuretics 
are commonly used as a first line treatment in hypertension. Guidance on prescribing 
for hypertension has been issued by the Bristol South & West Primary Care Trust and 
the United Bristol Healthcare Trust in 2002 and has been made available to all general 
practices in Bristol, recommending the use ofbendrofluazide and atenolol as first-
choice agents for the treatment of high blood pressure.231 Once-daily preparations were 
the preferred choice of drugs to be used in the monitors because this dosing frequency is 
the most common in the drug treatment of high blood pressure. Ideally, we would have 
used more than one electronic monitor if participants were taking more than one blood 
pressure lowering drug, but for cost reasons this was not feasible. Study participants 
were asked to transfer the chosen drug into the electronic monitor themselves. 
5.9 Interventions 
5.9.1 Theoretical background 
We developed this pragmatic intervention using primarily the self-regulatory model of 
illness behaviour developed by Leventhal, which has been described in more detail 
earlier in this thesis (Section 2.4.9).128,130 The particular strength of this model is that it 
takes into account the individual symptom perception, emotional responses to a health 
threat and coping strategies such as avoidance. The main aim behind the theoretical 
development of the intervention was to help patients understand their diagnosis of high 
blood pressure and why treating their high blood pressure can improve their health 
outcomes, while simultaneously taking into account individual perspectives of their 
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1 ess and Its treatment. Thus the development of the intervention was largely guided 
by the theoretical frameworks and trial evidence outlm' ed m' th . h e preVIOUS c apters. 
5.9.2 Design of the intervention 
The intervention that was developed for this trial can be classified as a 'complex' 
intervention, that is, an intervention that consists of interconnecting and different 
art 233 C l' . . p s. omp ex Intervenhons can be dIfficult to define and reproduce. They pose, 
therefore, many challenges if they are to be tested in randomised trials.233,234 Campbell 
and colleagues described a framework for the design and evaluation of complex 
interventions to improve health and advocated a phased approach.233 
The development of this trial was to a certain extent based on this framework and 
included sequential phases. The first phase consisted of the review of the literature (see 
Chapters 2 and 3), which examined the relevant background theory to identify the best 
choice of the intervention and to predict important confounders and design problems. 
We aimed to identify the components of the intervention and mechanisms through 
which they may influence the outcomes by evaluating the qualitative literature in this 
field. For practical and economical reasons we were unable to conduct an exploratory 
trial. However, we refined the intervention in consultation with patients, practice nurses, 
general practitioners and experts in the field and tried to standardise the intervention as 
much as possible to make this study reproducible. 
Key elements of the intervention 
Four key features of Leventhal's self-regulatory model were used to develop the main 
elements of the intervention, which we summarised in a consultation prompt sheet 
(Appendix 5) for the nurses who delivered the intervention. First, patients' responses to 
health threats are often guided by illness representations. Part of the intervention was 
therefore to ask patients about their perceived health risks from high blood pressure and 
discuss misconceptions. Second, Leventhal describes two parallel and partially 
independent motivational processes: one that is focused on the problem and one that is 
focused on emotions. We encouraged nurses to ask patients how they feel about their 
medication and what they felt their problems were. Third, patients' mental constructs 
often have both abstract-conceptual and concrete-perceptual content, which the nurses 
addressed by establishing patients' health beliefs and what they perceived to be their 
biggest problem with regard to medication taking. Finally, "if-then" cognitive rules 
often link representations, behaviours and appraisal of outcomes. We therefore 
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-encouraged nurses to design individual solutions to medication problems presented by 
study participants, taking into account the key features of Leventhal's model. 
5.9.3 Delivery of the adherence-support intervention 
Since many problems around medication taking result from poor communication 
between health professionals and patient, the overall objective of the intervention was to 
find a way to help improving the communication between practice nurses and patieI.lts. 
The key tasks for the participating practice nurses were therefore to elicit the patients' 
main problems, the patients' perception of these and the social impact of these problems 
on patients and their families.235 Relationships between health professionals and patients 
can take different forms. Three models commonly referred to in treatment decision-
making are the paternalistic, the shared, and the informed model.236 For implementing 
the intervention we encouraged the practice nurses to follow the shared model by 
sharing all stages of the decision-making process simultaneously.151,237 
Practice nurses invited participating individuals to attend an adherence support session 
lasting a maximum of20 minutes, followed by a shorter reinforcement session (10 
minutes) two months later. The aim of the intervention was to provide an opportunity 
for patients to talk about any problems with their blood pressure lowering medication in 
a safe and non-threatening atmosphere and was led by the patients themselves. 13,79,167 
During the consultation, practice nurses investigated whether patients understood their 
diagnosis and agreed with the treatment process. We encouraged the practice nurses to 
address patient concerns with their medication and to agree tailored strategies to resolve 
any medication problems. 13,238 To increase consistency, the practice nurses were asked 
to record the content of the consultation on a one-page prompt sheet (Appendix 5) This 
prompt sheet contained suggestions for potential issues to be raised, including the most 
common barriers to adherence. 
We 'designed this intervention in such a way that it could easily be introduced into 
routine practice. The only adherence-related training provided for the practice nurses 
was an explanation of the prompt sheet. We encouraged the nurses to find individual 
solutions to patients' problems taking into account their experience and knowledge of 
their patients. 
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5.9.4 Care in the control group 
The control group received standard care delivered at their respective practices, apart 
from blood pressure checks at similar intervals as the participants in the intervention 
group. Wherever possible, these checks were carried out by another practice nurse who 
was not involved in delivering the intervention. Given the potential for contamination, 
all practice nurses were made aware of this risk and strongly and repeatedly encouraged 
not to change their 'usual practice' for the control patients. Blood pressure was 
measured according to the guidelines laid out in Figure 1. 
5.10 Sample size 
We designed this trial to detect a difference in adherence between the two intervention 
groups receiving adherence support and usual care. We estimated from the existing 
literature that about 50-60% of patients would be adherent to medication in the absence 
of the intervention. I0,41 For a target difference in adherence of 15 percentage points (for 
example 75% in the intervention group and 60% in the control group), a 2-sided 5% 
significance level and 80% power, we required a total sample size of about 330 
participants. However, it is worth remembering that considerable uncertainty exists 
about the levels and variability of adherence outcomes, resulting in additional 
uncertainty for the sample size calculation, and that this sample size calculation might 
imply an unrealistic degree of precision. So far, there is little high quality evidence on 
the relationship between adherence and blood pressure. However, we felt that from a 
clinical point of view an increase in adherence of 15% would be important, although we 
appreciated that this would largely depend on the particular drug in question. 
With respect to blood pressure at follow-up, this sample size would be sufficient (85% 
power, 2-sided 5% alpha) to detect differences between the two groups 0[0.42 standard 
deviations. For standard deviations in diastolic blood pressure of about 9 mmHg, this 
corresponds to differences between groups of about 3.2 mmHg. There is good evidence 
from RCTs that a difference of 5 to 6 mmHg in diastolic blood pressure leads to a 
reduction in stroke of 38% and in coronary heart disease of 16%.5,37 
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5. 11 Randomisation 
5.11.1 Sequence generation 
Eligible study participants were stratified by age and sex and allocated to the 
intervention and control groups by using computer-generated random numbers. Because 
of the risk of imbalance in prognostic characteristics that can occur by chance with 
simple randomisation or block randomisation, we performed stratified randomisation by 
general practice as well as by age and sex.239 
5.11.2 Allocation concealment and implementation 
I collated an anonymised list of study participants, which only contained patients' 
initials, their age group, sex and the name of the general practice from which they were 
recruited. Separate lists for every practice were passed on to Tim Peters, who as a 
member of the research team was not involved in practice and patient recruitment and 
who then generated the randomisation sequence?40 Based on this sequence, I printed 
separate data collection sheets, which were clearly marked either 'intervention' or 
'control'. These data collection sheets were subsequently sent to the practice nurses. 
5.12 Blinding (masking) 
In this open ReT both the study participants and the practice nurses became aware of 
the group assignment at completion of the baseline period. 
5.13 Data collection and management 
I had the ultimate responsibility for data collection, storage and processing. The practice 
nurses were repeatedly informed about the importance of accuracy in collecting the data 
to provide high quality information. The data collected for this trial aimed to answer the 
key questions outlined before and were kept to a minimum. 
5.13.1 Data collection 
At each appointment, the practice nurses collected data and entered these onto a 
specially designed data collection form (Appendix 5). This form allowed entering 
patient data as well as process data of relevance to the study. In addition, further data 
were collected from the practice nurses using a separate questionnaire. Missing or 
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-incomplete data were collected in personal or telephone intervi~wswith the 
participating practice nurses or their respective practice managers. 
Study participants were asked to bring the electronic monitors with them on every visit 
to the practice nurse. The practice nurses downloaded data from the electronic monitors 
onto a personal computer in the consulting rooms using an electronic device called a 
communicator (Appendix 7), and adherence data were stored on a personal computer in 
the treatment room using PowerView® software. 
5.13.2 Data processing 
I collected the data sheets from each practice after the last follow-up appointment. Data 
from the electronic monitors were downloaded from the practice computer and stored 
on a floppy disk. Patient and practice data were coded and entered into a Microsoft® 
Access database as soon as they were received. Ideally, data should have been entered 
twice by two different people to detect inconsistencies and identify queries, but this was 
not feasible given the scope of this research project. Data from the electronic medication 
monitors were transformed into a Stata® database.241 All data were backed up every 
night and stored on a secure off site network server. 
5.13.3 Data cleaning 
Before the analysis all the data were examined with logical, range and coding checks to 
identify inconsistencies and outliers. All extreme or for any other reason suspicious 
values were checked against the original data forms. 
5.13.4 Confidentiality 
At all times all data collected from patients and practice nurses were treated as 
confidential, since this trial used individual patients' data.242 Original data sheets were 
stored in a locked cupboard in a locked office according to regulations set out in the 
Data Protection Act 1998. All patient data were anonymised prior to the analysis. 
5.14 Outcomes 
The outcomes for this trial were chosen at the planning stage of the trial and were 
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largely determined by the nature of the trial and the research questIOn. Althou t s 
trial has been described as a pragmatic trial, it is relatively close to being an 
'explanatory' trial, for which a single main outcome may have been appropriate. For 
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-clinicians and other healthcare decision makers it was, however~ important to add 
information in terms of additional outcome measures to help them weigh up the 
benefits, risks and costs of the adherence support intervention. Ideally, further outcomes 
should have included functional status, satisfaction with management and treatment, 
subsequent use of health services as well as long-term outcomes such as cardiovascular 
morbidity and mortality. These outcomes, however, were not included for practical 
reasons in terms of study duration and sample size. There is also an increased risk of 
reaching statistical significance by chance alone if multiple outcomes are being used, 
and Peto and colleagues have argued that large trials in particular should focus on a 
small number of simple outcomes.244 
5.14.1 Description of terms relating to electronic monitoring 
This section gives a brief overview of the different terms and definitions used when 
measuring adherence with electronic monitoring, which includes the terms that are 
important for understanding the way electronic monitoring works and definitions of the 
calculated results that are displayed in the summary provided by the PowerView® 
software. PowerView® can be used to summarise data generated by the electronic 
monitors and produce data summary sheets for individual patients. It can generate data 
tables that can be transformed into different database formats and analysed using 
statistical software packages. 
Electronic monitor 
The main tool in measuring adherence in this trial was the electronic monitor. An 
electronic monitor consists of a container similar to traditional drug bottles and a larger 
lid, which holds a microchip and a pressure release system (see Appendix 7). This 
system is activated each time a monitor is opened and closed, called a medication event 
(see next paragraph). The monitor stores the exact time and date of each opening 
sequence, and summary data can be downloaded onto a personal computer. Results 
based on electronic monitoring have been reported in over 350 publications, including 
over 50 peer-reviewed original research papers, and have a failure rate of less than 
1%.67 
Medication event 
The medication event is an electronically detected, time-stamped manoeuvre made by 
the electronic monitor, which is a necessary condition for removing a dose of a drug. In 
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practice, this is assumed to designate the taking of a prescribed drug dose. The software 
allowed manual exclusion of events. In this study events were not taken into account in 
the calculations in certain circumstances, for example if the monitor was opened during 
a consultation or when a participant made a note that the monitor was opened for a 
reason other than taking the medication. An excluded event was never deleted and could 
be undone at any time. 
Dose taken 
An event saved in the electronic monitor corresponded to a prescribed dose taken and 
was created by an opening and closing of the monitor cap. If the monitor stayed open 
for more than two hours, the programme generated a new event when closing occured. 
If the monitor recorded two events in an interval of less than 15 minutes, only the first 
event was taken into account. The second one was filtered on the assumption that the 
second event represents the patient having mechanical difficulties with the closure. 
Start of the dosing day 
The dosing day did not start at midnight, because we assumed that some participants 
might have taken doses at around midnight, perhaps slightly before or after. This could 
have created different daily dose counts and might have given the impression of rather 
erratic dosing, when in fact these differences were only due to a few minutes of day-to-
day variation. We therefore designated the start of the dosing day to a time when dosing 
was least likely to occur, which for most people would be 03 :OOh in the morning. 
However, this time may not have given the best results for patients who worked night 
shifts or other unusual hours, so the 03 :OOh start was a default that was changed for 
individual patients. It is worth noting that shifting the start of the dosing day from 
midnight to 03:00h did not alter the basic data. 
Observation periods 
These were periods defmed by the appointment dates with the practice nurse. 
Observation period one was used to describe baseline adherence, and observation period 
2 defined adherence during the follow-up period (see Table 2). 
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Table 2 Observation periods used for calculating adherence 
Observation period Description 
1 Base~ine period, that is, the time between the initial 
appointment and the intervention appointment 
2 T.ime between intervention appointment and final follow-up at 
SIX months 
Non-monitored periods 
If participants were unable or unwilling to use the electronic monitor for a specified 
period, these so-called non-monitored periods could be defined by their dates and were 
excluded from all calculations. Unlike the event exclusion where only single events 
were not taken into account, more of the events in the non-monitored period were taken 
into account, and the duration of the non-monitored period was subtracted from the 
observation period. 
5.14.2 Ethical considerations relating to electronic monitoring 
One important question at the planning stage of this trial was the extent to which 
information about electronic monitoring should be given to trial participants.
245 
There is 
some evidence from a short-term study of the use of inhalers that covert monitoring 
yielded superior data compared to conventional approaches where study participants 
were aware of being monitored?46 
However, we decided to inform all study participants that during the course of the trial 
medication adherence would be monitored and that the purpose of the trial was not to 
identify individual patients' performance, but rather to produce high quality 
generalisable knowledge. We also emphasised that this study aim was of mutual 
interests to study participants and investigators. In addition, we pointed out that the 
individual level of adherence would not be disclosed to the practice nurses or GPs 
without permission by the study participants. 
In most studies that used electronic monitoring, patients have been informed that the 
medication monitor counts and keeps a log of their medication doses.
132 
A study by 
Cramer and colleagues has shown that dosing patterns, perhaps surprisingly, have not 
been shown to be influenced by patients' knowledge that medication monitoring is 
occurring.247 The practice nurse handing out the electronic monitors in this trial was 
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-asked to tell participants that the electronic monitor would gather data on medication 
taking patterns, without putting too much emphasis on how exactly the monitor works. 
She also provided participants with an information sheet on how to use the electronic 
monitor (see Appendix 8).98 
One may argue that adherence may not always be beneficial and that not all strategies to 
increase adherence to medication are in the patients' best interest. 248,249 Although 
promoting and measuring adherence within a clinical trial can have potential risks as 
well as benefits, we felt that on balance these risks, that is, an increased incidence of 
adverse effects, were indeed small and did not affect the ethical issues around autonomy 
and privacy substantially. 
5.14.3 Definitions of adherence 
As highlighted in Chapters 2 and 3, adherence has been defined in different ways. When 
using electronic monitoring for outcome measurement of adherence, the following 
definitions are the ones that are most commonly used. 
Timing compliance 
Timing compliance is the strictest of the adherence measures described here and was the 
main outcome used for this trial. It can be defined as the percentage of the prescribed 
number of doses taken within a correct interval. The correct interval between two doses 
is determined by the prescribed drug regimen. For a regimen with one dose per day the 
correct inter-dose interval is 24 hours, for two doses per day it is 12 hours, and for three 
doses a day it is eight hours. Allowing for a tolerance of ±25%, for a regimen of one 
dose a day the correct inter-dose interval is between 18 and 32 hours. The percentage of 
doses taken within a correct interval is the number of correct inter-dose intervals 
divided by the total of doses taken less one, because there is one less interval between 
doses than the total number of doses taken. 
Correct dosing 




Taking compliance is the number of doses taken divided by the number of doses 
prescribed during the monitored interval. The number of doses prescribed corresponds 
with the number of monitored days multiplied by the number of doses prescribed per 
day and provides the equivalent data to a 'pill count'. This adherence measure is the 
least strict of the three described so far. 
Therapeutic coverage 
The therapeutic coverage corresponds to the percentage of time that the patient has 
maintained therapeutic drug action, given the measured or assumed value for duration 
of action and the measured inter-dose intervals. A therapeutic coverage of 1000/0 
signifies that all inter-dose intervals are shorter than the duration of action. It decreases 
as the number and the duration of intervals longer than the duration of drug action 
increase. Although the therapeutic coverage appears to be a valuable additional measure 
of adherence, it has not been used for this study. The main reason for is that drugs used 
in the electronic monitors varied between participants and have different 
pharmacological properties including half-lives, and the exact durations of action for 
many drugs that were used in this study are not known. 
5.14.4 Primary outcome 
The primary outcome with respect to the effectiveness of the intervention was timing 
compliance in the six months period following the intervention, controlling for 
adherence in the baseline period (see Figure 10 for study timeline and Table 2). 
5.14.5 Secondary outcomes 
Adherence 
Secondary adherence outcomes were the two less strict measures of adherence, correct 
dosing and taking compliance as defined above. 
Blood pressure 
The main secondary outcome used in this trial was blood pressure. At each visit, the 
practice nurses measured systolic and diastolic blood pressures according to the British 
. S . t ·d 1· es and an evidence based review by McAlister & Straus HypertensIOn OCle y gw e m 
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(F' ) 19,250 . . - . 19ure 1 . Smce practices used different methods for checking the blood pressure, 
that is, manual or automatic devices, we asked the practice nurses to use the same 
measurement instrument for each patient during the study, whichever was the preferred 
system at that time. Since we were calculating the differences in blood pressure levels at 
follow-up, adjusted for baseline values, any differences between results from manual 
and automatic blood pressure readings can assumed to be negligible.251 
5. 15 Statistical analysis 
The statistical analysis was conducted according to an analysis plan that was agreed 
before the start of the analysis. Data were analysed using Stata version 8.241 Baseline 
comparability of the groups in terms of cardiovascular risk factors, age, sex, medication 
usage and treatment duration was investigated by using descriptive statistics. Process 
measures were evaluated in terms of non-attendance at follow-up between the groups 
and the extent to which the practice nurses followed the protocol for the intervention. 
The distributions of the main outcome variables and residuals were investigated by 
producing frequency histograms and graphical plots. 
We used an intention-to-treat analysis because this helps preserve the prognostic 
balance in the study arms and reduces the influence of study withdrawals and patients 
lost to follow-up.252 The primary intention-to-treat analyses used multivariable 
regression models, adjusting for the values of the outcome variables at baseline as well 
as the stratifying variables. By using analysis of covariance, each participant's follow-
up score was adjusted for her or his baseline score while still producing p-values and 
95% confidence intervals for differences between the intervention and control groupS.253 
This analysis compared timing compliance at final follow-up between the intervention 
and control groups. The influence of missing values was investigated by comparing the 
intention-to-treat model with a model in which missing values were replaced with the 
last observation carried forward. 
The secondary analyses comprised first additional adjustment in these regression 
models in terms of any potentially influential variables exhibiting some degree of 
imbalance at baseline and, secondly, process variables. Subgroup analyses were kept to 
a minimum because they are unreliable and have a relative high risk of producing false 
positive chance findingS. 254 Pre-planned subgroup analyses were therefore only 
conducted for age, sex, drug group and total number of drugs prescribed by introducing 
appropriate interaction terms to investigate differential effects. I included these 
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parameters in the subgroup analysis because they were either known confounders or 
were assumed to potentially influence the relationship between intervention and 
outcome. 
The relationship between timing compliance and blood pressure was explored by using 
scatter plots and calculation of correlation coefficients as well as linear regression 
models adjusting for the stratifying variables. 
5.16 Summary 
This chapter described the study methods used for the ReT of nurse-led adherence 
support in hypertension. It highlighted some of the problems that are associated with 
research in adherence and discussed the rationale for the sometimes difficult decisions 
that were made at each stage of the trial, from the planning phase to the final analysis. 
The following chapter describes a study comparing an adherence self-report to.ol with 
electronic medication monitoring, and the trial results will be presente~ in Chapter 7. 
92 
-6 Comparison of an adherence self-report tool with electronic 
medication monitoring 
6. 1 Introduction 
In this chapter I describe the methods and results of a study that validated a newly 
developed adherence self-report tool aiming to predict adherence to blood pressure 
lowering medication. 
As outlined in Chapter 2, a variety of measurement tools are available to assess patient 
adherence to medication. Many of these instruments have disadvantages and often 
produce results of doubtful validity. The method that comes closest to a 'gold standard' 
is electronic monitoring, but due to costs this method has mainly been used as a 
research tool and is at present not suitable for use in day-to-day clinical practice. 
The simplest method of measuring adherence in clinical practice is self-report, as it can 
be easy to use, is non-invasive and relatively quick. However, there is a common 
perception among health professionals that patients do not always tell the truth about 
their medication taking. Hippocrates wrote: 
"Keep a watch also on the faults of the patients, which often make them lie 
about things prescribed" (Hippocrates, 5th century BC)14 
nfirm thi . 255,256 Although studies in the past decades have appeared to co s perceptIOn, 
recent evidence has shown that this view may be outdated, and self-report scores of 
adherence have been shown to be useful in the primary care setting.2,257 To date, only a 
few adherence questionnaires are available, and even less have been validated with 
.. h d f . dh 89,90,257 
more obJ ectlve met 0 s 0 measunng a erence. 
In the following sections I describe the development and subsequent validation of a new 
adherence self-report tool, which has been designed on the basis of previous research. 
6.2 Background 
Patients are often reluctant to admit non-adherence to health professionals.
2 
However, 
accurate information about patient adherence to medication can be useful for health 
professionals to target interventions more effectively and efficiently, particularly if non-
response to pharmacological treatment is present.172,258 Home and colleagues developed 
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-and evaluated a new method for assessing the cognitive representation of medication 
, 
the Beliefs about Medicines Questionnaire.123 This study showed that this method was 
useful in assessing beliefs that patients commonly hold about the medicines that they 
are being prescribed for a particular condition and about medicines in general. This 
method, however, is more useful for research into patients' perspectives of treatment 
rather than to assess adherence to treatment in day-to-day clinical practice. 
Ogedegbe and colleagues recently developed and evaluated a 26-item medication self-
efficacy scale.259 The authors aimed to identify situations in which patients have low 
self-efficacy, which is a known predictor for a wide range of health behaviours. This 
scale showed good internal consistency and stable scores, and it was easy to use and 
understand for patients. However, it is unclear how applicable this scale would be for 
UK primary care, as it has only been evaluated among African-Americans in the US. 
This study did also not determine how well this scale predicts adherence to prescribed 
antihypertensive medications and blood pressure control. 
Self-report of adherence appears to be a flexible and practical method for assessing 
adherence, but there are concerns about their ability to detect true non-adherence. The 
sensitivity of self-report adherence measures was below 60% in a number of studies 
published in the past decades, indicating false negative results for at least 40% of people 
with true non-adherence. 86,97,255,260-263 
Despite this somewhat discouraging outlook, the development of adherence self-report 
tools has become a focus of interest again in recent years, and two studies used 
electronic monitors to validate newly developed adherence self-assessment tools.89,90 
Svarstad and colleagues designed a Brief Medication Questionnaire to screen for 
adherence and barriers to adherence.89 Their tool includes a 5-item Regimen Screen 
asking patients how they took their medicines in the past week, a 2-item Belief Screen 
asking about drug effects and bothersome features, and a 2-item Recall Screen about 
potential memory difficulties. The validity of this instrument was assessed in 20 patients 
who were prescribed ACE inhibitors by using electronic monitors (MEMS~ as a 
comparator (see Section 2.4.4). Their results showed 80-100% sensitivity for different 
types of adherence, suggesting that this tool is more sensitive than existing instruments. 
This study was the first to demonstrate that sensitivity levels vary by type of non-
adherence and type of screening tool. 
De Klerk and colleagues developed a new adherence questionnaire for use in 
rheumatology.90 This questionnaire aimed to measure adherence and identify factors 
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that contribute to sUb-optimal patient compliance in 127 patient~ with rheumatoid 
arthritis (RA), polymyalgia rheumatic a (PMR), and gout, using MEMS® for 
comparison. This study showed a sensitivity and specificity to detect what the authors 
described as "good taking compliance" of 62% and 95%, respectively. 
A study by George and colleagues investigated the value of four different methods of 
assessment of adherence in patients in UK primary care who were prescribed tricyclic 
antidepressants?57 They found that electronic monitoring was the most infonnative 
technique, but that self-report using a scale developed by Morisky and colleagues 
proved a useful screening technique with a sensitivity of 72.2% and a specificity of 
74.1 % for detecting ~80% adherence. 
Although the results of these studies are promising, it is difficult to know how 
generalisable they are to people on blood pressure lowering medication, because two of 
these studies were targeted at symptomatic patients with rheumatic disease or 
depression,90.257 whereas the other was small with only 20 study participants.89 
In addition, most of the self-report tools described above appear to address two aims at 
the same time, that is, to establish (a) whether non-adherence is present or not and (b) 
the reasons for non-adherence. There are two main disadvantages of this combined 
approach for use in clinical practice. First, the number of issues increases, which adds to 
the time needed for completion, and second, many questions are redundant for patients 
who take their medicines regularly and do not have any problems. 
The study described in this chapter focuses on the first question, that is, whether non-
adherence is present or not. If this question can be answered quickly, then patients who 
have problems with taking medicines can be given the opportunity to talk about any 
problems with the health professional in a similar way as described in the adherence 
support intervention (see Chapter 5). If patients do not have any problems with their 
medication, then both the patient and health professional can centre their attention on 
other reasons for non-response to phannacological treatment. The aim of this study was, 
therefore, to develop a new short self-assessment tool that could be used as a brief 




The objective of this study was to validate a newly adapted adherence self-report tool 
aiming to predict adherence to blood pressure lowering medication against electronic 
monitors (MEMS~ as the comparative' gold standard' in uncontrolled hypertensive 
patients in a primary care setting. 
6.3.2 Design of the adherence self-report tool 
The design of this adherence self-report tool is based on an instrument that has been 
developed by de Klerk and colleagues, who used six descriptions of patients with 
different levels of adherence?64 Patients were asked to indicate which of these fictitious 
patients would describe them best (Figure 11 below). 
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Figure 11 Patient descriptions used in patients with rheumatic diseas~s 
Instruction Below .yo~ find si~ descriptions of six different patients. 
Try to indicate which of the descriptions describes 
yourself best. It is possible that only part of the 
descr~pt~on desc.ribes you. In that case, try to select the 
description that IS most appropriate for your situation. 
Where the description says 'he' you can of course also 
read 'she' 
Patient 1 Patient 1 is very punctu~1 in everything he does. He gets up 
every day at the same time, eats at the same time and takes 
his drugs at the same time. There is never more than 15 
minutes difference in the time of taking the drug. Forgetting to 
take the medicines never occurs. 
Patient 2 Patient 2 is also very punctual but somewhat less so than 
pati~nt 1. Every now and then he deviates a little from the daily 
ro~tlnes. He takes essentially all medicines, but the timing with 
which he takes them may vary a little. Very infrequently, for 
example twice a month, he forgets to take his anti-rheumatic 
medicines. 
Patient 3 Patient 3 is less punctual. He likes change. He also does not 
want to have his life dictated by his disease or medicines. He 
is also less punctual in taking his medicines. He takes most of 
the prescribed tablets, but the timing varies, and it happens 
every now and then, consciously or unconsciously, that he 
skips a scheduled dose (approximately six times per month) 
Patient 4 Patient 4 does not care much about his medicines. There may 
be many causes for this, like inactive disease or other things 
that require attention. Therefore there is not much regularity in 
taking the drugs, and it happens often that he does not take 
the medicines (approximately 15 times per month) 
Patient 5 Patient 5 does almost not take any of the medicines 
prescribed by his rheumatologist. Sometimes there is a period 
in which he takes a couple of tablets, but overall there are 
more days when he does not take any drugs than when he 
does. 
Patient 6 Patient 6 denies being ill. The rheumatologist may say that 
there is something wrong, but he does not agree with that at 
all. Of course, this has consequences for taking the drugs, as 
these are almost never taken. 
264 Source: de Klerk et aI., J RheumatoI1999;25:2635-41. 
These patient descriptions were based on about 40 patient interviews, past research and 
analyses of various datasets of patients with rheumatic diseases, which were obtained 
using MEMS®.264 Patients identifying with description one or two were classified as 
'compliant', whereas descriptions 3 to 6 were regarded as 'non-compliant'. These 
patient descriptions were used as a 'surrogate gold standard' for the development of a 
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questionnaire to explore the likelihood and underlying factors for variable patient 
compliance on antirheumatic drug therapy, but no data on sensitivity or specificity were 
provided. I adapted these patient descriptions as described below to develop a tool for 
quick assessment of adherence in a clinic setting. 
Planning 
When using structured questionnaires or self-report tools it is important that both the 
researchers or health professionals and patients have a similar theoretical frame of 
reference and interpret the contents of the tool in question in the same way.265 The aim 
of altering the above patient descriptions was to make them even simpler, while being 
aware of the effects that changes in the wording could have on the type of responses 
patients might give. This was done with permission from the developers of the original 
scale. 
The planning stage involved a review and simplification of the tool. The descriptions 
were shortened and the format of the one-page form designed. The response format (that 
is, a dichotomised answering frame in terms of a yes/no response) was kept, assuming 
that each item meant the same to each study participant. The advantage of this pre-
coded response was that it was relatively easy to analyse. However, we were aware that 
the given responses may have forced participants to give inappropriate answers. There 
was also a risk of these questions prompting participants to give a certain 'desired' 
answer, leading to social desirability bias.265 This we hoped would be pre-empted by 
careful wording of the instructions. 
We decided to use the self-report tool in participants who were recruited to the trial 
described in Chapters 5 and 6. The most appropriate timing for administering this self-
assessment tool appeared to be the beginning of the run-in phase (see Figure 10 on page 
78). During this run-in phase, all study participants used electronic monitors for a 
baseline assessment of timing compliance for about 30 days, and the data obtained with 
the self-report tool would be validated with the data obtained from the electronic 
monitors. Allocation to the treatment groups was revealed and came into effect at the 
end of this run-in period. 
Piloting 
After refining the wording in the self-report tool, we tested the self-report form on 
researchers and other members of staff. The contents were further discussed with the 
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-participating practice nurses and some patients. Main issues of interest were the layout, 
whether the wording was easy to understand, whether all reasonable alternatives were 
included and how people generally felt about the fonn. Constructive comments received 
during this process were used to further develop and pilot the fonn. The final version 
was approved by the South & West Multi-centre Research Ethics Committee. 
Figure 12 Summarised contents of the self-assessment tool 
Please find below six examples of how some people describe how they take their 
medication. 
We would be grateful if you could tick the one description that you feel comes closest 
to describe how you take your blood pressure tablets: 
Level Description 
1 "I always take all of my tablets at the same time of day". 
2 "I manage to take all my tablets - but not always at the same time of day". 
3 "I sometimes do not take all of my tablets, knowingly or unknowingly, but never omit more than one dose at a time". 
4 "I miss many tablets and about three to four times a year I miss my tablets, knowingly or unknowingly, for two or more days". 
5 "I miss many tablets, knowingly or unknowingly, and at least once a 
month I miss my tablets for two or more days". 
6 "I take hardly any of my blood pressure tablets". 
We are not looking for a particular answer and would be grateful for an honest . 
response. PLEASE TICK ONL Y ONE BOX. Neither the researchers nor your practice 
nurse will in any way mind what answer you give. 
6.3.3 Patient recruitment 
The study population consisted of patients who were recruited for the RCT described in 
Chapters 5 and 6 (for details about the recruitment process please refer to Section 5.6). 
6.3.:4 Completion of the self-report tool 
The study participants were asked to complete the adherence self-report tool at the 
beginning of their first appointment with the practice nurse. The practice nurses were 




I analysed the data using Stata Version 8.241 The analysis used multivariable regression 
models, adjusting for the stratification variables age, sex and practice, which were the 
stratifying variables in the trial. Pre-planned subgroup analyses were conducted for age, 
sex, and the total number of drugs a patient is taking by introducing appropriate 
interaction terms to investigate differential effects. These variables were chosen because 
of their potential effect on the answers given in the self-report tool. 
Although previous studies that used MEMS® to validate self-assessment tools 
calculated sensitivity, specificity and predictive values,89,90,257 it was decided not to 
calculate these test parameters because this would have required reducing timing 
compliance and/or the answers from the questionnaire into binary variables, that is, 
'adherent' and 'non-adherent'. Timing compliance is a continuous variable and the 
results of the completion of the self-assessment questionnaire provide ordered 
categorical data. Although many studies have used artificial cut-off points to define 
adherence (for example, 80% or 90%), these are often meaningless and very much 
depend on the particular drug being used (see also Sections 3.6.3 and 4.3)132,134,266. For 
this reason, multivariable regression analysis appears to be the more appropriate 
approach to compare the adherence self-report tool with electronic monitoring. 
6.4 Results 
Of 837 eligible patients with uncontrolled hypertension, 249 attended the first 
appointment and entered the 30-day run-in period (see CONSORT trial flow, Figure 
15). Four patients dropped out during the run-in period (one died, one became unwell, 
one moved away, and for one the reason was not known). Of the 249 participants 
entering the run-in period, 235 (94.4%) completed the self-report questionnaire. All 
participants for whom data were missing showed more than 80% timing compliance. 
6.4.1 Baseline characteristics of patients 
Details about the baseline characteristics of the study participants can be found in 
Section 7.2.4. Out of235 participants who completed the questionnaire, 161 (68.5%) 
identified themselves with the first patient description (,perfect adherence '), 45 (19.1 %) 
with the second, and 26 (11.1 %) with the third. The numbers in the subsequent patient 
d . t' ry small (Table 3) Patient descriptions four to six were, therefore, escnp IOns were ve . 
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combined with description two for the analysis, which raised th~ number of participants 
in this group from 26 to 29 (12.3%) 
Table 3 Numb~rs of participants who identified themselves with the six patient descriptions 
(levels 1 to 6) In the self-assessment tool 
Level Number of participants Per cent 
Level 1 161 68.5 
Level 2 45 19.1 
Level 3 26 11.1 
Level 4 2 0.9 
Level 5 1 0.4 
Level 6 0 0 
Table 4 presents key baseline characteristics for these three groups. There were no 
important differences in tenns of blood pressure, age, or sex between the three levels. In 
the 10 participants who did not complete the self-assessment questionnaire, mean 
baseline timing compliance was 93.6% ± an SD of7.3%, with a mean systolic blood 
pressure of 154.8 + 14.1 nunHg and a mean diastolic blood pressure of 88.4 ± 8.7 
nunHg. 
Table 4 Key baseline characteristics for study participants identifying themselves with one of the 
first three patient descriptions (adherence levels) on the self-assessment tool 
Level 1 Level 2 Level 3 
(n=161) (n=45) (n=29) 
Baseline systolic 
blood pressure in 150.2 ± 17.6 148.6 ± 13.0 151 ± 15.3 
mmHg, mean ± SO 
Baseline diastolic 
blood pressure in 82.6 ± 9.7 84.3 ± 8.3 85.1 ± 10.3 
mmHg, mean ± SO 
Age in years, mean 68.5 ± 9.2 66.6 ± 10.8 67.6±11.8 
±SO 
Per cent men 55.3 (89/161) 57.8 (26/45) 44.8 (13/29) 
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6.4.2 Analysis 
The 'gold standard' used for the analysis was timing compliance, which is the 
percentage of a prescribed number of doses taken in a specified correct interval. Table 5 
presents the mean timing compliance for each level that study participants identified 
themselves with on the self-assessment tool and the respective 95% confidence 
intervals. These results show that from one level to the next lower down the timing 
compliance measured through MEMS® dropped by about 5% per level. 
Table 5 Timing compliance for each level of the adherence self assessment tool with 95% 
confidence intervals 
Level Level 1 Level 2 Level 3 
Mean timing 94.8 89.6 84.7 
compliance (%) 
95%CI 93.3 to 96.3 83.4 to 95.8 76.5 to 92.8 
Table 6 presents the results of a regression model of the relationship between the results 
of the adherence self-report tool and the corresponding mean timing compliance. 
Participants identifying themselves with patient description (Level) 2 had on average 
5.8% (95% CI: 0.6% to 10.9%) lower timing compliance than those who identified 
themselves with level 1. Participants who identified their pattern of medication taking 
with level 3 had on average 5.00/0 lower timing compliance than those who identified 
themselves with level 2 (95%CI: -2.0% to 12.0%). Thus there is strong evidence that a 
drop in one level from level 1 to level 2 and from level 2 to level 3 is associated with a 
decrease in timing compliance of about 5% (p=0.0004). 
Table 6 Regression model of the relationship between the results of the adherence self-report 
questionnaire and timing compliance, adjusted for age, sex and practice 
Difference in 95% confidence 
timing p-value a interval 
compliance (%) 
Level 2 versus level 1 5.8 0.6 to 10.9 
0.0004 
Level 3 versus level 2 5.0 -2.0 to 12.0 
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6.4.3 Additional analyses 
Supplementary analyses were planned at the protocol stage and finalised in the study 
protocol before the trial was analysed. These analyses considered whether there is any 
evidence that a trend in mean timing compliance across the levels is different across, for 
example age, sex, or the total number of drugs a patient is taking. The following tables 
show the differences in timing compliance for the different levels that participants 
marked in the self-assessment questionnaire for these different groups of participants. 
There was no evidence for a differential effect for any of the variables that were 
investigated in these analyses. However, there is a difference of more than five 
percentage points for timing compliance in level three between the two age groups, 
which could suggest a possible differential effect for age. There is also a difference of 
11 percentage points in level three for the number depending on total drug usage (Table 
9). It is important to appreciate that this type of analysis has limited power and does not 
necessarily exclude an interaction if there is one?54 Interestingly, results from Table 9 
lead to the hypothesis that Level 3 participants on six or more drugs may have higher 
timing compliance than those on fewer oral drugs. 
Table 7 Mean timing compliance (% :f SD) for the different self-report levels, stratified by age 
Age group Level 1 Level 2 Level 3 p-value a 
Under 60 95.4 ± 8.6 91.1 ± 10.1 80.8 ± 12.7 
0.31 Age sixty and 94.6 ± 8.5 89.1 ± 19.0 86.2 ± 19.7 over 
a Test for interaction 
Table 8 Mean timing compliance for the different self-report levels, stratified by sex 
SeX' Level 1 Level 2 Level 3 p-value a 
Men 94.2 ± 9.4 91.0 ± 14.8 84.1 ± 20.5 
0.50 
Women 95.6 ± 7.0 87.4 ± 20.5 85.2 ± 19.9 
a Test for interaction 
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Table 9 Mean timing compliance for the different self-report levels stratified by the total number 
of oral drugs ' 
Total number 
of oral drugs Level 1 Level 2 Level 3 p-value a 
1 to 2 95.6 ± 4.7 87.9 ± 21.9 75.5 ± 8.4 
3 to 5 93.7 ± 10.4 93.1 ±8.0 86.9 ± 23.5 0.27 
6 or more 94.6 ± 8.8 80.8 ± 28.1 89.7 ± 7.2 
a Test for interaction 
6.5 Discussion 
Electronic medication monitoring would in theory be a useful method to screen for non-
adherence, but its application as a screening tool is largely limited by its costs. Self-
report of adherence is much simpler, and this study aimed to validate a newly developed 
adherence self-report tool against data obtained by electronic monitoring in 
hypertensive participants recruited for the RCT. 
6.5.1 Interpretation of findings 
This study showed that a brief self-report tool based on six patient descriptions could 
predict adherence to medication in patients taking blood pressure lowering medication. 
A drop to a lower level (that is, from levell to level 2 or from level 2 to level 3) was 
associated with a decrease in timing compliance of around 5%. Because most study 
participants showed high levels of adherence, it is difficult to know how this tool would 
perform in people with lower levels of adherence. There is strong evidence to suggest 
that the self-report tool described in this thesis can to a certain extent predict adherence 
levels in patients with high blood pressure. The self-report tool appears to perform well 
irrespective of the number of drugs taken, which is an important issue as suggested in 
our systematic review described in Chapter 3. 
6.5.2 Discussion of findings in the light of previous research 
This study confirms the findings from previous studies that self-assessment tools can to 
. d dh ·b d d· . 86 89 90,257,264 H 
a certaIn extent etect non-a erence to prescn e me lcatlon. ' , owever, 
the self-report tool described in this study was different to most previous research in 
that it only aimed to focus on the question whether non-adherence is present or not, 
rather than establishing the reasons for non-adherence. This tool is also considerably 
104 
shorter than most other self-assessment questionnaires, which perhaps makes it more 
suitable for use in a busy primary care or hypertension clinic. 
Consistent with high timing compliance in the study sample, study participants 
identified themselves with one of the first three patient descriptions, ranging from 
'perfect' adherence to 'occasionally missing a tablet', which could limit the 
generalisibility of the results to patients with lower adherence. Nevertheless, our results 
are remarkably similar to findings in a non-trial popoulation by de Klerk and 
colleagues, who found that patients with rheumatological conditions also showed high 
self-perceived adherence rates, with patient descriptions 1 to 3 being used by the 
majority of patients. 
As well as the RCT described in this thesis, most previous studies used only one 
electronic monitor per participant. This assumes that the results obtained for the drugs 
used in the monitor are representative of compliance levels for other drugs. The results 
in Table 9 are surprising and raise the possibility that this adherence self report tool 
could be superior to electronic monitoring, in that it takes account of all the drugs a 
patient is taking rather than a single drug. However, on current evidence this statement 
is speculative and further studies are required for it to be substantiated. 
6.5.3 Limitations of this study 
Baseline timing compliance was high in this study, which suggests the potential for 
response bias, as patients with lower adherence levels were perhaps less likely to take 
part in this study. Unfortunately, due to data protection reasons we were unable to 
obtain data on eligible patients who refused to take part, which would have allowed us 
to investigate any systematic differences between these individuals and the study 
participants. 
We do not know how the results of this study may have been affected by variations in 
the behaviour of the practice nurses and their reactions or attempts to influence the 
behaviour of the patients. 
6.5.4 Implications for practice 
This study has shown that a brief adherence self-report tool can be effective in screening 
for suboptimal adherence in hypertensive patients. Patients were able to complete the 
self-report tool quickly, and in future the results could be used immediately for patient 
and health professional to discuss any problems with medication taking. The main 
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implications for practice relate to the distinction between non-adherence and non-
response to medication, which can be difficult and sometimes impossible in clinical 
practice. If patients do not have any problems with their medication, then they would 
not waste any time in completing long questionnaires and can together with the health 
professional focus their attention on other reasons for non-response to pharmacological 
treatment. Because of its brevity and simplicity, this self-assessment tool could be used 
routinely in the assessment and review of all hypertensive patients. The above results 
support the use of this tool in the routine assessment and review of hypertensive 
patients, although they require further evaluation and validation. It is worth bearing in 
mind that detection of poor adherence does not always relate to inadequate control per 
se. 
6.5.5 Implications for future research 
Further research is required to investigate the validity of this self-report tool in patients 
with lower adherence levels and in a non-trial population. More evidence is needed to 
predict future adherence levels and to determine the best method to administer this self-
report tool. Future studies should evaluate this tool in different clinical settings and in 
different medical conditions. 
6.6 Summary 
This chapter described a study comparing an adherence self-report tool with electronic 
medication monitoring. This study showed that a brief self-report tool based on six 
patient descriptions could predict adherence to medication in patients taking blood 
pressure lowering medication. Patients identifying themselves with levels 2 or 3 had 5% 
and 10% lower timing compliance as measured by MEMS@, respectively, than those 
participants describing themselves as being 'perfect' adherers. These results confirm the 
value of MEMS® in measuring adherence and further justify the use of this method in 
the randomised trial, the results of which are reported in the following chapter. 
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7 Results of the ReT of nurse-led adherence support in 
hypertension 
7.1 Introduction 
This chapter describes the results of a pragmatic randomised controlled trial evaluating 
the effectiveness of practice nurse-led adherence support. It begins with descriptive 
statistics of recruitment to the trial in terms of general practices and study participants. I 
then present the results of the baseline comparability of the intervention and control 
groups. The main part of this chapter consists of the primary analysis for the adherence 
and blood pressure outcomes. Following this are the results of secondary and subgroup 
analyses. Finally, I summarise the main findings of this study. 
7.2 Descriptive results 
This sections presents descriptive results for the practices and participants in terms of 
recruitment, participant flow, and other parameters relevant to this study. 
7.2.1 Recru itment 
Recruitment of practices 
Of the 172 practices in what used to be Avon Health Authority, a sample of 82 were 
contacted and invited to take part in the study, of which 23 (28%) agreed to participate. 
The main reasons for declining the invitation to take part were workload and staff 
related. It is worth pointing out here that at the time when this ReT was conducted, 
there was a national shortage of practice nurses in the UK.267,268 This led to some 
practices experiencing major problems in providing treatment room services. 
Two practices subsequently had to withdraw their participation. The first practice was a 
single-handed practice that, because of software problems, was unable to perform a 
search of the practice computer for hypertensive patients. A second practice had to 
withdraw after patients had been recruited, because the practice nurse who was 
conducting the research fell ill and went on long-term sick leave. 
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Recruitment of participants 
A total of5170 patients in 22 general practices were eligible for recruitment. Of these, 
the practice nurses and GPs identified 572 patients who did not meet the inclusion 
criteria or who were considered unsuitable for the study because of illness or personal 
circumstances. A random sample of 837 patients fulfilling the inclusion criteria was 
invited to take part in the study (see Figure 15 for the CONSORT flow diagram below). 
Of these, 371 (44.3%) consented to receive further infonnation about the study, which 
raises the possibility of this sample being a selected subgroup of the eligible 
hypertensive patients.269 Having obtained the study infonnation and a consent fonn, 326 
out of the 371 patients (87.9%) finally consented to take part in the study. Forty-five 
patients (12.1 %) did not return their consent fonn for unknown reasons. Because 
patients were initially contacted by the practices, I was not given their names or 
addresses. For reasons of confidentiality it was not possible to contact those patients to 
investigate whether they were systematically different from the ones who agreed to take 
part. 
The number of men and women recruited to the study groups in each practice are 
presented in Figure 13 and Figure 14. The aim of recruiting eight women and men into 
both intervention and control groups was only fully achieved in two practices, with 
some differences in recruitment rates between practices. 
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Figure 13 Number of male participants recruited per practice in both intervention groups 
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Figure 14 Numbers of female participants recruited per practice in both intervention groups 
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7.2.2 Participant flow 
The CONSORT flow diagram in Figure 15 below provides an overview of the 
participant flow. 230 Having agreed to receive further infonnation about the study and a 
consent fonn, 326 participants returned this and initially consented to take part in the 
study. Before the first appointment, which was the start of the run-in or baseline period, 
77 participants dropped out for reasons given in the flow diagram. Their distribution in 
terms of the stratifying variables age and sex is presented in Table 10. All of these 
dropouts were predominantly men (87.0%) aged 60 years and over, with no dropouts in 
the under 60s group. 
Table 10 Dropouts between initial consent and first (baseline) visit by age and sex 
Age <60 years Age ~60 years Total 
Men, n (0/0) 0(0) 67 (87.0) 67 (87.0) 
Women, n (0/0) 0(0) 10(13.0) 10 (13.0) 
Total 0(0) 77 (100) 77 (100) 
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Figure 15 CONSORT flow diagram 
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Table 11 shows the numbers and percentages of dropouts between consent and the 
initial appointment for individual practices. Dropouts at this stage occurred in 14 out of 
22 practices (63.6%). Seven or more participants dropped out in six practices. 
Table 11 Dropouts between initial consent and first (baseline) appointment by practice 
Practice number Frequency 0/0 Cumulative % 
2 2 2.6 2.6 
3 7 9.1 11.7 
4 2 2.6 14.3 
5 1 1.3 15.6 
8 1 1.3 16.9 
9 3 3.9 20.8 
10 4 5.2 26.0 
11 4 5.2 31.2 
12 8 10.4 42.0 
13 2 2.6 44.2 
15 9 11.7 55.8 
17 8 10.4 66.2 
21 9 11.7 77.9 
22 17 22.1 100 
Total 77 100.0 
Four participants dropped out in the run-in period prior to randomisation, of which one 
died, one was too unwell to take part any longer, one moved away and one did not 
attend without giving a reason. Table 12 shows the losses to follow-up, which were all 
men, in the baseline period by practice and age group. A total of 245 study participants 
were randomised to receive either adherence support (n 128) or usual care (n=117). 
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Table 12 Losses to follow-up in the baseline period prior to randomisation (only men lost to 
follow-up at this stage) 
Practice no. Age <60 years Age ~60 years Total 
6 1 0 1 
8 0 1 1 
13 0 1 1 
19 0 1 1 
Total 1 3 4 
After randomisation and delivery of the first part of the intervention, a total of 13 
participants of the 245 who were randomised (5.3%) were lost to follow-up before their 
first follow-up appointment at two months, with eight (61.5%) in the intervention group 
and 5 (38.5%) in the control group. More than half of these losses to follow-up were 
due to a practice nurse having left in one single practice and not passing on 
responsibility for the study to another nurse. 
The differential losses to follow-up after randomisation will be described below in 
Section 7.3, where I also investigate the effect of process measures on the effect of the 
intervention, which includes attendance at follow-up appointments. 
7.2.3 Characteristics of recruited practices 
Comparison with regional and national data (external validity) 
Data on list sizes and number of partners of practices taking part in this RCT compared 
with those in Avon and the UK are provided in Table 13. The data for Avon are based 
on the 'Avon Practice Comparisons', which were provided by the Avon IM&T 
Consortium to general practices in 2001. Data for the UK are for 2001 and based on the 
RCGP Information Sheet No.2 'Profile of UK Practices'. Since the UK data were 
derived only from practices falling under the General Medical Services (GMS) contract, 
these data may not represent practices that have recently changed to Personal Medical 
Services (PMS). 
The overall mean list size in study practices (10,285) was smaller than for Avon 
practices (13,789). However, the mean number of patients per general practitioner was 
higher in study practices compared to the national average (2,132 versus 1,841). 
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Although there appear to be differences in list sizes between the study practices and 
practices in Avon and in the UK as a whole, these are not excessive and unlikely to 
affect the external validity of the study. 
In tenns of the number of principals by size of practice, there were slight differences 
between study practices and UK practices with respect to smaller practices (0.9% versus 
8.50/0 for single handed and 3.6% versus 12.1 % for 2-partner practices) and larger 
practices (54.5% versus 31.3%). The numbers of principals in medium size practices 
were well balanced. The 22 practices taking part in this study were located in inner city, 
suburban and rural areas and served deprived as well as affluent practice populations. 
Table 13 Characteristics of practices taking part in the study compared to those in Avon and the 
UK 
Practices taking 
part in ReT Avon (2001)a UK (2001)b 
Mean number ± SO 13,789 of patients per 10,285 ± 4461 Not available (SO not available) practice 
Mean number ± SO 
of patients per 2132±411 Not available 1,841 partner (full-time (SO not available) 
equivalent) 
Number of 
principals by type of 
practice (%) 
Single-handed 1 (0.9) Not available 2,900 (8.5) 
2 partners 4 (3.6) Not available 4,122 (12.1) 
3 partners 9 (8.2) Not available 4,716 (13.9) 
4 partners 16 (14.5) Not available 5,844 (17.2) 
5 partners 20 (18.2) Not available 5,675 (17.0) 
6 or more partners 60 (54.5) Not available 10,652 (31.3) 
Sources: a Avon Practice comparisons, Avon IM& T Consortium 2001 (CD ROM) an~ b Royal 
College of General Practitioners RCGP Information Sheet No.2 (Profile of UK practices, 
available online at http://www.rcgp.org.ukl) 
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Other characteristics of participating practices 
Further characteristics of participating general practices, which are important in tenns of 
the generalisability of this study, are summarised in Table 14. It shows that the number 
of practice nurses working in the practices (median 3.5) was similar to the number of 
practice nurses involved in the management of hypertension (median 3). More practices 
provided teaching (63.6%) in this study than those that did not. All practices used a 
recall system for managing their hypertensive patients, and 36.4% had a dedicated 
hypertension clinic. 
Although no regional or national data were available for these categories, the study 
practices appear to provide a reasonably good mix of different practice types and 
practice populations, although the percentage of teaching practices is likely to be higher 
than the national average. 
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Table 14 Characteristics of participating practices 
Characteristic Study practices 
Number of nurses managing 
3 (1 to 7) hypertension, median (range) 
Total number of practice nurses, median 
3.5 (1 to 7) (range) 
Number of practices (%) receiving Culyer 
11 (50) research funding 
Number of practices (%) involved in 
teaching 
Undergraduate only 5 (22.7) 
Postgraduate only 1 (4.6) 
Both 8 (36.4) 
None 8 (36.4) 
Type of list, n (%) 
Shared a 9 (40.9) 
Individual b 13(59.1) 
Using a recall system for hypertensive 22 (100) patients C 
Dedicated hypertension clinic, n (%) 8 (36.4) 
a 'Shared' means that patients are free to choose any doctor for a consultation, although they 
may be 'registered' with a particular GP 
b Patients are registered with a single GP whom they see for most if not all consultations 
C A system in which patients with high blood pressure are identified, coded and, either by 
computer or other system, followed up systematically and according to an agreed practice 
protocol 
Characteristics of participating practice nurses 
The characteristics of participating practice nurses are summarised in Table 15. The 
nurses taking part in this study were experienced and well qualified. More than half the 
nurses were grade F (54.5%), and eight (36.4%) were graded at sister or nurse 
practitioner level. All nurses had been qualified for a minimum of six years and had 
worked in their respective general practice for at least two years. All had received 
training in the management of hypertensive patients, either through in-house training, 
external courses, or both. All nurses used a standardised protocol that was available in 
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their consulting room and that had been adapted by the practice from the British 
Hypertension Society Guidelines for the management of hypertension. 19 It is difficult to 
know whether the nurses taking part in this study are representative of nurses in the UK, 
as no national data on the characteristics presented in Table 15 were available to allow a 
companson. 
Table 15 Characteristics of participating practice nurses 
Characteristic Practice nurses in study 
Nursing grade, n (%) a 
C 1 (4.6) 
E 1 (4.6) 
F 12 (54.6) 
G 5 (22.7) 
H 3 (13.6) 
Number of qualifications, median (range) 3 (1 to 4) 
Length of time since qualification in years, 17 (6 to 42) 
median (range) 
Length of time working in the practice in years, 3.5 (2 to 18) 
median (range) 
Training in hypertension management, n (%) 
Practice based training only 2 (9.1) 
Both internal and external training 20 (90.9) 
Using a standardised protocol, n (%) 22 (100) 
a Nurses in the NHS are graded according to experience. Grades A, Band C are used for health 
care assistants. The '0' grade corresponds to a newly qualified staff nurse, and grade E is 
assigned to more experienced nurses. An F grade is a senior staff nurse and G grade is a 
charge nurse or sister. Any grade above the G grade usually implies more management 
responsibilities. 
7.2.4 Baseline characteristics of study participants 
In this section I summarise the baseline characteristics across the trial anTIS. All study 
participants were of Caucasian ethnic origin. 
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Table 16 describes the baseline demographic and clinical characteristics of both trial 
groups in terms of the stratifying variables age and sex. The trial groups were 
comparable for these two variables, although more men than women were eventually 
taking part in the study (55% versus 45%). Age ranged from 36 to 91 years in the 
intervention group and from 39 to 87 in the control group. 
Table 16 Baseline demographic and clinical characteristics of trial groups in terms of the 
stratifying variables 
Adherence support group Usual care group (n=117) Characteristic (n=128) 
Mean age (years) ± SO 67.9 ± 10.3 (n=126) 68.2 ± 9.4 (n=116) 
Men (%) 56.3 (721128) 53.9 (63/117) 
Mean timing compliance was relatively high and similar for both groups at baseline 
(Table 17). The distributions for systolic and diastolic blood pressure were very close to 
our pre-defined cut-off point of 150/90 mmHg and similar in both groups. 
Table 17 Baseline clinical characteristics in terms of the. main outcome variables timing 
compliance and blood pressure 
Adherence support group Usual care group (n=117) 
Characteristic (n=128) 
Mean timing compliance 90.8 ± 15.6 (n=101) 94.5 ± 7.6 (n=88) (%) ± SOa 
Mean blood pressure at 
baseline in mmHg) ± SOb 
Systolic 149.0 ± 15.2 (n=127) 152.1 ± 17.5 (n=114) 
Oiastolic 83.7 ± 9.3 (n=127) 83.1 ± 9.9 (n=114) 
a Measured over one month baseline period 
b This is the mean of the blood pressures at the beginning and the end of the one month 
baseline observation period prior to administration of the intervention. 
Figure 16 shows the frequency distribution of timing compliance for all study 
participants. As expected, the distribution was skewed to the left. As can be seen from 
Figure 17 and Figure 18, there were no major differences in the frequency distributions 
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of timing compliance in both intervention groups. The majority of participants showed 
high timing compliance. 
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Figure 19 and Figure 20 show the frequencye distributions for the secondary outcome 
blood pressure. As expected, both systolic and diastolic blood pressure were normally 
distributed in the study participants. 
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Table 18 compares the means of the adherence variables ' correct dosing' and ' taking 
compliance ' for the intervention and control groups. Adherence was well balanced 
between the two groups when using these less strict measures of adherence. As 
expected, adherence was higher in both groups compared to the stricter measure of 
'timing compliance '. 
Table 18 Baseline adherence in terms of 'correct dosing' and 'taking compliance ' 
Adherence support Usual care group (n=117) Characteristic group (n=128) 
Correct dosing (% of days 
on which the correct 95.6 ± 9.5 (n=1 01) 97.6 ± 4.4 (n=88) number of doses was 
taken) ± SO 
Taking compliance (% of 
prescribed number of 98.6 ± 7.3 (n=1 01) 99.4 ± 3.8 (n=88) 
doses taken) ± SO 
Information about the distribution of important cardiovascular risk factors in both 
groups is provided in Table 19. The distributions of smoking status, body mass index, 
cholesterol, family history of hypertension, and a diagnosis of diabetes mellitus are very 
similar. There was a 4.7% difference between the study groups with regard to a past 
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history of cardiovascular disease (that is, a diagnosis on the practice register of stroke, 
angina, or myocardial infarction). 
Table 19 Baseline characteristics in terms of important cardiovascular risk factors 
Characteristic 
Adherence support group 
(n=128) Usual care group (n=117) 
Smokers (%) 10.0 (13/128) 9.4 (11/117) 
Mean body mass index 
29.1 ± 5.2 (n=118) (8MI, kg/m2) ± SO 29.3 ± 5.2 (n=106) 
Mean cholesterol (mmolll) 
5.3 ± 1.3 (n=99) 5.4 ± 1.2 (n=82) ±SOa 
Family history of 48.4 (60/124) 50.9 (59/116) hypertension (%) 
Diabetes mellitus (%) 17.1 (21/123) 16.2 (19/117) 
Past history of 36.6 (45/123) 31.9 (37/116) 
cardiovascular disease (%) 
a 'Latest' blood samples, taken between 4 November 1987 and 18 January 2002 
The characteristic~ of the trial participants in each randomisation group with respect to 
their medication usage are presented in Table 20 and Table 21. For the number of blood 
pressure tablets per dose and the total number of oral drugs, the distributions between 
trial groups were similar. However, there were differences between intervention and 
control groups for most other variables. About 8% more participants in the intervention 
group used over the counter medicines (55.7% versus 47.4%). The proportion of 
patients on twice daily regimen for the tablet dispensed by the electronic monitor was 
also higher in the intervention group (4.8% versus 1.8%). The drug group used in the 
electronic monitor was less likely to be a diuretic (47.2% versus 53.9%) or a calcium 
antagonist (11.0% versus 17.4%) in the intervention arm and more likely to be an ACE 
inhibitor (13.4% versus 6.1 %). 
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Table 20 Baseline characteristics in relation to medication usage 
Characteristic Adherence support group 
(n=128) Usual care group (n=117) 
Additional use of over the 
55.7 (68/122) counter medicines (%)a 47.4 (55/116) 
Drug group dispensed from 
the electronic monitor (%) 
Diuretic 47.2 (60/127) 53.9 (621115) 
Beta blocker 21.3 (27/127) 18.3 (21/115) 
Calcium antagonist 11.0 (14/127) 17.4 (20/115) 
ACE inhibitor 13.4 (17/127) 6.1 (71115) 
Other 7.1 (9/127) 4.4 (5/115) 
Doses dispensed from the 
electronic monitor per day, 
(%) 
Once daily 94.4 (118/125) 98.2 (107/109) 
Twice daily 4.8 (6/125) 1.8 (21109) 
Three times daily 0.8 (1/125) 0(0/109) 
Number of blood pressure 
tablets per dose dispensed 
from the electronic monitor 
(%) 
One 98.4 (123/125) 100 (109/109) 
Two 1.6 (21125) 0(0/109) 
Total number of oral drug 
prescriptions (%) 
1 to 2 21.6 (19/88) 20.3 (15/74) 
3 to 5 54.6 (48/88) 58.1 (43/74) 
6 or more 23.9 (21/88) 21.6 (16/74) 
Most trial participants had been on blood pressure lowering medication for a number of 
years. The proportions of participants with a duration of blood pressure treatment of one 
year or less was similar between groups (Table 21). A higher percentage of participants 
in the intervention group were on treatment for between one and five years (39.1 % 
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versus 27.4%). The control group had a higher percentage of participants who had been 
on blood pressure treatment for more than five years (65.0% versus 50.8%). There were 
also more participants in the control group who had a blood pressure change in the 
preceding 12 months due to poor blood pressure control (57.9% versus 43.3%). 
Table 21 Baseline characteristics in relation to treatment duration and changes in blood 
pressure lowering medication 
Adherence support group 
Usual care group (n=117) Characteristic (n=128) 
Duration of blood pressure 
treatment (%) 
< 6 months 2.3 (3/128) 2.6 (3/117) 
6 to 12 months 6.3 (8/128) 5.1 (6/117) 
> 1 year to 5 years 39.1 (50/128) 27.4 (32/117) 
> 5 years 52.3 (67/128) 65.0 (76/117) 
Change in blood pressure 
medication in past 12 46.7 (57/122) 42.0 (47/112) 
months (%) 
Reason for change in blood 
pressure medication (%) 
Side effects 19.4 (13/67) 17.5 (10/57) 
Poor control 43.3 (29/67) 57.9 (33/57) 
Both 14.9 (10/67) 7.0 (4/57) 
Other 7.5 (5/67) 0(0/57) 
Summary 
The general practices and participants recruited to the trial appear to be broadly 
representative in terms of external validity. The study groups did generally not show 
major differences in terms of basic baseline characteristics, indicating a successful 
randomisation procedure. However, for some variables, in particular the characteristics 
of drug use, there were some differences between the groups, which were further 
investigated in secondary analyses (see section 7.5 below). 
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7.3 Process measures in the intervention and control groups 
between recruitment and follow-up at six months 
This RCT was complex in terms of its various stages from baseline to final follow-up as 
well as in terms of its intervention. This section presents data of process measures that 
were observed as part of the follow-up of study participants and the delivery of the 
intervention. Where differences were observed between the different groups, the effects 
of these process measures on the relationship between explanatory variables and the 
outcomes of interest are presented in Section 7.5.2. 
7.3.1 Non-attendance at follow-up 
Participants attended their baseline appointments between 28 January 2001 and 27 May 
2002. The appointments for delivery of the intervention took place between 2 January 
2001 and 26 March 2002. The follow-up at two months occurred between 7 February 
2001 and 16 August 2002, and the final follow-up at six months took place between 12 
April 2002 and 11 December 2002. 
As shown in the CONSORT flow diagram (Figure 15), the numbers of participants who 
were not followed up were similar in the intervention and control groups. Moreover, 
there were on the whole no major differences in losses to follow-up between the groups 
when analysed within the strata of the pre-determined stratifying variables age and sex. 
Table 22 presents the results for the numbers of men and women lost to follow-up in 
both comparison groups at each stage of the trial. Losses to follow-up were reasonably 
well balanced between the groups in terms of sex apart from a higher percentage of 
women at six month in the usual care group (10.2% versus 3.9%). However, this 
difference was not statistically significant (p = 0.39). 
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Table 22 Losses to follow-up in % (numberltotal) in both comparison groups by sex 
Adherence support group Usual care 
(n=128) (n=117) 
Men Women Men Women p-value 
Two month 3.9 (5/128) 2.3 (3/128) follow-up 2.5 (3/117) 1.7 (21117) 0.92 a 
Six month 3.9 (5/128) 3.9 (5/128) 0.39 b follow-up 5.1 (6/117) 10.2 (121117) 
at = 0.008, df=1 b X2 = 0.75, df = 1 
Table 23 presents the results for the number of participants by age group who were lost 
to follow-up in both comparison groups at two and six months after randomisation. 
Losses to follow-up for the over 60s age group were slightly higher in the intervention 
group compared to controls (5.5% versus 3.4%). At six months, the differences in this 
age group were reversed, and losses to follow-up were higher in the usual care group 
(13.6% versus 5.5%). Both differences were, however, not statistically significant. 
Table 23 Losses to follow-up in % (numberltotal) in both comparison groups by age group 
Adherence support group 
(n=128) Usual care (n=117) 
<60 60 and over <60 60 and over p-value 
Two month 0.8 (1/128) 5.5 (7/128) 0.9 (1/117) 3.4 (4/117) 0.72a follow-up 
Six month 2.3 (3/128) 5.5 (7/128) follow-up 1.7 (21117) 
13.6 (16/117) 0.21 b 
at = 0.13, df=1 b t = 1 .56, df = 1 
Figure 21 shows the total number of losses to follow-up in the intervention and control 
groups at six months for each practice. A total of 41 out of the 245 patients randomised 
(16.7%) were lost to follow-up, with generally small numbers of follow-up occurring in 
16 practices. Five of the practices for which patients were randomised did not have any 
losses to follow-up, and the maximum number of losses to follow-up in a single practice 
was eight. 
One practice withdrew entirely from the study because the practice nurse fell ill after 
participants had been recruited but before they were invited for the initial appointment 
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(practice 22). Another practice had a total loss to follow-up of 8 participants at the two 
month follow-up, because the practice nurse had resigned without handing over 
responsibility for following up the trial participants (practice 17). Six losses to follow-
up in Practice 15 were due to sudden long-term illness of the practice nurse responsible 
for running the study in that centre. 
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Figure 21 Total number of losses to follow-up at six months by practice 
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In summary, there were no important statistically significant differences between the 
intervention and control groups in tenns of age or sex in tenns of differential losses to 
follow-up. However, there were differences in losses to follow-up between practices, 
the main reason being that practice nurses were leaving or falling sick. 
7.3.2 Process measures in the intervention group 
The intervention evaluated in this trial consisted of a nurse-led adherence support 
intervention, lasting about 20 minutes, and a reinforcement follow-up appointment two 
months later (Figure 10). 
First adherence support consultation 
The intended length of the appointment for delivering the intervention was 20 minutes, 
and all practice nurses booked appointments for study participant at these intervals. 
Although the nurses did not record the exact timing of each appointment, based on 
verbal feedback they all found this time adequate to deliver the intervention. None of 
the practice nurses routinely asked detailed questions about medication adherence 
before taking part in this trial, although two of them reported that they occasionally, but 
not in a structured way, asked whether patients had any problems with their medication. 
This section presents results on how consistently the practice nurses delivered the 
intervention. The practice nurses were given a data collection sheet (see Appendix 5) 
and were asked to complete a log of the topics they discussed with their patients during 
the adherence support intervention. This process included an introduction aiming to put 
patients at ease and outlining the reason for the appointment. The next question aimed 
to provide the basis for a discussion about any problems that patients had with taking 
their medicines. 
Table 24 presents the number of nurses who recorded that they have addressed these 
questions or statements with their patients. The nurses reported having covered these 
topics at the start of the consultation in more than 80% of participants. Investigating this 
at practice level, eight out of the 21 practice nurses delivering the intervention (38.0%) 
reported covering these questions in all their patients, and one practice nurse did not tick 
these questions for any of her patients. The mean percentage of missing data for the 
remaining 12 practices was 63.1 % (SD 20.2, range 12.5 to 80), which indicates varying 
recording habits from practice to practice. 
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Table 24 Process measures in relation to the introductory questions during the adherence 
support intervention 
Questions/statements by the practice 
nurses when delivering the Discussed during adherence support 
intervention intervention (n=128) 
Introduction statement made: "Please 
state that many people find it difficult to 85.2 (109/128) 
take their medication all the time" (%) 
Explained that " ... the reason for the 
appointment is to discuss ANY problems 82.0 (105/128) 
with taking blood pressure tablets" (%) 
The next process measure of interest in the intervention group was the extent to which 
the nurses addressed single problems with medication (Appendix 5). In 103 participants 
(85.8%) did the nurses cover all potential problems with their patients' medication. 
However, in 12 participants (9.4%) did the practice nurses not record coverage of 
individual barriers at all. 
Medication problems in the intervention group 
A major component of the intervention was structured questioning about any problems 
with medication taking, that is, barriers to medication adherence. The findings with 
regard to problems with medication taking in the intervention group are presented in 
Table 25. Only about one quarter of participants reported having a problem with their 
medication, with the most common problem being side effects (14.1 %) followed by 
forgetfulness (10.9%). 
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Table 25.Numbers of participants who admitted to problems with medication taking in the 
intervention group 
Problem Per cent of intervention group 
Participants who admitted having problems 
24.2 (31/128) with their medication (%) 
Total number of problems (%) 
0 72.3 (81/112) 
1 18.8(21/112) 
2 7.1 (8/112) 
3 1.8 (21112) 
Missing 12.5 (16/128) 
Side effects (%) 14.1 (18/128) 
Size or taste of tablets (%) 2.3 (3/128) 
Number of doses per day (%) o (0/128) 
Acceptability of blood pressure treatment (%) 1.6 (21128) 
Forgetfulness (%) 10.9 (14/128) 
Comprehension (%) 2.3(3/128) 
Total number of tablets (%) 1.6 (21128) 
Process measures in the intervention group with respect to the strategies that were 
agreed to resolve medication problems 
An important part of the intervention was for patient and practice nurse to agree a 
strategy to address any problems with medication taking. Table 26 presents information 
on the numbers of participants in the intervention group in whom nurses and patients 
agreed a strategy to address medication problems, if these were present. In five 
categories of barriers to medication adherence, namely (1) the size or taste of tablets, (2) 
acceptability of blood pressure treatment, (3) forgetfulness, (4) comprehension of what 
high blood pressure is, and (5) the total number of tablets per day, the nurses and 
patients agreed strategies in all cases. Figures for side effects (72.2%) were lower. 
Reasons for this were that participants did not want to see their GP (3 participants) or 
had already discussed this with the GP and decided to put up with the side effects (2 
participants). The strategies adopted for reducing side effects and dealing with an 
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unpleasant size or taste of the tablets consisted of referrals back to the GP in all cases. 
To reduce forgetfulness, nurses and patients mainly introduced tailoring of medication 
taking to daily habits (12 participants) and family support, that is, reminders by the 
partner at home, in two participants. 
Table 26 Pe.rcenta~es ?f part~cipants in the intervention group in whom a strategy to address 
problems with medicatIOn takmg was agreed 
Per cent of Participants in participants 
presenting with whom strategy 
Problem in the intervention group this problem was agreed 
Side effects (%) 10.2 (13/128) 72.2 (13/18) 
Size or taste of tablets (%) 2.3 (3/128) 100 (3/3) 
Number of doses per day (%) o (0/128) n/a (0) 
Acceptability of blood pressure treatment (0/0) 1.6 (21128) 100 (212) 
Forgetfulness (%) 10.9 (14/128) 100 (14/14) 
Comprehension (%) 2.3 (3/128) 100 (3/3) 
Total number of tablets (%) 1.6 (21128) 100 (212) 
Process measures in the intervention group with respect to the success of the 
strategies used to address medication problems 
Table 27 presents information about the success of the strategies adopted for the 
individual medication problems that study participants presented with. Amongst 
participants who agreed a strategy to address the size or taste of tablets, the acceptability 
of blood pressure treatment, or comprehension or the total number of tablets, all (100%) 
of the participants stated that the strategy used had been successful and that the problem 
had ceased to exist. The percentages for forgetfulness (92.9%) and side effects (76.9%,) 
were slightly lower, with missing values (forgetfulness) and reluctance to make an 
appointment with the GP (side effects) being the main reasons. 
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Tabb/~ 27 N~mbers ?f p.articip~nts in the intervention group in whom the strategy to address 
pro ,ems with medication takmg was successful 
Per cent of Per cent of participants in 
whom this participants in 
problem was whom the strategy 
Problem in the intervention group addressed was successful 
Side effects (%) 7.8 (10/128) 76.9 (10/13) 
Size or taste of tablets (%) 2.3 (3/128) 100 (3/3) 
Number of doses per day (%) 0(0/128) nla (0) 
Acceptability of blood pressure treatment 1.6 (21128) 100 (212) (%) 
Forgetfulness (%) 10.2 (13/128) 92.9 (13/14) 
Comprehension (%) 2.3 (31128) 100 (3/3) 
Total number of tablets (%) 1.6 (21128) 100 (212) 
7.3.3 Appointments for the control group and potential for contamination 
The appointment for the control group consisted of simple blood pressure checks and 
downloading of the electronic monitors, which took place at the same intervals as the 
follow-up appointments in the intervention group. The length of these appointments 
varied from five to 10 minutes, according to local usual practice. In the majority of 
practices, another nurse who was not involved in delivering the intervention conducted 
the follow-up in the control group. In four practices, however, the same nurses followed 
up both groups. All these nurses reported that they only delivered their 'usual care' to 
the control group and that they did not start to talk about medication adherence, unless 
this was something they would normally do. 
7.4 Primary analysis of outcomes 
7.4.1 Comparison of medication adherence between the intervention and 
control participants (primary outcome) 
As discussed in Chapter 5, the primary outcome determined a priori was adherence to 
medication, defined as 'timing compliance', which is the percentage of a prescribed 
number of doses taken in a specified correct interval. This measure is the 'strictest' 
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-compared to other measures of adherence such as ' taking com 10 , , 011 ' P lance or pI counts 0 
For the primary intention-to-treat analysis data from th 1 tr 0 0 
, e e ec ornc morn tors were 
available for 160 participants wOth 85 f 12 0 0 0 
,lout 0 8 randomlsed partIcIpants (66.4%) in the 
intervention group and 75 (6401 %) in the control groupo 
Figure 22 shows a histogram of timing compliance with a superimposed normal 
distributiono This is an informal way of looking at the dlOstn°b to ft O 0 10 u lOn 0 lmmg comp lanceo 
Although the histogram is skewed to the left, it appears to be close enough to the normal 
distribution to allow the data to be used for regression analysis without further 
transformation given the reasonably large sample size. 
Figur~ 22 Frequency distrubution of timing compliance over the six months follow up with 
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Table 28 presents results from the regression model, comparing adherence between the 
intervention and control groups in the six months period following the interventiono 
There were no overall differences in timing compliance between the intervention and 
control groups (adjusted difference between means of timing compliance: -l.0%, 95% 
CI -5.1 to 3.1, p=0.63). Similarly, for 'correct dosing' and 'taking compliance' there 
were also no important differences between the groups. Adherence was generally high 
in both comparison groups for the three definitions of adherence. As expected, mean 
adherence was higher if less strict definitions of adherence were applied. 
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Tab/~ 28 Regressi~n model ~ompa~ing adherence between intervention and control rou sin 
the SIX months peno~ ~ollowln.g the Intervention, controlling for baseline measureme~ of p 
adherence and stratifying vanables (general practice, age group and sex) 
Nurse-led Adjusted 
adherence difference (AS-
support Usual care UC)a between (AS) (UC) means (95% CI) p-value 
Timing compliance (% 
of days in which the 
correct number of 87.2 (20.1) doses were taken on 90.2 (16.2) -1.0 (-5.1 to 3.1) 0.63 
time), mean (SD), 
n=159 
Correct dosing (% of 
days on which the 
correct number of 90.8 (16.6) 92.4 (15.2) -0.5 (-4.2 to 3.1) 0.77 
doses was taken), 
mean (SO), n=159 
Taking compliance (% 
prescribed number of 95.6 (16.4) 95.6 (15.7) -0.6 (-3.2 to 4.4) 0.76 doses taken), mean 
(SD), n=159 
aA positive difference indicates an increase in adherence for AS compared with UC 
7.4.2 Comparison of blood pressure between the intervention and control 
participants (secondary outcome) 
The following two figures show histograms for the secondary outcomes systolic and 
diastolic blood pressure at the six month follow-up. Not surprisingly, these are close to 
the normal distribution, allowing regression analysis without further transformation of 
the data. 
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Figure 23 Frequency distribution of systolic blo d - .-
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Systolic blood pressure at six month follow up 
Figure 24 Frequency distribution of diastolic blood pressure at six month follow-up with 
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Diastolic blood pressure at six month follow up 
Table 29 presents results from a regression model comparing blood pressure between 
the intervention and control groups at six months. There was also no difference between 
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-the intervention and control groups at the six months follow-u~ in- terms of systolic 
(adjusted difference between means -2.7mmHg, 95% CI: -7.2 to 1.8, p=O.24) or 
diastolic blood pressure (adjusted difference between means (nunHg): 0.2, 95% CI: -1.9 
to 2.3, p=0.85). 
Table 29 Regressi~n model comparing mean blood pressure between the intervention and 
cont~ol.group~ at SIX months, controlling for baseline measurement of blood pressure and 
stratlfymg vanables (general practice, age group and sex) 
Nurse-led Adjusted 
adherence Usual care difference {AS-UC} 
support {AS}, {UC}, mean between means 
mean {SO} {SO} {95% Cl}a p-value 
Systolic blood 
pressure 142.9 (17.6) 147.7 (20.9) -2.7 (-7.2 to 1.8) 0.24 (mmHg), 
n=200 
Diastolic blood 
pressure 80.4(10.1) 79.9 (9.7) 0.2 (-1.9 to 2.3) 0.85 (mmHg), 
n=200 
a A negative difference (AS-UC) indicates a reduction in blood pressure 
7.4.3 Missing values 
The number of missing values for the main outcomes at six months was relatively high 
and amounted to n 85 (43 intervention and 42 control) for timing compliance and n=41 
(18 intervention and 23 control) for systolic as well as diastolic blood pressure. The 
following tables present the results of the regression models for the effect of the 
intervention on timing compliance and adherence, comparing the ITT model with a 
model where any missing values were replaced with the last observation from the two 
month follow-up. If this was also missing, the baseline observation was carried forward. 
This model assumes that the observations did not change and therefore may provide a 
conservative estimate. As shown in the tables, replacing the missing values with the last 
observation carried forward did not lead to any important changes in the results. 
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-Tab~e 30 Results of.the r~gr~ssion model for the effect of the intervention on timing compliance 
at SIX month, replacmg m/ssmg values with the last observation carried forward 
Difference 
between means 
(%) 95% CI p-value 
ITT 
-1.0 
-5.1 to 3.1 0.63 
Last observation carried forward 1.5 
-1.8 to 4.7 0.38 
Table 31 Res.ults of the regression model for the effect of the intervention on systolic blood 
pressure at SIX month, replacing missing values with the last observation carried forward 
Difference 
between means 
(mmHg) 95%CI p-value 
ITT 
-2.7 -7.2 to 1.8 0.24 
Last observation carried forward -0.9 -4.7 to 2.8 0.64 
Table 32 Results of the regression model for the effect of the intervention on diastolic blood 
pressure at six month, replacing missing values with the last observation carried forward 
Difference 
between means 
(mmHg) 95%CI p-value 
ITT 0.2 -1.9 to 2.3 0.85 
Last observation carried forward 1.3 -0.8 to 3.5 0.22 
7.5 Secondary analyses 
The secondary analyses comprised first additional adjustment in the regression models 
in terms of any potentially influential variables that exhibited possible imbalance at 
baseline. Secondly, pre-planned subgroup analyses for age, sex, drug group and total 
number of drugs prescribed were conducted by introducing appropriate interaction 
terms to investigate differential effects. 
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7.5.1 Additional adjustment for variables that showed imbalance at 
baseline 
Seven variables showed at least some degree of imbalance at baseline between the 
intervention and control groups. In order to exclude a potential effect of even a minor 
imbalance on the main study outcomes, it was decided to conduct additional adjustment 
for these variables. In this section will report the results of the comparison between 
intervention and control groups, adjusting for these variables. 
Adherence 
Table 33 presents the results of the regression model for timing compliance at six 
months, adjusting for additional variables that showed some potential imbalance at 
baseline. Adding these variables to the basic model did not lead to any important 
changes in the results. The difference in timing compliance between groups increased to 
5.6% in favour of the intervention when adding reasons for changing blood pressure 
medication to the model, but the confidence intervals were wide and the difference not 
statistically significant, which is likely due to the relatively large number of missing 
values. Residuals from the models were examined graphically for normality through a 
histogram and normal plot. For all models, the residuals were distributed relatively 
close to the normal distribution (data not shown). 
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-T~ble 33 Results o~ ~ regres~ion model for the effect of the intervention ~n timin com fiance at 
SIX month after additional adjustment for variables that showed imbalance at ba!fine getween 
the groups 
Difference 
Additional factors adjusted between means 
for (%) 95% CI (%) p-value 
'ITT' model (n=159) 
-1.0 
-5.1 to 3.1 0.63 
History of cardiovascular 
-1.1 disease (n=155) -5.3 to 3.2 0.62 
Use of over the counter 
-0.9 medicines (n=153) -5.2 to 3.4 0.68 
Total number of doses per day 
-0.9 -5.2 to 3.4 0.68 (n=155) 
Drug group used in electronic 
-1.2 -5.3 to 2.9 0.57 monitor (n=159) 
Duration of blood pressure 
-1.3 -5.6 to 2.9 0.53 treatment (n=159) 
Change in blood pressure 
medication in past 12 months -1.2 -5.3 to 3.0 0.58 
(n=153) 
Reason for changing blood 
pressure treatment in past 12 5.7 -1.2 to 12.3 0.10 
months (n=71) 
Self assessment of adherence 0.8 -3.1 to 4.7 0.69 (n=154) 
Systolic blood pressure 
Table 34 and Table 35 present the results for the difference between the means for 
systolic and diastolic blood pressure with confidence intervals and p-values, after 
adjusting for variables that showed an imbalance at baseline. Adjusting for these 
variables did not substantially alter the basic model. As for the adherence data, the 
residuals were normally distributed (data not shown). 
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Table 34 Results of a regression model for the effect of the intervention on systolic blood 
pressure at six months after additional adjustment for variables that showed imbalance at 
baseline between the groups 
Systolic blood pressure: Difference 
Additional factors adjusted between means 
for individually (mmHg) 95% CI (mmHg) p-value 
'ITT' model (n=200, see 
-2.7 
-7.2 to 1.8 0.24 Table 29) 
History of cardiovascular 
-2.7 disease (n=196) 7.3 to 1.9 0.25 
Use of over the counter 
-2.5 
-7.1 to 2.1 0.28 medicines (n=194) 
Total number of doses per 
-3.3 
-8.0 to 1.4 0.16 day (n=193) 
Drug group used in electronic 
-2.7 -7.3 to 1.9 0.24 monitor (n=200) 
Duration of blood pressure 
-2.8 -7.3 to 1.8" 0.23 treatment (n=200) 
Change in blood pressure 
medication in past 12 months -2.6 -7.2 to 1.9 0.25 
(n=193) 
Reason for changing blood 
pressure treatment in past 12 -2.1 -9.3 to 5.1 0.57 
months (n=1 01) 
Self assessment of 
-2.8 -7.3 to 1.7 0.22 
adherence (n=194) 
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-Table 35 Results of a regress' d I&. t . --
. 10~ m.o e ,or he effect of the mtervention on diastolic blood 
f~:s;::;~p:t SIX months after adJustmg for variables that showed imbalance at baseline between 
Diastolic blood pressure: Difference 
Additional factors between means 
adjusted for (mmHg) 95% CI (mmHg) p-value 
'ITT' model (see Table 29) 
0.2 (n=200) -1.9 to 2.3 0.85 
History of cardiovascular 0.2 disease (n=196) -1.9 to 2.4 0.83 
Use of over the counter 
medicines (n=194) 0.2 -1.9 to 2.4 0.84 
Total number of doses per 0.4 -1.9 to 2.6 day (n=193) 0.76 
Drug group used in 0.4 -2.1 to 2.2 electronic monitor (n=200) 0.97 
Duration of blood pressure 0.1 -2.1 to 2.3 0.92 treatment (n=200) 
Change in blood pressure 
medication in past 12 0.4 -1.7 to 2.5 0.74 
months (n=193) 
Reason for changing blopd 
pressure treatment in past 1.26 -2.3 to 4.8 0.48 
12 months (n=101) 
Self assessment of 0.3 -1.8 to 2.5 0.76 
adherence (n=194) 
7.5.2 Secondary explanatory analyses with additional adjustment for 
process variables 
This ReT was designed as a pragmatic trial, and all the analyses described above were 
carried out on what was essentially an intention-to-treat basis. Since the intervention 
evaluated in this study was complex, it is important to investigate whether process 
measures may have influenced any effects of the intervention on the main outcomes. 
In this section, I present the results of secondary analyses for the primary and secondary 
outcomes. These analyses therefore take an explanatory approach and move away from 
being primarily pragmatic. 
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Time between appointments 
As outlined in Chapter 5, the trial schedule consisted of an initial visit for distribution of 
the electronic monitors, allowing baseline measurement of adherence prior to the 
intervention. This was followed by the appointment for the main intervention and 
further follow-up at two and six months. In this section I consider whether there are any 
differences between the comparison groups in terms of the time between these 
appointments, which could have altered an effect of the intervention according to the 
length of these periods. 
Table 36 presents descriptive results for the length of follow-up in both comparison 
groups in terms of days between practice visits. The means for the length of follow-up 
for the three periods were close to the desired intervals as stated in the protocol and 
even slightly longer for the baseline period. 
Table 36 Comparison between the intervention and control groups in terms of time between 
appointments 
Nurse-led 
Time between adherence 
appointments support Usual care Total 
Baseline (initial appointment 
to date of intervention) in 38.7 (15.6) 37.1 (17.7) 38.0 (16.6) 
days, mean (SO) 
Two month following the 
intervention in days, mean 64.4 (18.9) 64.3 (18.0) 64.4 (18.4) 
(SO) 
Six months following the 
intervention in days, mean 183.2 (27.4) 184.0 (33.5) 183.6 (30.2) 
(SO) 
Table 37 shows the estimates for the differences in means and 95% confidence intervals 
between the groups for the time between practice visits. These differences were small 
and not statistically significant, indicating that the practice nurses were successful in 
adhering to the study protocol for both comparison groups. 
Adjusting for the time between visits made essentially no difference to the results for 
adherence, systolic and diastolic blood pressure (results presented in Table 38, Table 39 
and Table 40). 
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Table 37 Estimates and 95% confidence intervals (el) for the difference (Control minus 
Intervention) in mean time between practice visits 
Difference (usual 
care minus 




appointment to date 
-1.6 (2.2) 
-5.9 to 2.7 0.45 of intervention) in 




-5.0 to 4.8 0.96 intervention in days, 
mean (SE) 
Six months 
following the 0.75 (4.3) -7.8 to 9.3 0.86 intervention in days, 
mean (SE) 
a Two-sample t-test assuming equal variances 
Table 38 Regression model for the effect of the intervention on timing compliance, adjusted for 
time between practice visits 
Difference 
between means 
(%) 95% CI (%) p-value a 
'ITT model (n=159) -1.0 -5.1 to 3.1 0.63 
Length of baseline period 
-0.8 -5.0 to 3.4 0.70 (N=154) 
Length of two month follow-up 
-0.7 -4.9 to 3.5 0.75 in days (n=155) 
Length of six month follow-up 
-0.4 in days (n=156) -4.6 to 3.7 0.83 
a Two-sample t-test assuming equal variances 
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-Table 39 Regression model for th ffl t f' . - -
for time between practice visits e e ec 0 the mterventlon on systolic blood pressure, adjusted 
Difference 
between means 
(mmHg) 95% CI (mmHg) p-value 
'ITT' model (n=200) 
-2.7 
-7.2 to 1.8 0.24 
Length of baseline period 
-1.9 (N=193) -6.5 to 2.7 0.42 
Length of two month follow-
-2.4 up in days (n=192) -6.9 to 2.2 0.31 
Length of six month follow-up 
-2.3 -6.8 to 2.2 in days (n=195) 0.31 
Ta?le 40 Reg!ession model for the effect of the intervention on diastolic blood pressure 
adjusted for time between practice visits ' 
Difference 
between means 
(mmHg) 95% CI (mmHg) p-value 
'ITT' model (n=200) 0.2 -1.9 to 2.3 0.85 
Length of baseline period 0.1 (N=193) -2.0 to 2.3 0.90 
Length of two month follow-
-0.4 
up in days (n=192) -2.2 to 2.1 1.0 
Length of six month follow- 0.2 -2.0 to 2.3 0.88 
up in days (n=195) 
7.5.3 Descriptive statistics for the intervention and control groups, taking 
account of process measures in the intervention group 
As shown in Table 26 and Table 27 above, the number of patients who had in fact 
problems with taking their medication and subsequently received the 'full' intervention 
in terms of a strategy to address their medication problems, was relatively small. The 
number of participants in the intervention group who had at least one problem with their 
medication was 37 (28.9%), which means that only about one in three participants who 
were randomised to receive the intervention received adherence support in its true 
sense, whereas the remaining patients did not admit to any problems and therefore did 
not perceive themselves as requiring any further adherence support. 
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An obvious secondary analysis was therefore to investigate and compare descriptive 
statistics for the three groups of participants: (1) participants who were randomised to 
the intervention group, had problems with their medication and agreed a strategy to 
resolve these problems (these participants received the intervention as intended), (2) 
participants randomised to the intervention group who did not have any problems with 
their medication and therefore did not agree a strategy to resolve problems (these 
participants did not receive the intervention as intended), and (3) participants 
randomised to the control group (who mayor may not have had problems with taking 
their medication). 
Results of descriptive statistics for baseline and outcome variables comparing 
participants in terms of the 'amount' of intervention they have received are presented in 
Table 41. The percentages of men were slightly higher in the group of participants 
without medication problems (68.7%) and the usual care group (62.5%) compared with 
the group of participants in the intervention group who had medication problems 
(43.8%). Timing compliance was higher in the usual care group at baseline (94.5%) 
compared to the other two groups (88.2% for participants in the intervention group with 
medication problems and 92.0 for those without). At six months, timing compliance 
among participants in the intervention group who had medication problems (80.3%) 
was almost 10% lower than for the group who did not have medication problems and 
the usual care group (both 90.2%). There were no obvious differences in either systolic 
or diastolic blood pressure between the groups. 
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Table 41 Descriptive statistics n b f . --
intervention group who did and 0; d as~ ~ne and outcome .vanables comparing participants in the 





with medication medication Usual care 
problems, n=32) problems, n=96) (n=117) 
Men, (%) 43.8 (14/32) 60.4 (58/96) 53.8 (63/117) 
Age in years, mean ± SO 69.2 ± 12.2 67.5 ± 9.6 68.1 ± 9.4 
Timing compliance at 
88.2 ± 18.5 baseline (%), mean ± SO 92.0 ± 14.3 94.5 ± 7.6 
Timing compliance at 6 
month follow-up (%), 80.3 ± 25.5 90.2 ± 16.6 90.2 ± 16.2 
mean ± SO 
Systolic blood pressure 
at baseline (mmHg), 150.0 ± 17.5 148.0 ± 14.4 152.1 ± 17.5 
mean ± SO 
Systolic blood pressure 
at 6 months follow-up 145.7 ± 22.2 141.8 ± 15.4 147.7 ± 20.9 
(mmHg), mean ± SO 
Diastolic blood pressure 
at baseline (mmHg), 86.7 ± 8.5 82.7 ± 9.4 83.1 ± 9.9 
mean ± SO 
Diastolic blood pressure 
at six months follow-up 83.8 ± 9.7 79.1 ± 10.1 79.9 ± 9.7 
(mmHg), mean ± SO 
7.5.4 Subgroup analyses 
Subgroup analyses were planned at the protocol stage and finalised in the study protocol 
before the trial was analysed. They were kept to a minimum and only included variables 
that were either stratifying variables, that is, age and sex, or other variables that based 
on the literature review could influence the effect of the intervention on the main 
outcomes, such as the total number of drugs a patient is taking or the drug group that 
was used in the electronic monitor. The following tables show the results for timing 
compliance, systolic and diastolic blood pressure at six months follow-up, stratified by 
age, sex, the total number of different drugs a patient is taking and the type of drug 
which was dispensed from the electronic monitor. 
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-The following three tables present the results for timing complian~e and blood pressure 
at six months, stratified by age. The effect of the intervention did not differ by age for 
timing compliance (interaction p=O.36), systolic blood pressure (interaction p=O.30) and 
diastolic blood pressure (interaction p=O.24). 
Table 42 Me~n (SO) timing compliance at six months follow-up in the intervention and control 
groups, stratified by age 
Adherence 
support Usual care p-valuea 
Age under 60 88.5 (20.7) 95.2 (5.4) 
Age 60 or over in 0.36 
86.8 (20.1) 89.1 (17.6) years 
a Test for interaction: coefficient 4.S, 9S% CI -S.S to 1S.1 
Table 43 Mean (SO) systolic blood pressure at six months follow-up in the intervention and 
control groups, stratified by age 
Adherence 
support Usual care p-valuea 
Age under 60 138.8 (13.8) 136.5 (10.4) 
Age 60 or over in 0.30 144.2 (18.5) 150.6 (21.1) years 
a Test for interaction: coefficient -S.S, 9S% CI -17 to S.3 
Table 44 Mean (SO) diastolic blood pressure at six months follow-up in the intervention and 
control groups, stratified by age 
Adherence 
support Usual care p-valuea 
Age under 60 87.8 (7.4) 85.1 (6.9) 
0.24 
Age 60 or over in 78.0 (9.8) 78.6 (9.9) years 
a Test for interaction: coefficient -3.2, 9S% CI -S.6 to 2.2 
The next three tables show mean timing compliance at six months follow-up, stratified 
by sex. These results show very weak evidence, that is, almost reaching statistical 
significance at the 5% level, that the treatment effect on timing compliance might differ 
by sex (interaction p=0.09, coefficient 7.0, SE 4.1,95% CI -1.2 to 15.2). (Note that the 
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means given in these tables are crude values whereas the interaction coefficients are 
from the fully adjusted models.) This could point towards a potential interaction, in that 
women may be more likely to show increased adherence after the intervention than 
men. There were no differences between the sexes for systolic and diastolic blood 
pressure (interaction p=0.20 and 0.23 respectively). 
Table 45 Mean (SD) timing compliance at six months follow-up in the intervention and control 
groups, stratified by sex 
Adherence 
support Usual care p-valuea 
Men 87.0 (20.0) 90.0 (15.8) 
0.093 
Women 87.4 (20.5) 90.6 (17.0) 
a Testfor interaction: coefficient 7.0,95% CI -1.2 to 15.2 
Table 46 Mean (SD) systolic blood pressure at six months follow-up in the intervention and 
control groups, stratified by sex 
Adherence 
support Usual care p-valuea 
Men 143.3 (14.8) 145.8 (16.4) 
0.20 
Women 142.3 (20.8) 150.4 (25.7) 
a Test for interaction: coefficient -S.B, 95% CI -14.7 to 3.0 
Table 47 Mean (SD) diastolic blood pressure at six months follow-up in the intervention and 
control groups stratified by sex , 
Adherence 
support Usual care p-valuea 
Men 80.7 (10.5) 79.8 (8.4) 
0.23 
Women 80.1 (9.7) 80.1 (11.3) 
a Test for interaction: coefficient -2.6, 95% CI -6.B to 1.7 
As shown in the following tables, the intervention effect differed neither by the number 
of different drugs that participants were prescribed, nor by the drug group dispensed 
through the electronic monitor. 
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Table 48 Me~n (SO) timing compliance at six months follow-up in the intervention and control 
groups, stratified by total number of different drugs 
Adherence 
support Usual care p-valuea 
Total number of 
different drugs 
1-2 73.1 (28.0) 95.4 (5.3) 
3-5 91.4 (13.1) 91.6 (15.0) 0.23 
6 or more 86.0 (23.4) 81.9 (25.3) 
a Test for interaction 
Table 49 Mean (SO) systolic blood pressure at six months follow-up in the intervention and 
control groups, stratified by total number of different drugs 
Adherence 
support Usual care p-valuea 
Total number of 
different drugs 
1-2 136.8 (9.5) 141.6 (12.3) 
3-5 145.6 (19.1) 151.9 (26.2) 0.99 
6 or more 145.1 (17.8) 149.7 (18.4) 
a Test for interaction 
Table 50 Mean (SO) diastolic blood pressure at six months follow-up in the intervention and 
control groups, stratified by total number of different drugs 
Adherence 
support Usual care p-valuea 
Total number of 
different drugs 
1-2 80.3 (9.2) 82.7 (8.9) 
3-5 80.5 (10.4) 79.2 (9.8) 0.45 
6 or more 80.3 (11.3) 77.1 (8.1) 
a Test for interaction 
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Table 51 Mean (SD) timing compliance at six months follow-up in the intervention and control 
groups, stratified by drug group 
Adherence 
support Usual care p-valuea 
Drug group 
Diuretic 88.0 (18.4) 87.3 (20.3) 
Beta-blocker 92.0 (15.4) 95.2 (6.8) 
Calcium antagonist 82.7 (21.0) 92.3 (10.8) 0.12 
ACE inhibitor 83.9 (27.6) 94.2 (6.3) 
Other 79.6 (31.0) 92.8 (9.6) 
a Test for interaction 
Table 52 Mean (SD) systolic blood pressure at six months follow-up in the intervention and 
control groups, stratified by drug group 
Adherence 
support Usual care p-valuea 
Drug group 
Diuretic 139.9(16.1) 147.1 (18.8) 
Beta-blocker 147.7 (19.1) 150.0 (33.8) 
Calcium antagonist 147.4 (17.1) 148.3 (16.4) 0.94 
ACE inhibitor 136.1 (17.9) 145.7 (11.1) 
Other 152.6 (17.3) 147.8 (11.3) 
a Test for interaction 
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-Table 53 Mean (SD) diastolic blood pressure at six months follow-up in the intervention and 
control groups, stratified by drug group 
Adherence 
support Usual care p-valuea 
Drug group 
Diuretic 79.8 (11.0) 79.3 (11.0) 
Beta-blocker 80.4 (8.0) 79.6 (9.1) 
Calcium antagonist 76.4 (9.7) 80.6 (8.4) 0.13 
ACE inhibitor 83.6 (12.3) 80.8 (8.0) 
Other 86.1 (10.1) 83.8 (6.2) 
a Test for interaction 
7.6 Relationship between timing compliance and blood pressure 
There was no evidence to suggest that in this study timing compliance was correlated 
with blood pressure. Notwithstanding the clear ceiling effects, Figure 25 and Figure 26 
show that there are no obvious patterns in the scatter plots for the relationship between 
timing compliance, systolic and diastolic blood pressure (correlation coefficients -0.02 
and -0.01, respectively). 
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- -
Figure 25 Scatte~ plot of t~e relationship between timing compliance (y-axis, %) in the six 
months after the intervention and systolic blood pressure at the six month follow-up 
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Figure 26 Scatter plot of the relationship between timing compliance (y-axis, %) in the six 
months after the intervention and diastolic blood pressure at the six month follow-up 
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Table 54 shows the results of the regression model for the relationship between timing 
compliance and blood pressure at final follow-up. There was no evidence of an effect of 
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-timing compliance on blood pressure for all participants comb~ed or for any of the two 
intervention groups individually. 
T~ble 54 Results of t~e regression model for the relationship between timing compliance in the 
SIX months after th~ mtervention and blood pressure at the six month follow-up controlling for 
age, sex and practice ' 
Difference 
between means 
(%) 95%CI p-value 
Systolic blood pressure 
All participants 0.02 -0.2 to 0.2 0.84 
Control group 0.05 -0.2 to 0.3 0.67 
Intervention group -0.03 -0.2 to 0.2 0.80 
Diastolic blood pressure 
All participants 0.01 -0.03 to 0.1 0.23 
Control group 0.08 -0.05 to 0.2 0.24 
Intervention group 0.03 -0.07 to 0.1 0.52 
7.7 Summary 
The aim of this open pragmatic randomised controlled trial was to evaluate the 
effectiveness of practice nurse-led adherence support on increasing adherence to blood 
pressure lowering medication in study participants with uncontrolled hypertension. 
A total of 331 participants in 22 general practices in and around Bristol took part in the 
study. The practices, practice nurses and participants appeared broadly representative of 
respective populations in the UK. 
The intervention was not effective in increasing adherence or in reducing blood 
pressure. There was no evidence of an effect of the intervention on timing compliance 
(difference between means: -1.0, 9S% CI -S.1 to 3.1, p=0.63) or on less strict measures 
of adherence such as correct dosing (-O.S, 9S% CI -4.2 to 3.1, p=0.77) or taking 
compliance (-0.6, 9S% CI -3.2 to 4.4). There was also no difference between the groups 
in terms of systolic blood pressure (difference between means (mmHg): -2.7, 95% CI: -
7.2 to 1.8, p=0.24) or diastolic blood pressure (0.2, 95% -1.9 to 2.3, p=0.8S). In 
addition, neither of these differences is of important clinical significance. 
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Adjusting for variables that showed imbalance at baseline, which included (1) a history 
of cardiovascular disease, (2) use of over the counter medicines, (3) the total number of 
doses per day, (4) the drug grouped used in the electronic monitor, (5) the duration of 
blood pressure treatment, (6) a change in blood pressure medication in the past 12 
months, (7) the reason for changing blood pressure medication during this period, and 
(8) self assessment of adherence did not substantially alter the findings from the primary 
analyses. 
Pre-specified subgroup analyses showed that the intervention effect did not differ by 
age, the total number of drugs that were prescribed for a patient, and the drug group 
used in the electronic monitor. There was, however, very weak evidence of a possible 
interaction of sex on the effect of the intervention on timing compliance (interaction 
p=0.09, coefficient 7.0, SE 4.1,95% CI -1.2 to 15.2), but not on systolic or diastolic 
blood pressure. 
There was no evidence of a correlation or association of timing compliance in the six 
months after the intervention and blood pressure at the six month follow-up. 
In conclusion, there was no evidence of a benefit or disbenefit of the intervention on 
timing compliance, systolic or diastolic blood pressure. In the following chapter I will 
present an economic evaluation of the trial intervention. I will then discuss the findings 
of these studies including the RCT with reference to existing knowledge in Chapter 9. 
156 
8 Economic evaluation: methods and results 
8. 1 Introduction 
The previous chapter reported the results of a randomised controlled trial of the effect of 
nurse-led adherence support on medication adherence and blood pressure. The trial was 
pragmatic in that it evaluated the intervention in a realistic setting, so that in case the 
intervention was effective, it could be adopted into routine general practice. 
In addition to evaluating the clinical effects of the intervention on medication adherence 
and blood pressure, it is also important to consider its cost implications and relative cost 
effectiveness in comparison with usual care. This economic evaluation mainly describes 
the costs incurred by the health service providers in primary care. As health care 
funding is limited, managers in general practice would want to know that any extra 
benefits from the intervention would be worth any additional expenses that may result 
from introducing nurse-led adherence support. 
8.2 Methods 
This section describes the methods used for this economic evaluation. Details about 
methodological issues that are relating to the conduct of the trial are described in 
chapters 5 and 6. These are not repeated here but will be referred to in the following 
sub-sections. 
8.2.1 Objective 
The objective of the economic evaluation described in this chapter was to compare 
outcomes and costs of usual care versus nurse-led adherence support (in addition to 
usual care) from the viewpoint of general practices. 
8.2.2 Economic importance 
Introducing nurse-led adherence support is likely to have resource implications, which 
would affect the choices decision-makers in general practice would have to make. Both 
alternatives, that is, maintaining the status quo in tenns of usual care or adopting nurse-
led adherence support, are realistic options, and conducting an economic analysis is 
therefore important. 
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8.2.3 Viewpoint of the economic evaluation 
This economic evaluation has been conducted from the viewpoint of the provider 
institutions in the primary care sector. Managers in the primary care sector would be the 
key decision makers in deciding whether to introduce nurse-led adherence support into 
routine practice or to maintain the status quo and continue with usual care. The funding 
streams for nurses working in primary care follow various models, with nurses being 
employed by different organisations. For example, some practice nurses are directly 
employed by their general practice, which may be under the General Medical Services 
or the new Personal Medical Services Contract. Others are employed by the primary 
care trusts and, although working in the same building, are not directly accountable to 
their general practice. Therefore, this evaluation was carried out from the viewpoint of 
the primary care sector, which encompasses the various funding options. Although costs 
resulting from the adherence support intervention may also fall on patients, mainly in 
terms of time, and the wider NHS, in terms of hospital admissions or use of other NHS 
services, the focus of this chapter is on costs to the primary care sector only. 
8.2.4 Selection of the alternative intervention 
The choice of the alternative intervention, that is, usual care, was designed to get a close 
measure of the costs that would incur with introducing nurse-led adherence support, and 
both study interventions are described in detail in Chapter 5. Usual care, although 
differing to a certain extent from practice to practice, is obviously the most widely used 
alternative treatment. 
8.2.5 Form of evaluation 
The objective was to evaluate the cost-effectiveness of two alternative interventions, 
adherence support and usual care, which were evaluated in a pragmatic RCT. This trial 
found that the health effects of nurse-led adherence support and usual care were neither 
statistically nor clinically significantly different in terms of their effect on medication 
adherence and blood pressure. It was, therefore, more appropriate to use a cost-
minimisation analysis rather than a cost effectiveness study. Costs are reported 
according to randomisation group .. 
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8.2.6 Data collection 
Details of the design and the results of the RCT, that is, the selection of study 
population, the method of allocating participants to a comparison group, analysis by 
intention-to-treat, and effect sizes with confidence intervals, are described in Chapters 5 
and 6. 
Identification of costs 
The costs associated with usual care and additional nurse-led adherence support were 
identified in collaboration with a sample of the participating practice nurses and listed 
after a 'brain storming' exercise. Ideally, all resource use between randomisation and 
final follow-up should have been identified and collected, which would have included, 
for example, all GP consultations, the use of district nurses, costs associated with any 
medication changes resulting from the study intervention, hospital admissions and 
patient costs. However, collecting these data was either not feasible in this study or was 
relevant for viewpoints other than from the primary care sector perspective. Costs were 
further categorised into: (a) fixed costs, that is, those that do not vary with changes in 
treatment, (b) semi-fixed costs, which would include staff costs, and (c) variable cost, 
that is, those that vary directly with levels of the treatment like consultation times. The 
scope of this project did not allow the measurement of indirect costs and outcomes, 
which might, for example, have included time off work or away from other activities for 
the participating study participants. Any items that would not have occurred outside the 
trial were not relevant and were therefore excluded from the economic analysis. The 
major difference in cost between the two intervention groups was nursing time, which is 
the reason why this was included in the main analysis. 
Measuring costs and outcomes 
Data on resource use were collected by the participating practice nurses on data 
collection forms. This analysis primarily investigates the direct costs that result from the 
study intervention. 
Generalisibility 
The RCT included general practices in Avon that on the whole appear representative of 
practices in the UK (see chapter 6). In addition, this was a pragmatic RCT, which 
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increases the generalisibility of the study and therefore its value for an economic 
evaluation. 
8.2.7 Resource use and costing 
Interpreting the resource use as part of the trial was difficult, because the intervention 
that was tested in the ReT was complex. Nurse-led adherence support consisted of a 
number of different components, and everything done to a participant during the trial 
could have affected the main outcomes. Even visits to the surgery solely for data 
collection may have influenced medication adherence. For the purpose of this economic 
evaluation only the nurse time was costed, as this was the main factor determining costs 
as part of the intervention. 
8.2.8 Training costs 
Before the start of the trial I visited all participating practices and their practice nurses 
to explain the details of the trial and the alternative interventions. The nurses were 
provided a structured prompt sheet, which reminded them of the main barriers to 
medication adherence. I then explained to practice nurses the use of this prompt sheet 
for 10 minutes, but did not provide wider training on adherence-related issues (see 
Chapter 5 for further details). In essence, no formal training was provided for the 
practice nurses, since the intervention was designed to be pragmatic without the need 
for extensive training. 
8.2.9 Consultation costs 
Even without the intervention, patients normally visit the practices to consult either their 
GP or the practice nurse in connection with the management of their hypertension. 
Since most patients with uncontrolled hypertension require regular follow-up, with the 
freq~ency of visits depending on the blood pressure level and other risk factors, a 
change to nurse-led adherence support and the small number of extra visits was not 
expected to affect practice costs such as building maintenance or administrative staff 
costs substantially. 
The lengths of the consultations of study participants with the practice nurses were 
obtained from the data collection sheets or from the practice computers. Practice nurses 
were asked to book patients in for the adherence support appointment for no longer than 
an additional 20 minutes, with 10 minutes allowed for the reinforcement appointment 
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two months later. The costs per minute of nurse consultation were taken from Unit 
Costs of Health and Social Care provided by the Personal Social Services Research Unit 
at the University of Kent. 270 
8.2.10 Main analysis 
The primary outcomes for this economic evaluation are adherence to medication (timing 
compliance) and blood pressure (mmHg). Comparison between the groups in a 
pragmatic trial is a contrast between two policies or strategies of care. In a similar 
fashion as for the analysis of the main outcomes, comparing the two groups as 
randomised (on an intention-to-treat basis) means that the adherence support 
intervention is also costed just as one part of the intervention policy. Since both study 
interventions resulted in the same type of health gain in terms of the two main outcomes 
and the outcomes have been compared in an objective way, there is no need to value 
these benefits in monetary terms. 
Since there was no evidence of a clinically or statistically significant effect of the nurse-
led adherence support, neither on adherence nor blood pressure, a cost-minimisation 
analysis was performed. Information on resource use was calculated for each participant 
and reported by randomisation group. 
The calculation ofp-values in the context of this trial is of doubtful value because of the 
uncertainty surrounding the mean costs obtained for this study. Rather than addressing 
statistical imprecision, it seemed more important to use a sensitivity analysis to 
investigate uncertainties. 
8.2.11 Sensitivity analysis 
The estimation of the value of different parameters used in this economic evaluation 
was based on a number of assumptions. Unfortunately, data were not always complete, 
and some costs had to be calculated using arithmetic means across the practices. I 
therefore did not carry out statistical tests leading to confidence intervals. 
Various approaches exist that can be used to perform sensitivity analyses. For example, 
one-way sensitivity analysis investigates in a systematic way the influence of each 
variable by varying it across a logical range of values, while all other variables are being 
held at their best estimate. In extreme scenario sensitivity analyses, each variable is 
being set to take the most optimistic or pessimistic value to generate a best or worst case 
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scenario. Probabilistic sensitivity is based on a number of simultaneous simulations, 
using various values of the underlying variables within a plausible range. 
For this study I chose to use a simple one-way analysis, which is the most common type 
of analysis. This approach seemed the most appropriate for this study, as it allowed 
altering one or more variables to determine its effect on the final result. The sensitivity 
analysis included the duration of the appointments. 
Scenario of different length and frequency of appointments 
In the trial, the appointment length for the nurse-led adherence support was determined 
in close collaboration with the practice nurses, who estimated the time it would take 
them to talk about barriers to medication adherence. In addition, a two-month follow-up 
appointment was scheduled for every study participant in the intervention group 
regardless of whether there were any problems with medication taking or not. Since 
baseline adherence was high and the prevalence of medication problems was low in all 
study participants, the adherence support consultation could have been much shorter for 
the majority of patients. For these patients, the two-month reinforcement appointment 
was also unnecessary. In routine practice, adherence support could be provided as part 
of the ongoing care of hypertensive patients, with little extra time needed. This scenario 
assumes that the total time required to provide adherence support in addition to usual 
care lasted 20 minutes instead of24.7 minutes (see Table 55). 
8.2.12 Discounting 
Although costs and benefits of the interventions may occur in the future in terms of 
increased or decreased medication usage or reduced incidence of cardiovascular events 
such as myocardial infarctions or strokes, this analysis does not discount costs and 
benefits to their present day equivalent value. 
8.3 Results 
In 10 out of the 21 practices taking part in the study, the practice nurses were employed 
by the Primary Care Trust, whereas in the remaining 11 practices, the practice nurses 
were paid by the practice. The main element of cost in the trial was the cost of extra 
consultation time in connection with delivering the adherence support intervention. 
Although I spent about 10 minutes with the practice nurses before the start of the trial 
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explaining how to use the prompt sheet, this did not consist of fonnal training on 
adherence related issues and was therefore not included in the analysis. 
8.3.1 Extra consultation costs 
The practice nurses spent on average an extra 13.4 minutes in direct patient contact in 
the intervention group (9.3 minutes for the adherence support intervention and 4.1 
minutes for the reinforcement consultation), based on an average of 15.4 minutes in 
both the intervention and control groups. Table 55 shows the cost per consultation with 
the practice nurse from the perspective of the practices. The extra time spent in 
connection with the adherence support intervention almost doubled the costs for 
individual consultations. 
Table 55 Costs per consultation with the practice nurse form the perspective of the practices 
Usual care Adherence support 
Usual time per standard 15.4 15.4 consultation (minutes) 
Extra time per adherence 
support consultation 0 9.3 
(minutes) 
Extra time per 
reinforcement consultation 0 4.1 
(minutes) 
Cost per minute a £0.33 £0.33 
Practice cost per £5.08 £9.50 b 
consultation 
a Consultation costs of nurses taken from Netten & Curtis270, including both contact and non-
contact time . 
b This is the total for the 'consultation package', that is, the adherence support consultation plus 
the additional reinforcement conSUltation 
The time spent on writing to or telephoning patients to invite them for appointments or 
preparing for consultations was the same for both comparison groups and was not 
included in the analysis. If patients were invited by the receptionists, the time spent on 
this ~as also not included. No data were collected on the totat time, including the 
waiting time, the study participants spent at the practice. 
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8.3.2 Sensitivity analysis 
Table 56 presents the results of the sensitivity analysis in comparison with costs 
incurred in the control group and the costs that were observed in the trial, which would 
represent the likely maximum costs associated with the intervention. Assuming the 
scenario that the adherence support consultation lasted 20 minutes instead of 24.7 
minutes and that no reinforcement appointment was provided reduces the practice costs 
per consultation by £2.90 to £6.60. However, the total costs are not reduced to the levels 
observed in the control group, since we would still expect practice nurses to spend some 
extra time on adherence support even in the absence of a formal adherence support 
consultation. 
Table 56 and Table 57 provide the cost per nurse consultation under trial conditions as 
well as the projected cost per patient under a more realistic scenario, to help decision 
makers in general practice to extrapolate these results to their own setting. It should be 
possible to adapt these data to a range of different general practice settings, using local 
data on consultation and follow-up rates for hypertension. The practice protocols for 
follow-up of patients varied between practices in the trial. Whereas some practices 
followed up patients with uncontrolled hypertension at regular intervals, others used a 
more flexible approach depending on other cardiovascular risk factors, patient 
preferences, and response to treatment. 
Table 56 Cost for the primary care sector per nurse consultation for the scenario, assuming a 
different duration of the adherence support consultation and no additional follow-up 
Control Intervention 
Observed Projected 
Costs for primary 
care sector per £5.08 £9.50 £6.60 
consultation 
8.3.3 Costs for the primary care sector 
Table 57 shows the costs for the primary care sector, assuming average list sizes and 
numbers of uncontrolled hypertensive patients per general practice list. For practical 
reasons as outlined above, costs were calculated from the primary care sector 
perspective rather than distinguishing between general practices and, for example, 
primary care trusts. 
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-Table 57 Total practice costs, assuming different numbers of patients with d' . f 
h rt
· t' a lagnosls 0 
ype ens Ion per prac Ice 
Projected 
Number of uncontrolled intervention Projected 
hypertensive patients per Current policy costs (as in additional costs 
practice (usual care) Table 56) per practice 
235 (mean observed in the trial) £1193.80 £1551.00 £357.20 
130 £660.40 £858.00 £197.60 
330 £1676.40 £2178.00 £501.60 
8.3.4 Limitations 
This study has only taken the viewpoint of general practices into account, and we did 
not obtain data on costs to patients (in terms of time off work or travel to practices). We 
also did not investigate cost implications for the wider NHS - for example, the 
intervention could have affected medication use on the whole or the number of hospital 
visits. 'Usual care' varied slightly between practices in terms of the protocols 
determining the frequency of follow up for hypertensive patients, which this economic 
analysis also did not take into account. Possible implications from these limitations are 
that they might introduce bias in terms of systematically overestimating or 
underestimating the costs of the intervention and that they might affect the precision of 
the results. 
8.3.5 Summary 
This chapter reported the results of an economic evaluation of a RCT of nurse-led 
adherence support for hypertensive patients in primary care. The results of this study 
showed that nurse-led adherence is more costly than usual care alone. There is no 
evidence to suggest that nurse-led adherence support is more efficient in improving 
medication adherence or reducing blood pressure than usual care. While some flexibility 
was considered within the sensitivity analysis, costing of other methods of delivering 
the intervention requires as well as their impact on prescribing costs and GP 
consultation rates require further research and development work. 
In the following chapter I discuss the overall findings of the research described in this 
thesis in Chapter 9. 
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9 Discussion 
9. 1 Introduction 
The previous chapters have desribed the theories behind research in adherence, the 
fmdings from past research, as well as the methods and results from individual studies 
that were conducted in the context of this thesis. In this chapter I briefly summarise the 
key findings again before considering the limitations of this study. Taking these 
limitations into account, I interpret the findings from this RCT and relate them to the 
results of previous research. Following on from this, I outline the implications of this 
thesis for clinical practice and future research. Finally I evaluate the overall contribution 
of this thesis. 
9.2 Summary of the studies described in this thesis and their 
findings 
The overall aim of this research was to find ways of helping hypertensive patients with 
taking their blood pressure lowering medication. Four studies contributed to this aim 
from different angles. 
The systematic review synthesised the current evidence from RCTs on the effectiveness 
of interventions to increase adherence to blood pressure lowering medication. It 
highlighted strengths and weaknesses of such trials and provided the basis for the 
development of an intervention suitable for the UK primary care setting. 
One of the main problems in adherence research is outcome measurement of adherence. 
A study comparing an adherence self-report tool with electronic monitoring was 
therefore conducted. 
The RCT evaluated the effectiveness of a nurse-led adherence support intervention 
compared with usual care, followed by an evaluation of the economic implications of 
the intervention. 
9.2.1 Summary of key findings from the systematic review 
We conducted a systematic review ofRCTs of interventions aiming to increase 
adherence to blood pressure lowering medication. This review suggests that 
simplification of dosing regimens appears to be the most promising intervention to 
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increase adherence in hypertension. There was mixed and inconclusive evidence for the 
effect of motivational and more complex interventions. 
The trials included in this review were heterogeneous in terms of study populations, 
interventions and outcomes. The study popUlations included, for example, participants 
with newly diagnosed or established hypertension, who had either 'controlled' or 
'uncontrolled' high blood pressure. Furthermore, the included studies tested a variety of 
different interventions, which we categorised into simplification of dose regimens, 
patient education, motivational strategies and more complex health and organisational 
interventions. Outcomes were measured in many different ways, including patient self-
report, pill counts, drug blood levels or electronic monitoring. In addition, many studies 
were small and of poor methodological quality. 
Due to clinical heterogeneity and the low overall quality of the studies, the results of 
this review should be interpreted with caution. The findings emphasized the need for 
further RCTs of adherence improving strategies in hypertension with sufficient power 
and of rigorous methodology. 
9.2.2 Summary of key findings from the ReT 
To my knowledge this was the first randomised trial of nurse-led adherence support in 
UK primary care. In addition, there has thus far not been an assessment of medication 
adherence in hypertension through electronic medication monitoring in the UK. The 
aim of this trial was to evaluate the effectiveness of practice nurse-led adherence 
support in increasing adherence to blood pressure lowering medication in study 
participants with uncontrolled hypertension, using a patient-centred and pragmatic 
approach. 
In essence, this was a negative trial in terms of timing compliance as the primary 
out~ome, and systolic and diastolic blood pressure as secondary outcomes. Baseline 
timing compliance was more than 90% and thereby high in both comparison groups, 
and mean blood pressure levels were close to the pre-specified cut-offpoint of>150/90 
mmHg. 
There was no evidence of an effect of the intervention on timing compliance or on the 
less strict measures of adherence such as correct dosing or taking compliance. There 
was also no difference between the groups in terms of systolic or diastolic blood 
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pressure. Additional adjustment for variables that showed any degree of imbalance at 
baseline did not alter the basic intention-to-treat model. 
Pre-specified subgroup analyses showed that the effect of the intervention did not differ 
by age, the total number of drugs prescribed, or the drug group used in the electronic 
monitor. There was, however, very weak evidence of a possible interaction of sex on the 
effect of the intervention on timing compliance, but not on systolic or diastolic blood 
pressure. There was also no evidence of a correlation or association of timing 
compliance with blood pressure. 
9.2.3 Summary of key findings from the economic evaluation 
To consider the cost implications of nurse-led adherence support and its relative cost 
effectiveness in comparison with usual care we conducted an economic analysis. A 
change from usual care alone to introducing nurse-led adherence support in addition to 
usual care led to increased costs per practice per year, ranging between £357.20 for 
smaller numbers of hypertensive patients to £501.60 for larger numbers. This finding is 
based on the sensitivity analysis, which took into account a more realistic scenario. 
There is no evidence to suggest that nurse-led adherence support is a more efficient way 
of improving medication adherence or reducing blood pressure compared to usual care 
alone. 
9.3 Limitations of the ReT 
Every research study has its limitations, and it is important to recognise these when 
interpreting the findings. This study has a number of limitations, some of which could 
have affected the study results. For this reason I consider these limitations first before 
interpreting the results of this study. 
9.3.1 Potential for response bias 
Practices 
Both general practices and eligible patients were invited to take part in this study, but 
not all invited practices and patients decided to take part. Only 23 out of 82 practices 
(23%) agreed to take part in this study, which raises the possibility of response bias in 
tenns of practice recruitment. The overwhelming majority of practices who stated their 
reasons for not taking part in the study gave staff shortages and workload implications 
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as the main rationale for declining. There is no reason to believe that the practices that 
refused to take part were substantially and systematically different from the ones that 
took part. However, no data were available on the proportion of teaching practices in the 
UK, making a comparison with the trial practices difficult. 
Study participants 
Our recruitment strategy aimed to provide equal chances for all hypertensive patients 
registered with a surgery to be included in the study. Nearly one third of the eligible 
population (29%, 245/837) took part in our study. Since baseline blood pressures in 
both groups were close to our chosen cut-offpoint of~150/90, there is potential for 
response bias, as patients with higher blood pressures, who may also be less adherent to 
medication regimens, were perhaps less likely to take part in this study. Due to data 
protection reasons, I was unable to obtain data on eligible participants who refused to 
take part, which would have allowed an investigation of any systematic differences 
between these individuals and the study participants. 
9.3.2 Potential for contamination 
With the method of randomisation used in this trial, that is, randomisation by individual, 
there was potential for contamination. Because every practice had patients both in the 
intervention and control groups, this raised the possibility of participants in the control 
group inadvertently receiving the intervention. We were aware of this risk at the time 
we planned and designed this study. It was, therefore, decided to try to avoid this 
problem as much as possible by having separate nurses provide care for the intervention 
and control groups and by explicitly making the nurses aware of this risk and its 
possible implications for the validity of the study. Outcomes were, wherever possible, 
assessed by practice nurses not delivering the intervention. The median number of 
nurses per practice was 3.5 (range 1 to 7), which allowed the follow-up for both 
intervention groups to be conducted by different nurses in the majority of practices. The 
risk of contamination therefore seems relatively small, but would have been even 
smaller if this had been a cluster randomised trial. 
9.3.3 Effect of electronic monitoring on adherence 
Study participants were aware that medication adherence was assessed through the use 
of electronic medication monitors, thus raising the possibility of a Hawthorne effect, 
that is, the possibility that taking part in the study or using electronic monitors for 
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assessment of compliance may have changed study participants' behaviour. We do not 
know if and by how much the monitoring process, or indeed just taking part in this 
study, have affected the medication taking patterns of study participants. We were 
aware of this risk, which is one of the reasons why we followed study participants up 
for six months and tried to explain carefully to participants that this study was not about 
'checking up' on them but to obtain more infonnation on medication taking patterns. 
There is evidence from previous studies that adherence patterns change in tenns of an 
increase in adherence around the dates of clinic visits. This change, however, is not 
usually sustained, and after about one week up to a maximum of four weeks most 
patients returned back to their usual medication-taking pattern. 101 , 132,266 We assumed 
that this effect would have occured in both the intervention and control groups and, 
therefore, investigated the differences between the groups, which should not have been 
affected in an important way by a general increase in adherence in both groups. 
However, in view of the skewed distribution of adherence data and high baseline 
adherence levels there is a possibility that, particularly in the region of higher timing 
compliance levels, this may have affected the study results, although this risk again is 
likely to be small. 
9.3.4 Economic evaluation 
This economic evaluation provides an approximation of the additional costs that 
practices would incur if they introduced nurse-led adherence support. This study 
focussed on the costs associated with nursing time, which appeared to be the main 
factor for additional practice expenses. However, the impact of the intervention on 
prescribing costs or GP time, which may have been positively or negatively affected, 
was not taken into account. Future studies of the economic consequences of adherence 
support interventions should take these factors into consideration. 
9.4 Interpretation of the ReT results 
Taking the limitations 'of this study into account, I discuss and interpret the results of the 
trial and the economic analysis in this section. I consider important issues in connection 
with the conduct of the study, and try to explain what the findings mean. This section 
starts by reflecting on issues affecting the internal validity of the study, before 
considering the wider generalisability of the study findings in terms of their external 
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validity. The internal validity is more important than the external validity, because it 
would be inappropriate to apply invalid findings to a wider population.271 
9.4.1 Baseline comparability of study groups 
There were no major differences between the comparison groups in terms of important 
clinical variables at baseline, and the groups were well balanced in this respect. Even 
where minor differences existed between the groups, adjusting for these factors in the 
regression analysis did not alter the results from the original intention-to-treat analysis, 
which suggests that the randomisation process was successful. 
9.4.2 Losses to follow-up 
Losses to follow-up were also similar for both groups, with no important differences 
between the groups in terms of age, sex, or differential losses to follow-up. However, 
there were differences in losses to follow-up between the practices. The main reason for 
this was that practice nurses left the practice or were off sick without passing on the 
responsibility for conducting the trial. There is no reason to believe that this has affected 
the study results as a whole, because these losses to follow-up were not caused by the 
study participants themselves. In addition, the practice nurses who stopped taking part 
in the study did not app<:ar to be systematically different from the nurses completing the 
study. 
9.4.3 Precision of the study 
The total number of study participants randomised to the two comparison groups was 
245, which was smaller than the pre-specified desired sample size of330 participants. 
The trial did not show any evidence of an effect of the adherence support intervention 
on the primary outcome timing compliance compared with usual care, which raises the 
question as to whether this study may have been underpowered to detect a statistically 
significant difference between the two comparison groups with respect to the primary 
outcome. 
Although the total number of study participants was smaller than expected, the results 
attained by this study were precise enough to counter this argument. The values of the 
confidence intervals for the primary outcome enable us to rule out a benefit or disbenefit 
in excess of about five percentage points in timing compliance, which is small and 
considerably lower than the target difference specified in advance. 
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The precision gained in this study highlights the uncertainty that surrounded the original 
power calculation in terms of the assumptions we made about the primary outcome. The 
findings from this study should, therefore, be useful for future power calculations that 
use timing compliance as the main outcome. 
9.4.4 High baseline levels of timing compliance 
During the planning stage of this trial we assumed, based on past research, that lack of 
adherence to blood pressure lowering medication is widespread. In particular, we 
assumed that it occured in 50% to 60% of all hypertensive patients, and that it is an 
important contributing factor for poor control of hypertension in the community.2 
However, baseline timing compliance in this ReT was much higher than expected with 
a mean timing compliance in both groups of over 90%. This is inconsistent with past 
research and an interesting finding, which I will discuss in more detail in Section 9.5 
below. Ifbaseline levels of adherence are already high, this obviously provides much 
less of an opportunity for further improvement compared with a situation where 
baseline adherence was lower. 
The lack of an effect of the intervention in this study, therefore, needs to be seen in the 
context of already high adherence levels and is only generalisable to patients with high 
baseline timing compliance. We do not know what effect the intervention would have 
on people with lower adherence levels. 
Since in our patient information sheet we informed prospective study participants that 
electronic monitors would be used to assess adherence, this could have deterred 'poor' 
adherers from taking part, who may have felt that they would appear to be 'failing' the 
GPs and practice nurses by not taking their medicines as prescribed. 
Although the intervention was not successful in increasing overall adherence, a high 
percentage of the small number of participants who did have problems with their 
medication found the intervention effective (see Table 41). This raises the possibility 
that the intervention could be more effective in patients who indeed have problems with 
taking their medicines. An interesting observation was, however, that timing 
compliance dropped from 88.2% (SD 18.5) to 80.3% (SD 25.5) in this group, raising the 
possibility that although participants found the intervention helpful, the intervention 
may even have affected timing compliance in a negative way. These results have to be 
interpreted with caution due to the small number of individuals in the group who had 
medication problems. 
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9.4.5 Effectiveness of the intervention in subgroups of participants 
There was very weak evidence, that is, almost reaching statistical significance at the 5% 
level, that the treatment effect of adherence support on timing compliance might differ 
by sex (interaction p=0.09, coefficient 7.0, SE 4.1,95% CI -1.2 to 15.2), in that women 
may be more likely to show increased adherence after the intervention than men. Since 
this is the result of a subgroup analysis which can be unreliable, it has to be interpreted 
with extreme caution and should only be considered for the generation of new 
h thes 254 H hi" . ypo es. owever, t s rruses mterestIng questions as to whether there could be 
any differences between the sexes in their response to the intervention. All the practice 
nurses taking part in this research were female, and it is plausible that for various 
reasons men might respond differently to nurse-led adherence support than women. 
9.4.6 Baseline blood pressure levels 
We chose to recruit study participants with 'uncontrolled hypertension', using a widely 
agreed audit standard defined by the British Hypertension Society,19 because we felt 
that increasing adherence in this group of patients was more important than in patients 
who are already well controlled. However, mean systolic and diastolic blood pressure in 
study participants were below or around the British Hypertension Society Audit 
Standard, which raises the question as to whether the study participants were at the 
lower end of the range of 'uncontrolled' blood pressures identified through the search of 
practice registers. 
Unfortunately, for reasons of confidentiality and data protection we were unable to 
compare blood pressure levels of patients taking part in the study with those who 
declined to take part. Obviously, this leads to questions about the potential for response 
bias, which has already been discussed in Section 9.3. 
9.4.7 External validity 
The mean list sizes showed slight differences between the study practices and practices 
in Avon and the UK. as a whole, but these were not excessive and unlikely to have 
affected the external validity of the study. We selected a random sample from identified 
eligible patients in the practice registers, stratified by age and sex. This process aimed to 
increase the external validity of the study by selecting study participants in an age/sex 
ratio similar to the national average. This process appeared to be successful and resulted 
in a representative sample in terms of the age/sex distribution. 
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9.5 Discussion of the results in the light of previous studies 
9.5.1 Adherence levels in the community 
Baseline timing compliance, the strictest measure of adherence obtained through 
electronic monitoring, was in excess of 90% in study participants, challenging the 
widespread belief that adherence to blood pressure lowering medication is only about 
50-60%. However, this figure is based on studies that often used arguably unreliable 
methods of measuring adherence and that were mainly conducted in North America.2,41 
Our fmding of much higher adherence than expected in the study popUlation does not fit 
into the existing body oflrnowledge and is inconsistent with current theories. 
However, when comparing the results of this RCT with the five trials of simplified 
dosing regimens included in our systematic review that have used MEMS® for outcome 
measurement of adherence, a different picture emerges. Andrejak and colleagues found 
that correct dosing, which is the second strictest adherence measure next to timing 
compliance, was between 78.1 % and 94% during their study.182 A trial by Mounier-
Vehier and colleagues resulted in timing compliance between 74.80/0 and 92.5%.189 
Timing compliance in a study by Detry and colleagues was 52.8% and 78.7% in both 
comparison groupS.272 Leenen and colleagues found timing compliance to be between 
74% and 93%.188 Brigeen and colleagues reported timing compliance between 61.1 % 
and 86.6% for both comparison groupS.190 It is worth pointing out that these results are 
data from the follow-up period, and comparison with the baseline data from our trial is 
therefore of limited value. However, the findings from these trials illustrate that even in 
the control groups timing compliance was between 52.8% and 78.1 %, with three of the 
five trials showing mean timing compliance levels of 74% and over. These results 
confirm the doubts raised about the accuracy of the "average adherence of 50-60%" 
which is so often quoted.2 
Of course, we do not know whether the high adherence levels observed in the RCTs 
described in this thesis and elsewhere were due to a self-selected popUlation, or whether 
the results reflect generally higher adherence levels in the UK. This raises the question 
as to whether doctors and researchers in th~ UK have made the wrong assumptions 
about their patients' propensity for not taking their medicines as prescribed. Higher 
adherence levels in the UK would not be implausible, as the UK National Health 
Service is different from health care delivery in the US. Whereas patients in the UK 
only have to pay a prescription charge, hypertensive people in the US and Canada often 
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-have to pay for their medicine, which might explain higher levels of non-adherence in 
North American settings. In addition, the UK is unique in its organisation of primary 
care, with GPs being in charge of the overall care of their patients, which could 
positively affect medication adherence. 
9.5.2 Effectiveness of nurse-led care 
The lack of an effect of nurse-led adherence support on timing compliance in this RCT 
is perhaps not altogether surprising, given the inconclusive evidence that has often been 
provided by past RCTs.41 
There is evidence of potential benefits from nurse-led care in terms of improving 
adherence. Logan and colleagues compared worksite treatment in 457 untreated 
hypertensive patients aged 18 to 69 years with care by family physicians.206 Study 
participants in the group receiving the nurse intervention were more likely to be started 
on blood pressure lowering medication (95% versus 63%), to reach the agreed target 
blood pressure (49% versus 28%), and to show greater medication adherence (68% 
versus 49%). In an RCT by Nessman and colleagues, nurses and psychologists taught 
study participants self-determination, resulting in participants in the intervention group 
being 'adherent' for 1.3 more weeks.221 Phone calls in a trial by Kirscht and colleagues 
led to a 5% improvement in adherence (p<O.05). 
Another trial by Logan and colleagues, however, did not find any evidence for an effect 
of nurse-led worksite care on adherence.207 Oakeshott and colleagues conducted a 
review on the role of nurse-led blood pressure management in primary care on blood 
pressure control and prescribing.65 This review concluded that nurse-led management of 
people with high blood pressure could lead to improvements due to strict adherence to 
protocols, agreed target blood pressure, better prescribing and adherence, and regular 
follow-up, but that the evidence to support this view is not very robust. 
The ReT described in this thesis has provided some new evidence on the effectiveness 
of nurse-led care on adherence to blood pressure lowering medication. This trial is the 
first of its kind to measure baseline levels of adherence and compare these with 
adherence levels at follow-up. Our study provided some answers, but posed even more 
questions about the potential effectiveness of the intervention and adherence levels in 
the community. Possible approaches to answer these questions are further considered in 
Section 9.7 below. 
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9.6 Implications for practice 
The results of this study do not support the introduction of nurse-led adherence support 
for the management of hypertension in UK primary care. In addition to the lack of an 
effect in terms of increasing adherence, introduction of nurse-led adherence support can 
also not be recommended for reasons of cost effectiveness. The costs of delivering the 
intervention estimated in the economic analysis was, however, based on a number of 
assumptions, and it is likely that the actual cost of introducing the intervention into 
routine practice would be different to the costs incurred in the trial. The sensitivity 
analysis used a more realistic scenario to increase the external validity of the costs and 
to provide a better estimate of costs that would incur in actual practice. 
Although not based on evidence, there appear to be few reasons why practice nurses, or 
indeed GPs, should not routinely ask patients in more detail about their medication 
taking, particularly if they show a less than expected response to their medical 
treatment. The justification for this is that in the few study participants who did have 
medication problems, the intervention appeared to be very successful, although numbers 
were far too small to come to any robust conclusions. However, asking patients about 
their medication taking and trying to identify individual solutions could be performed 
opportunistically on selected patients with minimal extra costs and potential benefits in 
terms of improved adherence, better blood pressure control - and a possible 
improvement in communication between patient and health professional. 
9.7 Implications for future research 
The research in this thesis has created many more questions than answers, suggesting a 
number of new theories and hypotheses that should be further evaluated with 
appropriate research designs. 
9.7.1 Identification of 'true' adherence levels 
One of the most surprising findings of this thesis was that baseline adherence levels in 
this study were high in both groups, contrary to the common belief that average 
adherence levels are around 50-60%. This observation strongly suggests that further 
observational studies are required to investigate the epidemiology of adherence in 
treated hypertensive people in the UK. Previous studies often used varied and imprecise 
measurements and definitions of adherence and had relatively short follow-up periods. 
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Wherever possible, future studies should use reliable instruments to measure medication 
adherence such as electronic monitoring. 
9.7.2 The potential use of the adherence self-report tool to differentiate 
between non-adherence and non-response 
Clinically it can be very difficult to differentiate between non-adherence and non-
response, but this distinction is very important, as it prompts entirely different 
management strategies. For this reason we would have ideally screened all potential 
trial participants for non-adherence prior to randomisation. One option would have been 
to use electronic monitoring, which has successfully been used by Burnier and 
colleagues in a hospital setting to differentiate between non-adherence and non-
response.172,173 There were two reasons why we did not screen for non-adherence with 
electronic monitors. First, the intervention was meant to be pragmatic. Electronic 
monitors have so far mainly been used as research tools. Their use of a screening tool in 
routine primary care in the forseeable future appeared unrealistic, which made us avoid 
using this method for screening purposes. Second, if electronic monitors were used to 
screen for non-adherence, this would have contributed to the intervention itself, in that 
nurses would have become aware of medication adherence in individual patients, which 
may have influenced the management of their patients. The concurrent use of electronic 
monitors as part of the intervention and as an instrument for outcome measurement 
would have made the trial much more complex, making it even more difficult to 
disentangle the effects of individual components of the intervention. It was, therefore, 
felt that the role of electronic monitoring for the purpose of this trial should be limited 
to outcome measurement of adherence only. 
More research is thus needed on the use of a self-report tool to screen for non-
adherence. Although the study described in Chapter 6 comparing a self-assessment tool 
with electronic montoring has shown interesting and promising results, these need to be 
further validated in a less selective study population outside trial conditions. 
9.7.3 Evaluation of the intervention in patients with low adherence and/or 
higher blood pressure levels 
The patients taking part in this trial were essentially well controlled in terms of their 
blood pressure levels and showed high adherence, providing little opportunity for any 
intervention aimed at improving adherence to show an effect. Future studies of 
adherence improving strategies should therefore concentrate on patient who have been 
-identified as being non-adherent. This might either be achieved by using electronic 
monitoring (so-called 'measurement-guided medication management,172,173) or 
screening by using an adherence self-report tool as described and evaluated in this 
thesis. 
9.7.4 Evaluation of complex interventions in primary care 
The World Health Organization and the Working Party on Concordance advocate a 
multidisciplinary approach to make progress in the area of improving medication 
adherence?,13 Once more is known about the epidemiology of adherence in UK primary 
care, future research should involve evaluation of complex interventions, which should 
also include nurse-led care.65 Interventions should target those at greater levels of risk 
and always take patient preferences and concerns into account. 2 
Since the evaluation of complex interventions in randomised trials can be challenging, 
these should be rigorously developed in stages as advocated by the Medical Research 
Council. 233 The design of new interventions should be based on findings from both 
qualitative and quantitative research and needs to follow sequential phases including an 
exploration of the relevant theory, an identification of the components of the 
intervention, an exploratory trial and a definitive randomised controlled trial prior to an 
evaluation of the long tenn implementation. When designing and evaluating complex 
interventions, particular attention should be paid to selection bias, unmeasured 
contextual variables and uncontrolled interaction effects that arise because there is an 
interaction between the environment and the intervention.234 Greater recruitment rates 
might be achieved by clear and accurate patient information and an opportunity for 
prospective study participants to discuss concepts such as randomisation, which many 
people find difficult to understand and which may deter them from taking part in a 
trial. 273 
If adherence levels in the UK are confirmed to be low, then there will be a need for 
pragmatic primary care based trials of adherence improving interventions.2,41 Haynes 
remarked in an editorial on the testing of health care interventions that ''we need more 
effectiveness studies to sort the fool's gold from the true gold and efficiency studies to 
tell us if the price of the extraction is a bargain".274 In addition, it is important that 
I . 275 future trials address the research needs of primary care and are re evant to patIents. 
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9.7.5 Relationship between adherence and blood pressure control 
The lack of a simple relationship between adherence and blood pressure control, as 
demonstrated again in this trial, complicates the perceptions of patients and health 
professionals about the importance of complete adherence. Some medicines are very 
'forgiving', that is, a change to the treatment regimen in terms of missed or delayed 
doses may not affect the outcomes assessed in the study and may go unnoticed.88 Much 
more research is needed on the relationship between medication adherence and blood 
pressure control, which should involve researchers from multiple disciplines including, 
among others, pharmacologists, specialists in the field of hypertension, epidemiologists 
and clinicians. 
9.7.6 Strategies used by patients for increasing adherence 
Although many pUblications in the field of medication adherence have identified 
'barriers to adherence', little is known about strategies that patients have adopted to deal 
with non-intentional non-adherence. Unlike exercise or diet, adherence to medication 
has so far rarely been recognised as a behavioural issue.88 It is important to appreciate 
that the issue in improving adherence is not necessarily a change of patients' existing 
behaviour, but rather undertaking and getting accustomed to a new behaviour. There is 
thus a need for studies that investigate further the strategies that patients have already 
developed themselves, which might help inform the design of future interventions to 
improve adherence. 
Future studies should try to obtain high response rates by addressing barriers to 
participation in randomised controlled trials. These may include lack of staff and 
training and time constraints on the part of the health professionals and additional 
demands of the trial, patient preferences, worry caused by uncertainty, concerns about 
patient information, consent or randomisation on the part of the patients.276 
9.7.7 Economic evaluation 
The intervention evaluated in the trial was complex in that it consisted of two separate 
appointments. There are different options for the duration and content of adherence 
support and subsequent follow-up. These would include not using a separate 
appointment, but providing adherence support opportunistically on an ongoing basis, 
which should be taken in to consideration in future studies. 
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The intervention may be more effective in patients with higher levels of blood pressure. 
If this was the case, then the intervention may become more cost-effective, because the 
additional costs per practice were not large. 
9.7.8 Differentiation between different types of non-adherence 
This trial did not take into account the different types of non-adherence, which require 
further study. These different types include erratic adherence and unwitting non-
adherence, which can be described as 'non-intentional non-adherence' .88 Some patients 
may deliberately choose to discontinue or alter a medical regimen because they believe 
that this is in their best interest, leading to more 'intentional' non-adherence. Future 
studies should take into account these different types of adherence. They need to include 
patient based outcome measures to find out what patients think about adherence 
improving strategies and and what influence interventions have on patients' quality of 
life.277,278 Because adherence research is of direct relevance to patients, it is important to 
take patients' views into account when designing further qualitative and quantitative 
studies.279,280 
9.8 The contribution of this thesis 
9.8.1 Addressing the research aims 
The overall aim of this thesis was to find ways of improving adherence to blood 
pressure lowering medication. The systematic review ofRCTs was conducted according 
to standards set out by the Cochrane Collaboration and provided the latest evidence 
about the effetiveness of interventions to improve adherence in hypertension. 
We developed a new six -point adherence self-assessment tool, which was validated 
against electronic monitors. To my knowledge, this is the first study that has developed 
a tool designed purely to detect non-adherence (in contrast to longer questionnaires that 
also try to shed light on the reasons for non-adherence) and validated this against the 
current 'gold standard'. The results of this study are promising and highlighted the need 
for further validation studies in more representative populations and in different chronic 
conditions. If the validity of the adherence self-report tool can be further established, 
then it might prove useful for clinicians in their day-to-day work by helping them to 
distinguish between non-adherence or non-response to medical treatment. 
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The results of the ReT described in this thesis did not show any evidence of an effect of 
nurse-led adherence support compared with usual care. However, these results may 
have been influenced by the high adherence and low blood pressure levels at baseline in 
both comparison groups. Potentially, nurse-led adherence support might be more 
effective in patients who do not take their tablets regularly and/or who have higher 
blood pressure levels at baseline. This view is supported by the fact that indeed in the 
few patients who had difficulty with their medication, the intervention appeared to be 
successful, although the numbers were too small to provide a robust conclusion. 
9.8.2 Asking new questions 
Overall, this study answered some questions, but it highlighted even more uncertainties. 
It produced new theories, particularly about the extent of non-adherence in UK. primary 
care, which is an important result of this thesis. Theories are an important basis for 
clinical practice, health promotion and research, and it is essential to recognise new 
theories for scientific and practical reasons, as they can be immensely helpful in 
understanding healthcare?81 What are the 'true' adherence levels in hypertensive people 
in the UK? Is nurse-led adherence support effective in people with low adherence 
and/or poor blood pressure control? What is the relationship between adherence and 
blood pressure control? How much adherence is enough to lead to the desired effect of 
the drug in question? How robust is the self-assessment tool of adherence outside a trial 
setting and in people with lower adherence? Is this tool useful in day-to-day clinical 
practice to distinguish between non-adherence and non-response? Are there ways to 
separate intentional from non-intentional non-adherers? How do patients feel about 
nurse-led adherence support? How do study participants feel about using the electronic 
monitors? Does nurse-led adherence support lead to better communication between 
patients and health professionals? These questions will be useful for formulating new 
hypotheses and theories, the answer to which might help patients with chronic diseases 
to have a better quality of life. 
9.8.3 Future outlook 
We have come some way to improve our understanding of adherence in hypertension, 
but much more work needs to be done to appreciate fully the issues in adherence 
. research that are relevant to patients and health professionals alike. This need has been 
supported and summed up by a letter from one of the study participants that I received 
early in the study and with which I finish this chapter: 
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November 2(jh 2001 
Dear Dr Schroeder 
Thank you for your invitation to take part in your research concerning 
medication-taking in patients with high blood pressure. 
I have signed the consentform (which I herewith enclose), though morefrom 
curiosity than for any other reason - I cannot imagine how such research 
can be anything other than using up money which might be better spent on 
some other project. 
How can swallowing a pill at regular times, according to one's doctor's 
instructions, be made any easier? 
One opens one's mouth, puts in the pill, swallows and takes a sip of water. 
Not so very difficult. If one's pill is taken at the same time every day, it's 
surely no hardship. 
I rise every morning between 5.30 and 7.00, have a glass of grapefruit juice, 
a cup of coffee and a slice of dry toast with marmite or anchovy paste -
swallow my pill and drink a glass of water (the slice of toast is simply 
because the pill should be taken after food - and I am thus reminded to take 
the thing, otherwise why would I be eating at that hour? One is not hungry 
at 7.00 in the morning). 
Indeed I would be more interested in having explained to me, exactly what is 
high blood pressure and how does it work? (I understand about water 
pressure in taps - but do not understand what puts the pressure on blood -
one cannot expect a busy general practitioner to make time to explain it). 
Neither do I understand how a dose of some chemical, taken orally, can 
affect this mysterious blood pressure - and why there should be so many 
different sorts and brand names - and, if they are so "good" and necessary, 
why are there so many ominous side effects, and so many restrictions on 
what one may take at the same time - i.e. pain killers, "cold cures ", anti-
inflammation pills to aid mobility, etc. (any of which one may needfrom time 
. II to tzme./. 
I am naturally very reluctant to put anything into my body without knowing 
exactly what it is, how it works, and what it is likely to do to me. Only my 
fear of ending up like poor Princess Margaret a caused me to overcome my 
reluctance to start taking blood pressure tablets in the first place. 
Even so, I think I was conned. I was not told that beginning this wretched 
treatment meant continuing with it forever, that I would be a slave to a pill-
box for the rest of my life. I thought that this was a 'blip' and that once the 
pressure was reduced, I would be free again. Evidently not so. 
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1 had had a heart scan on March 2{/h and my heart was functioning perfectly 
normally and the blood pressure was only very slightly high (1 had been 
seeing the doctor fairly regularly about my "bad leg" - swollen ankles etc). 
And the pills are, of course, quite useless and taking them 1 became so 
lethargic 1 could no longer take my customary long walks, do the housework 
properly or even stay awake for any length of time. 1 would even fall asleep 
while sitting upright at my type-writer and indeed spent most afternoons and 
evenings lying on my back, fast asleep on the floor. What a waste of life. 
However, with determination, 1 have overcome this and now eight months 
later, can force myself to stay awake for most of the day. And my blood 
pressure continues to rise. Whatever it is, this 'blood pressure', there must 
be some other, better way of controlling it (this might be a suitable subject 
for research). 
To return to the point - unfortunately nothing is easier than obediently 
swallowing a pill, whatever damage it may do to one's natural good health, 
and 1fail to see how a (possibly costly) electronic pill-bottle can make it 
easier still. 
Perhaps your research should be confined to such as are unable to follow 
simple instructions, perhaps through reasons of memory loss or one of the 
disabilities now lumped together as "learning difficulties" - but if you think 
my contribution would be of any use to you, 1 am prepared to go along with 
it. 1 am curious about the nature of your research and why one should think 
it is worth doing - but 1 still think it a sorry waste of money at a time when 
money is so important. 
Yours faithfully 
u.P. 
a Princess Margaret endured poor health in the last years of her life. She was a heavy smoker, 
suffered at least two strokes, and died on 9 February 2002 aged 71. 
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10 Conclusion and recommendations 
The overall aim of this thesis was to find ways of helping people suffering from high 
blood pressure with taking their blood pressure lowering medication. Four studies were 
carried out, which led to the following conclusions: 
1. Based on a systematic review ofRCTs, simplification of dosage regimes seems to 
be a useful strategy to increase adherence to blood pressure lowering medication. 
There is a need for further trials evaluating more complex interventions testing 
different educational and motivational strategies, which may be delivered by nurses 
and other allied health professionals. The results of this review have to be 
interpreted with caution due to the methodological shortcomings in many included 
trials. 
2. A validation study of an adherence self-report tool compared with electronic 
monitoring showed that self-report can predict timing compliance at higher leveles 
of adherence. More research is needed on the usefulness of this tool in day-to-day 
practice and in a more representative study sample. 
3. Nurse-led adherence support is no more effective than usual care in terms of 
increasing adherence or reducing blood pressure, based on the results from a RCT. 
Baseline adherence levels were high in both comparison groups, leaving little room 
for improvement. In the few participants who had medication problems, the 
intervention appeared to be successful, but further research is needed to further 
consolidate this finding. 
4. There was no evidence from an economic evaluation that nurse-led adherence 
support was more cost-effective than usual care alone. 
This thesis contributes to the literature on adherence by providing an up-to-date 
overview of evidence from past randomised trials on the effectiveness of interventions 
to improve adherence. Although the main study of this thesis, that is, the randomised 
trial, produced negative results, it raised questions about the 'true' level of adherence in 
the community and the potential effect of nurse-led adherence support in people with 
lower adherence or less well controlled blood pressure. 
This thesis has developed many specific questions regarding the measurement of and 
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Appendix 1 In/out sheet used in the systematic review for inclusion or exclusion 
of titles or abstracts 
Interventions used to improve the adherence to treatment in patients with 





1. RCT, not before/after or other design? YIN 
2. Concerned with essential hypertension (not secondary)? YIN 
3. Ambulatory setting? YIN 
4. Intervention(s) aimed at improving adherence? YIN 
5. Outcomes adherence.+/- blood pressure? YIN 
In' Out Pending 
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Appendix 2 Data collection form systematic review 
Interventions used to improve the adherence with treatment 
in patients with high blood pressure 
1. IDENTIFICATION DETAILS 
Identifier/code for Refman 
Name of reviewer 
Last name of author and year of pUblication 
Notes and comments on quality of the study 
Source of key information (where found, information from unpublished sources and 
personal communications) 
2. VERIFICATION OF STUDY ELIGIBILITY AND METHODS 
Type of trial (e.g. parallel or cross-over) 
Study duration 
Hypothesis (clearly stated a priori?) 
Power calculation and outcome that it was based on 







Randomisation process (yes, no, unclear) and description 
2.3. DROPOUTS / LOSS TO FOLLOW-UP 
Drop-outs and reasons for drop-out 





Number of participants randomised in each group 













Type and description of interventions 
How were interventions delivered? 
Intervention in control group 
Who delivered interventions? 
Time frame / schedule of interventions 
Treatment length in total 
Duration of follow-up 
Type of follow-up 
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5. OUTCOMES: 
Stated primary outcome measures 
Reported primary outcome measures 
5.1. Blood Pressure 
5.1.1. Criterion 
5.1.2. How was blood pressure measured? 
5.1.3. Baseline blood pressure in intervention group (n=, mean, SD, CI, other) 
5.1.4. Baseline blood pressure in control group (n=, mean, SD, CI, other) 
5.1.5. Statistical difference between groups 
5.1.6. BP at final assessment in intervention group (n=, mean, SD, other) 
5.1.7 BP at final assessment in control group (n=, mean, SD, other) 
. 5.1.8. Statistical difference between groups 
5.1.9. Reduction in BP in intervention group 
5.1.10 Reduction in BP in control group 
5.2. Adherence 
5.2.1. Criterion 
5.2.2. How was adherence measured? 
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5.2.3. Adherence in intervention group (n=, %) 
5.2.4. Adherence in control group (n=, %) 
5.2.5. Statistical difference between groups 
5.3. Other outcomes 
5.3 .1. Other outcomes in intervention group 
5.3.2. Other outcomes in control group 
6. STATISTICS: 
Analysis/statistic test used 
Intention-to-treat analysis used or not? 
7. CONCLUSION: 
What conclusion has been reached in the paper? 
Does it correspond with the findings? 
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Appendix 3 Characteristics of RCTs included in systematic review 
Net effect on Blood 
adherence Blood pressure 
between pressure change Duration 
intervention change diastolic of 
Study (first Method of and control systolic in in mmHg follow-
author, year of Study measuring group (p- mmHg (p- (p- upin 




Pindolol 10mg Pindolol 10mg and 
and clopamide 
clopamide 
Asplund 1984183 160 Smg once daily Smg once PC,SR 28.2% (NS) + 2.8 (NS) +3 (NS) 4 Bias possible (single daily 
combination 
tablet) (separate tablets) 
Once-daily Twice daily , , 




Net effect on Blood 
adherence Blood pressure 
between pressure change Duration 
intervention change diastolic of 
Study (first Method of and control systolic in in mmHg foHow-
author, year of Study measuring group (p- mmHg (p- (p- upin 
publication) size Intervention Control adherence value) value)* value)* months Comments 
Verapamil 
Transdermal 120mg slow Bias possible. 
Burris 1991 185 clonidine release tablet PC, visual 1 58 0.1 mg/d plus plus assessment 59% (NS) 5 (p<0.05) (p<0.05). 2 Compared two 
placebo tablets transdermal different drugs 
placebo 
Once daily Twice daily 17.8% NS, but no Bias possible. Detry 1995186 320 amlodipine nifedipine PC,MEMS® (p<0.001) data NS 3 Compared two 5mg 20mg reported different drugs 
Twice daily Nicardipine Bias possible. 
Boissell 1996187 7274 nicardipine 20mg three SR 11 % (p<0.001) 0.2 (NS) 0.3 (NS) 3 Compared two 
slow release 
50mg times a day different drugs 
• I 
Once daily Diltiazem 
slow release Compared two Leenen 1997188 198 amlodipine MEMS® 8% (p<0.01) 6 (p<0.01) 1 (NS) 5 60mg twice different drugs. 5mg daily 
Mounier-Vehier Once daily Twice daily 17.7% 0.8 mmHg Compared two 
1998189 103 amlodipine nifedipine MEMS® (p<0.001 ) (NS) +1.1 (NS) 3 different drugs. 5mg 20mg 
212 
Net effect on Blood 
adherence Blood pressure 
between pressure change Duration 
intervention change diastolic of 
Study (first Method of and control systolic in in mmHg follow-
author, year of Study measuring group (p- mmHg (p- (p- upin 
publication) size Intervention Control adherence value) value)* value)* months Comments 
Girvin 1999190 Enalapril 20mg 
Enalapril 19.6% 5.3 1.0 Potential for 27 10mg twice MEMS® 3 
once daily (p<0.001 ) (p=0.068) (p=0.086) selection bias .. daily 
14% more 
Andrejak Once daily Twice daily with normal Study compared 







Educational compliant It 
programme via in Well-designed 
Sackett 197510 144 slide- Usual care PC 5% (NS) intervention NR 6 study 






Net effect on Blood 
adherence Blood pressure 
between pressure change Duration 
intervention change diastolic of 
Study (first Method of and control systolic in in mmHg follow-
author, year of Study measuring group (p- mmHg (p- (p- upin 
publication) size Intervention Control adherence value) value)* value)* months Comments 
Regular Randomisation Group Compliance process and 
Webb 1980191 education 
physician 
score 0.2 3.3 blinding to 92 appointments PC points higher NR (p>0.1 ) 3 outcome 
(p>0.10) assessment not 
reported. 
Written Adherence scores 
Kirscht 1981 192 343 educational Usual care SR 1% (NS) NR NR 18 unclear and 
material difficult to interpret. 
16% more 
Health patients 
education in 4% more had blood Outcomes 
Pierce 1984193 29 groups, four Usual care PC,SR Igood' pressure N/A 6 inadequately 
meetings of 90 adherers (NS) reduction reported 
minutes (p<0.05, Ir 
duration effect size 
unclear) 
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Net effect on Blood 
adherence Blood pressure 
between pressure change Duration 
intervention change diastolic of 
Study (first Method of and control systolic in in mmHg follow-
author, year of Study measuring group (p- mmHg (p- (p- upin 
publication) size Intervention Control adherence value) value)* value)* months Comments 
Education via 
visual aids and No Large dropouts 
10-minute intervention and 
Kerr 1985194 60 lecture, apart from SR 12.5% (NS) NR 4.6 (NS) 3 inconsistencies 
followed by paper and between text and 




groups of 15 
Marquez over 90 Unclear how 
Contreras 110 minutes and Usual care PC 24% (p<0.OO2) NR NR 6 dropouts were 
1998195 postal treated. 
information 
leaflets at 1, 3 ' , 







Net effect on Blood 
adherence Blood pressure 
between pressure change Duration 
intervention change diastolic of 
Study (first Method of and control systolic in in mmHg follow-
author, year of Study measuring group (p- mmHg (p- (p- upin 
publication) size Intervention Control adherence value) value)* value)* months Comments 
Eshelman Compliance Usual Drop-outs at least 100 medicine PC,DQ 2% (NS) NR NR NR 1976196 dispenser 33%. bottle 
Daily drug Small study, no 
reminder chart power calculation 
Gabriel 1977197 79 with No chart (Le. PC,DQ 12% (p=0.OO2) NR NR 3~ reported, 
usual care) unreliable pharmacist 
assessment of 
supervision adherence. 
Johnson Self-recording Study likely to be 
1978198 68 of blood Usual care PC 12% (NS) 2 (NS) NR 6 underpowered pressure 
Power calculation I, 
Johnson Monthly home not reported, study It 67 Usual care PC,SR 10% (NS) 2 (NS) NR 6 1978198 visits likely to be 
underpowered 
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Net effect on Blood 
adherence Blood pressure 
between pressure change Duration 
intervention change diastolic of 
Study (first Method of and control systolic in in mmHg fo II ow-
author, year of Study measuring group (p- mmHg (p- (p- upin 
publication) size Intervention Control adherence value) value)* value)* months Comments 
Nurse and Only 10% of 
psychologist Intervention eligible patients 
teaching self- group took part in the 
Nessman determination, Nurse and compliant for study with 
1980199 52 eight weekly protocol-run PC 1.3 more 6 (p<0.05) NR 2 potential selection training clinic weeks than the bias. Other 
sessions control group potential sources 
lasting 90 (p<0.001) of bias poorly 
minutes reported. 
Counselling 
(instructions High drop-out rate, 
on medication- study 




High drop-out rate, 
Special Usual study 
Rehder 1980211 50 medication medication PC 6%(NS) 1 (NS) NR 6 underpowered. 
container vials Results poorly 
reported. 
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Net effect on Blood 
adherence Blood pressure 
between pressure change Duration 
intervention change diastolic of 
Study (first Method of and control systolic in in mmHg follow-
author, year of Study measuring group (p- mmHg (p- (p- upin 
publication) size Intervention Control adherence value) value)* value)* months Comments 
Counselling 0.2 points (three Regular difference in Randomisation 
sessions with process and physician adherence 
Webb 1980191 86 trained social appointments Pill count score between NR 2.3 18 blinding to 
worker, lasting baseline and (p>0.1 ) outcome 
one hour each follow-up assessment not 
at three weekly reported. (p>O.10) intervals) 
Nurse phone Adherence scores Kirscht 1981 192 316 Usual care SR 5% (p<O.05) NR NR 18 unclear and 
calls difficult to interpret. 
Self-recording Adherence scores 
Kirscht 1981 192 203 of blood Usual care SR 0% (NS) NR NR 18 unclear and 








Net effect on Blood 
adherence Blood pressure 
between pressure change Duration 
intervention change diastolic of 
Study (first Method of and control systolic in in mmHg follow-
author, year of Study measuring group (p- mmHg (p- (p- upin 
publication) size Intervention Control adherence value) value)* value)* months Comments 
4% more Randomisation 
Self monitoring participants procedure prone to had blood Pierce 1984193 27 of blood Usual care PC,SR 6% (NS) NR 6 bias. Reporting of 
pressure pressure outcomes 
reduction 
(NS) inadequate 
Teaching No Large dropouts 
session on intervention and 
Kerr 1985194 59 how to take apart from SR 4% (NS) NR +0.4 NS 3 inconsistencies 
and record 
own blood paper and between text and pencil tests tables. pressure 
Family 
member 25% more Randomisation 
I, 
It 
support Usual care participants method not '. 




Net effect on Blood 
adherence Blood pressure 
between pressure change Duration 
intervention change diastolic of 
Study (first Method of and control systolic in in mmHg fo II ow-
author, year of Study measuring group (p- mmHg (p- (p- upin 
publication) size Intervention. Control adherence value) value)* value)* months Comments 
Counselling 
session with 
health 4% more Randomisation 
Morisky 1985209 65 educator Usual care SR 4% (NS) participants NR 60 method not directly after by physician controlled reported, complex 
doctor (NS) design. 
appointment 
(10 min) 
4% more Randomisation 
Morisky 1985209 62 Small group Usual care SR 0% (NS) participants No 60 method not training groups by physician controlled reported, complex 
(NS) design. 
Randomisation 
procedure not I, 




Net effect on Blood 
adherence Blood pressure 
between pressure change Duration 
intervention change diastolic of 
Study (first Method of and control systolic in in mmHg follow-
author, year of Study measuring group (p- mmHg (p- (p- upin 
publication) size Intervention Control adherence value) value)* value)* months Comments 
Electronic Small sample size, McKenney 70 medication aid Usual drug PC 17% NR NR 3 potential sources 1992208 vial (p=O.OOO2) of bias poorly 
cap reported. 
Skaer 1993214 151 Postal Usual care Prescription 8% (p<O.05) NR NR 12 Sources of bias 
reminder record not fully reported. 
Special unit- Prescription Sources of bias Skaer 1993214 dose reminder Usual care 11 % (p<O.05) NR NR 12 record not fully reported. packaging 
Postal 
reminder 
Skaer 1993214 combined with Usual care Prescription 23% (p<O.05) NR NR 12 Sources of bias special unit- record not fully reported. 
" 
dose reminder It 
packaging 
Telephone- Treatment provided blinded 
Friedman linked 4.7 4.4 
1996202 267 computer 




Net effect on Blood 
adherence Blood pressure 
between pressure change Duration 
intervention change diastolic of 
Study (first Method of and control systolic in in mmHg follow-
author, year of Study measuring group (p- mmHg (p- (p- upin 
publication) size Intervention Control adherence value) value)* value)* months Comments 
Pharmacy- Traditional Small sample size, 
Park 1996210 64 based pharmacy PC -2.3% (NS) NR NR 4 method of 
education and randomisation not 
counselling services reported. 
Home blood 2.9 (mean 
pressure PC (not 0.2 less doses arterial Zarnke 1997216 31 monitoring and Usual care clearly 
missed (NS) blood NR 2 Small sample size. 







in combination If 
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Net effect on Blood 
adherence Blood pressure 
between pressure change Duration 
intervention change diastolic of 
Study (first Method of and control systolic in in mmHg follow-
author, year of Study measuring group (p- mmHg (p- (p- upin 
publication) size Intervention Control adherence value) value)* value)* months Comments 
4% more Randomisation process not Physician-led compliant 
reported. Outcome 
Sackett 197510 144 work site care Usual care PC 3% (NS) and at goal NR 6 assessors were (augmented blood blinded to 






medication Potential sources 
and blood of bias well pressure 4 reported. Study 






Net effect on Blood 
adherence Blood pressure 
between pressure change Duration 
intervention change diastolic of 
Study (first Method of and control systolic in in mmHg fo II ow-
author, year of Study measuring group (p- mmHg (p- (p- upin 
publication) size Intervention Control adherence value) value)* value)* months Comments 
Self-recording Power calculation 
Johnson of blood not reported, study 





diagnostic Diuretic only: 
management Usual 7.6% (p<0.7) Hawkins 1148 of patients with physician Prescribing 4 (p<0.001) o (NS) 29 High losses to 1979204 hypertension record Diuretic plus follow-up (45%). 
and diabetes review methyldopa: 








Net effect on Blood 
adherence Blood pressure 
between pressure change Duration 
intervention change diastolic of 
Study (first Method of and control systolic in in mmHg fo II ow-
author, year of Study measuring group (p- mmHg (p- (p- upin 
publication) size Intervention Control adherence value) value)* value)* months Comments 
Counselling High drop-out rate, Usual study 
Rehder 1980211 50 and special medication PC 11% NS NR 18 6 underpowered. 
medication 








procedure prone to 
Self monitoring 4% more bias. Outcome ' , 
of blood had blood assessor blind to 
It 
Pierce 1984193 30 pressure and Usual care PC,SR 2% (NS)) pressure NR 6 treatment 
health reduction allocation. 




Net effect on Blood 
adherence Blood pressure 
between pressure change Duration 
intervention change diastolic of 
Study (first Method of and control systolic in in mmHg follow-
author, year of Study measuring group (p- mmHg (p- (p- upin 
publication) size Intervention Control adherence value) value)* value)* months Comments 
Education No Large dropouts through visual intervention and 
Kerr 1985194 116 aids and 10- apart from SR +2% (NS) +1 (NS) NR 3 inconsistencies 
minute lecture 
plus self- paper and between text and pencil tests tables. 
monitoring 
Education, 29% more Randomisation family member Usual care participants method not Morisky 1985209 72 support and by physician SR 5% (NS) controlled NR 60 reported, complex 
small training (p<0.01) design groups 
Home visits, 
Burrelle 1986201 education and Usual care PC,SR 21 % (p<0.001) 7 (p>0.05) +7 2 Small study. High 16 special dosing (p>0.05) likelihood of bias. I, 
devices It 
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Net effect on Blood 
adherence Blood pressure 
between pressure change Duration 
intervention change diastolic of 
Study (first Method of and control systolic in in mmHg fo II ow-
author, year of Study measuring group (p- mmHg (p- (p- upin 
publication) size Intervention Control adherence value) value)* value)* months Comments 
Written Randomisation 
reminders, method not Saunders 1991 patient-held reported. Data on 115 records and Usual care PC 16% (p=0.19) NR 7 (NS) 6 
212 home visits adherence only in 40% of (newly participants. diagnosed) 
Written Randomisation 
reminders, method not 
Saunders patient-held reported. Data on 





Net effect on Blood 
adherence Blood pressure 
between pressure change Duration 
intervention change diastolic of 
Study (first Method of and control systolic in in mmHg follow-
author, year of Study measuring group (p- mmHg (p- (p- upin 





reminder, possession Potential sources 
Sclar 1991 213 344 mailed Usual care PC ratio' 34% NR NR 6 of bias poorly 









reminder, possession Potential sources 
mailed " Sclar 1991 213 109 Usual care PC ratio' 41% NR NR 6 of bias poorly If reminder and higher reported. 





Net effect on Blood 
adherence Blood pressure 
between pressure change Duration 
intervention change diastolic of 
Study (first Method of and control systolic in in mmHg follow-
author, year of Study measuring group (p- mmHg (p- (p- upin 
publication) size Intervention Control adherence value) value)* value)* months Comments 
Postcard 
reminder, 3 points Small study, 
Hamilton nurse-led difference in 17.3 4.7 randomisation 
1993203 34 educational Usual care SR adherence (p=0.03) (p=0.22) 6 method not 
appointment 
score (p=0.12) reported. 
and follow-up 
phone call 
Patient-centred 0.3 points Only results from pharmaceutical self-report of Solomon difference in 6.9 
1998215 133 care model by Usual care PC adherence (p<0.05) 0.6 (NS) 6 adherence pharmacy score (p<0.05) reported. High 
residents likelihood of bias. 
, I 
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Net effect on Blood 
adherence Blood pressure 
between pressure change Duration 
intervention change diastolic of 
Study (first Method of and control systolic in in mmHg fo II ow-
author, year of Study measuring group (p- mmHg (p- (p- upin 






problems; Usual care, 18.6% Complete data on including delivered more blood pressure Blenkinsopp 180 advice, three times SR 12% (p<O.05) participants NR 6 only available on 2000180 information 100 participants. 
and referral to at two-month controlled High likelihood of intervals (p<0.05) general bias. 
practitioner by 
pharmacists 





author, year of Study 
publication) size Intervention 


























































a 'deck of cards'. 
* Net blood pressure reduction from baseline to follow-up in the intervention group compared to controls or percentage of participants with controlled blood pressure 
PC = pill counts 
DQ = direct questioning 
SR = self report 
NS = not significant (used when no p-value was reported) 
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Appendix 4 Quality assessment of included trials for the systematic review and potential sources of bias 
Outcome 
Randomisation assessor blind Losses to Power Hypothesis 
procedure to treatment follow-up calculation stated a Comments concerning the validity of 
appropriate? allocation? No (%) reported? priori? the study results 
Sackett 1975 NR yes 10/144 (6.9) NR yes No power calculation as such, but 
important differences a priori reported 
Eshelman NR NR 33/100 no no Drop-outs at least 33% with no differential 
1976 (33.0) loss to follow-up reported. 
Haynes 1976 yes yes 5/39 (12.8) yes yes Lacked statistical power. Power 
calculation was performed, but no exact 
figures were reported. 
Gabriel 1977 NR NR 0179 (0) no yes No power calculation performed 
Johnson 1978 NR yes 4/140 (2.9) (yes) yes Power calculation not reported in 
methods, but probability of type II error 
quantified in discussion 
'1 
Hawkins 1979 yes no 519/1148 no yes High losses to follow-up. 
(45.2) 
Logan 1979 NR yes 41/457 (9.0) no yes Differential loss to follow-up well reported. 
Nessman NR no NR no no Only 10% of eligible patients took part in 




Randomisation assessor blind Losses to Power Hypothesis 
procedure to treatment follow-up calculation stated a Comments concerning the validity of 
appropriate? allocation? No (%) reported? priori? the study results 
Rehder 1980 NR NR 52/100 (52) no no High drop-out rate and small sample size 
for a factorial trial. 
Webb 1980 NR NR NR yes no Unclear on what outcome and treatment 
difference the power calculation was 
based on. Unequal numbers due to drop-
outs after randomisation but before start 
of intervention (no reasons given) 
Kirscht 1981 NR NR 66/417 no no Adherence scores unclear and results 
(15.8) difficult to interpret. 
Logan 1983 yes yes 9/194 (4.6) yes yes Randomisation process unclear. 
Asplund 1984 NR NR 30/160 no yes Drop-outs not clearly reported. 
(18.8) 
Baird 1984 NR NR 50/289 no yes Detailed reasons for loss to follow-up 
(17.3) reported 
Pierce 1984 yes yes 2/115 (1.7) no no Outcomes poorly reported 
Kerr 1985 NR NR 52/116 no yes Large drop-outs in all groups. 
(44.8) Inconsistencies between denominators in 
tables and drop-outs that vary for blood 




Randomisation assessor blind Losses to Power Hypothesis 
procedure to treatment follow-up calculation stated a Comments concerning the validity of 
appropriate? allocation? No (%) reported? priori? the study results 
Morisky 1985 NR NR 110/400 no yes No significant differences between drop-
(27.5) outs and those who continued to receive 
care 
Becker 1986 NR NR 15/180 (8.3) yes yes Physicians blinded to treatment 
allocation. Were aware that compliance 
study was in progress but unaware of the 
aims of the study. 
Burrelle 1986 NR NR o (O) no no Small study, high likelihood of bias 
Burris 1991 yes yes 9/58 (15.5) no yes No p-values reported for adherence 
outcome 
Saunders no yes 33/224 yes yes Drop-outs were lower in the intervention 
1991 (14.7) groups but much higher in newly treated 
group than infrequent attenders. 
, , 
Sclar 1991 NR NR NR no no No drop-outs reported despite uneven 
number randomised. 
McKenney NR no NR no yes 9 patients required change of medication 
1992 during second phase, bp measurements 
were not included in analysis 
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Outcome 
Randomisation assessor blind Losses to Power Hypothesis 
procedure to treatment follow-up calculation stated a Comments concerning the validity of 
appropriate? allocation? No (%) reported? priori? the study results 
Hamilton NR NR 4134 (11.8) no yes Small sample size. 
1993 
Skaer1993 yes yes NR No Yes Losses to follow-up not reported 
Detry 1995 NR no 18/640 (2.8) no no Cross over RCT, patients double counted 
Boissell 1996 yes no 253/7274 yes yes No differential loss to follow-up reported. 
(3.5) High participant numbers due to large 
number of participating general 
practitioners 
Friedman NR yes 34/267 no yes Treatment provider blinded until baseline 
1996 (12.7) measurement was completed. 
Randomisation by 'paired randomisation 
protocol'. 
, I 
Park 1996 NR no 11/64 (17.2) yes yes Small study. 
Leenen 1997 yes yes 21/198 no yes Compared two different drugs. Only within 
(10.6) group comparison. 
Zarnke 1997 yes NR NR no yes No power calculation but primary and 
secondary hypotheses stated 
235 
Outcome 
Randomisation assessor blind Losses to Power Hypothesis 
procedure to treatment follow-up calculation stated a Comments concerning the validity of 
appropriate? allocation? No (%) reported? priori? the study results 
Marquez NR NR 15/110 no yes Differential loss to follow-up in both 
Contreras (13.6) treatment arms not reported. 
1998 
Mounier- NR no 18/103 no no Treatment allocation according to 
Vehier 1998 (17.5) 'enrollment order' and 'randomisation list'. 
Solomon NR no NR no yes Multiple sources of bias 
1998 
Girvin 1999 NR yes 2/27 (7.4) no Small study, methods not well reported. 
Andrejak yes no 29/162 no yes Differential loss to follow-up well reported 
2000 (17.9) 
Blenkinsopp NR NR 40/282 no yes Randomisation at pharmacy level, 
2000 (14.2) complete data on blood pressure only I, 
available on 100 patients 
Mehos 2000 NR NR 5/41 (12.2) no yes Inappropriate randomisation method, only 
single family practice setting, high 
likelihood of bias. 
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Appendix 5 Data collection sheets used in the ReT 
Appointment check list 
Stage I Timing 
- Procedure Check 
o After Patient invitation 
o 1. Arrange patient 




All patients 1. Fill out data collection 
sheet with patient 
2. Ask patient to fill in 
self assessment sheet 
3. Label drug 
containers: patient 
name, drug dose and 
frequency 
4. Give out patient 
information on 
monitors and go 
through it with patient 
~1 _______ ~ ___________________ ~ _______ (fi_ill~in~t~a~b=le~t_n_am _ e_) __ ~. _____ ~ 5. Arrange an appoi tment in 2 months time 
.... ..... .... . .......... . 
2 2 months Counselling 1. Counselling interview 
after (INTERVENTION INTERVENTION 
initial GROUP) GROUP ONLY) (see 
visit or separate sheet) 
bp check (CONTROL 2. Check blood pressure 
GROUP) 3. download electronic 
monitor 
3 4 months Re-inforcement 
" after appointment 
initial (INTERVENTION 
I visit GROUP) or I , 
I bp check (CONTROL ~ GROUP) 




GROUP ONLY) (see 
separate sheet) 
2. Check blood pressure 








visit 114 , ... , ... 
I months 
after 
o 0 IDltial 
visit 
.......... _, 
................... -." ..... ~ ... ...... ~ .. ,--" I BP check I 
I 
1. check blood pressure 
2. download monitors 
I 
I 
.. . .......... " ... ",. .. ~ ... ,~ ... ---.......... - .. -.... ~ 
I BP check 1. Check blood pressure 
I 




FIRST PATIENT MEDICATION COUNSELLING SESSION 
Patient Name Monitor Number Study 
---------------------- ----------ID Surgery ___ _ 
This consultation should last no longer than 10 to 20 minutes. It is meant to be a patient-centred 
approach to deal with any problems in medication-taking in a non-judgemental manner. 
Introduction 
1. Please state that many people find it difficult to take their 
medication all the time 
2. Explain that reason for appointment is to discuss ANY problems 
with taking blood pressure tablets 
Please tick if 
discussed 
l Please circle or 
I
I Assessment of problems with medication tick as 
I taking appropriate I-------------------~~~--~---------------------~ 
I Do you ever find it difficult to take your blood pressure tablets? 
If YES to above question, what is the main problem? 
. .... . .... ,....... . ... 
, II Is this a 
Problem problem for 






If YES, what 
solution strategy 
have you agreed ? 
I Side effects "Do you have any ! ~ I (e.g. refer back to GP) 
I problems with side I YIN 
I effects?" I _______ -:-' 
I, ~~:tasteof I:f~~b~:~!~=e I Y/ N· ·1 1 (e.g. refer back to GP) 
! for you?"! . _______ _ 
------' I '\ (e.g refer back to GP) 
I ~=:r~~ ~~ ~~::::o~ ~~~;"a . !...... ~. (~ . ________ -"" 
I .. '~ (e.g. discuss reasons, 
II Non- "Are you generally happy I negotiation of treatment 
acceptability taking your blood I YIN plan, refer back to GP if 
i pressure tablets?" I _________ -=.::nec:!::es:::::;s:=ary:..LL) ____ -' 
Forgetfulness 








.. ''Do you find it 
sometimes difficult to 
remember taking your 
blood pressure tablets?" 
"Do yoti:ili.o:;why you 
are being prescribed 
blood pressure tablets?" 
''Do you find it difficult 
for taking many different 
tablets?" 
1,1 Y··· . I····N· ... ....... -·~:~~~~yo:c:~~~, 
family support, modify or 
simplify treatment, refer I ~ba~ck~to~G~P)L-___ ~~ 
YIN 
YIN 
(explanation of diagnosis 
and riskslbenefits of 
treatment) 
(e.g refer back to GP) 
I-An---yt-b-jD-g-e-IS-e~I---------:-' 
! not covered by i 




TWO MONTH FOLLOW-UP CONSULTATION 
Patient Name Monitor Number Study 
ID --------------------~ ---------
This consultation should last no longer than 10 minutes. It is meant to be a follow up on the 
previous medication counselling to find out whether any strategies to help with medication 
taking have been successful. 
"' ..... 
I In what way 
I 
was the 
strategy Was a successful or 
strategy not 
agreed to successful? 
address (please 
this Has the describe and 
problem? strategy If YES, was the complete Problem (please been If not, for stragegy below if not Category tic~l followed? what reason? successful? enough space) 









Size or taste of I I 
Side effects YIN I _~ ______ Y_/N __ ~ _____ __ 
tablets I~ YIN , ____ ---' ___ Y_/:--N_--' 
~=~~~ ~ Y/ N I ____ ----' __ Y_I_N __ _ I I I I 
-'-'-' 
... ........................................ .. Non-
acceptability YIN 




Non- I V /1\.T I 
comprehension , ~~_________ ~~ ____ Y __ I_N ____ ~ 
Rf:n..u:
er ~ YIN I ____ .. --_:___~ .... ::_:::' ...... _--~Y_:___/_:_N_:___ .. --_:_' 
I 
I 











I Anything else 





(please state) I_ .... _ .... ~.-... ----...... _. ____ ....... " ...~~ ...~ .... ".. __=."._ .. . ::::::::::::_ ...... ".~ .. ........ ~-:---_---. 
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Appendix 6 Flow chart for choosing the drug for use in the electronic monitor 
Blood pressure medication adherence study 
How to choose the blood pressure tablet for the 
monitor: 
During this study patients will only take one type of blood pressure tablet 
out of the electronic containers. 
If patients are on a more than one blood pressure tablet, you will need to 
choose the drug that has to go into the container. 
Please choose the drug according to the hierarchy below (once daily 
before twice daily before three times daily, and diuretics before beta-
blockers before Calcium antagonists before ACE inhibitors before others). 
DIURETIC 
BETA-BLOCKER 
ONCE DAILY --'" .. CA-ANTAGONIST 
I 
ACE INHIBITOR I Choose in this order OTHER 
DIURETIC 
~, BETA-BLOCKER 
--. CA-ANTAGONIST TWICE DAILY .... 
ACE INHIBITOR I Choose in this order I OTHER 
DIURETIC 
'r BETA-BLOCKER 
THREE TIMES ........ CA-ANT AGONIST 
... ACE INHIBITOR DAILY I Choose in this order I OTHER 
240 
Appendix 7 Photo of equipment used: Electronic monitor and downloading port 
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Appendix 8 Patient information on MEMS electronic monitors 
Name 
-----------------------------
How to use the special tablet container 
In order to le.am more about dosing patterns in people who are prescribed blood 
pressu:e lowen?g tablets, we.are providing you with a special tablet container (MEMS-
contalner)~ This tablet conta~ner has an electronic watch in its screw-top closure. Thus 
we can regIster the date and time you 0 en the bottle for taking your tablets. 
When using the MEMS-container, please pay attention to the following: 
• Your doctor has prescribed you . Whenever 
you get a new prescription for these tablets, please take them out of 
the original packet and transfer them into the MEMS-container 
(preferably at the time when you would take a dose out anyway) 
• Take ________ only out of this MEMS-container. 
• Open the MEMS-container only when you intend to take a tablet of 
• Close the MEMS-container promptly after removing a tablet of 
• Never leave the MEMS-container open. 
• If for any reason there is a change in the pattern of your pill-taking {for 
example, due to a holiday, moving house, sudden illness etc.} we 
would be grateful if you could make a note in a little note book or on a 
sheet of paper and bring it with you to the next nurse appointment 
• If is being stopped by your GP, please 
contact the practice nurse to tell you which other blood pressure tablet 
you should put in the container instead 
Please take your MEMS-container with you whenever you see the nurse at the 
surgery and return it at the end of the study. 
Many thanks for your co-operation! We hope that taking part in this research will be 
interesting and rewarding for you. Please do not hesitate to contact D~ Schroeder (01.17 
928 ,7318) or your practice nurse at the surgery if you have any questIOns or would like 
further infonnation. 
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